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ABSTRACT 
 
Thyroid cancer is the most common malignancy of endocrine organs and accounts 
for about 1% of newly diagnosed cancer cases. Anaplastic thyroid carcinoma 
(ATC) is one of the most aggressive human tumors; it is characterized by local 
invasion, distant metastasis, chemoresistance and radioresistance. Effective 
systemic therapy capable of reversing the aggressive biology of this disease is 
currently not available. Therefore, there is an urgent need for a better 
understanding of the molecular mechanisms underlying anaplastic thyroid cancer 
pathogenesis. Through, a cDNA microarray analysis we have isolated Twist1 as a 
gene up-regulated in ATC. Twist1 is a basic helix-loop-helix transcription factor 
that has been shown to contribute to cancer development and progression but its 
mechanism of action is poorly defined. In this Dissertation we showed that 
approximately 50% of ATCs up-regulated Twist1 with respect to normal thyroids 
as well as to poorly and well-differentiated thyroid carcinomas. Silencing of 
Twist1 by RNA interference in ATC cells reduced cell migration and invasion and 
increased sensitivity to apoptosis. The ectopic expression of Twist1 in thyroid 
cancer cells induced resistance to apoptosis and increased cell migration and 
invasion. To uncover the molecular mechanisms underlying Twist1 biological 
effects, we have performed a gene expression profile of Twist1 ectopically 
expressing thyroid cancer TPC cells in comparison to vector control cells. We 
founded 158 genes up-regulated and 221 genes down-regulated by more than 1.5 
fold in TPC-Twist1 cells. We used the Ingenuity Systems Pathway Analysis (IPA) 
software to classify these genes. Consistent with the biological function of Twist1 
in ATC, the top three molecular and cellular functions enriched in TPC-Twist1 
cells were: cellular movement, cellular growth and proliferation, cell death and 
survival. In this dissertation we focused on the up-regulated genes by more than 4 
fold. Silencing of the 11 top up-regulated genes reduced cell viability of TPC-
Twist1 cells. Silencing of COL1A1, KRT7, PDZK1 induced also apoptosis. 
Silencing of HS6ST2, THRB, ID4, RHOB, and PDZK1IP, also impaired cell 
migration and invasion of TPC-Twist1 cells. Thus, our data demonstrate that 
Twist1 plays a key role in determining malignant features of anaplastic thyroid 
cancer cells. These effects are mediated by a set of genes whose expression is 
under Twist1 control. The identified target genes are potential novel molecular 
determinants of ATC. 
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1. BACKGROUND 
1.1 Thyroid tumors 
1.1.1 Morphological and clinical characteristics of thyroid tumors 
 
Thyroid cancer is the most common malignancy of endocrine organs and 
has rapidly increased in global incidence in recent decades (Jemal et al. 2011). The 
increased incidence is limited to the papillary type of thyroid cancer and is mostly 
due to tumors of small size (<1 cm) (Nikiforov and Nikiforova 2011).  
There are several histological types and subtypes of thyroid cancer with 
different cellular origins, characteristics and prognosis (Xing 2013). There are two 
types of thyroid cells: follicular thyroid cells and parafollicular C cells, from 
which thyroid cancers are derived. Follicular thyroid cell derived malignancies 
(~95% of cases), include papillary thyroid carcinoma (PTC), follicular thyroid 
carcinoma (FTC), poorly differentiated thyroid carcinoma (PDC) and anaplastic 
thyroid carcinoma (ATC). PTC and FTC are collectively classified as well 
differentiated thyroid carcinoma (WDTC). PTC and FTC account for ~80% and 
~10% of cases, respectively, PDC accounts for ~5%, ATC accounts for ~2% of 
cases. These tumors differ noticeably in aggressiveness, ranging from well 
differentiated to ATC (Figure 1). 
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Figure 1. Model of thyroid multi-step carcinogenesis. Scheme of step-wise dedifferentiation of 
follicular cell-derived thyroid carcinoma with underlined main histological features. 
 
 
PTC is characterized by typical features of the cell nuclei, including 
enlarged, vesicular and overlapping nuclei with clearing, fine dusty chromatin, 
grooves, inclusions and single or multiple micro or macronucleoli (De Lellis 2006) 
(Figure 1). PTC is closely linked to radiation exposure and its incidence sharply 
increased in children after the Chernobyl accident (Williams 2008). PTC is more 
frequent in women than men and affects patients of ~20-50 years old. 
FTC is characterized by follicular cell differentiation in the absence of the 
diagnostic nuclear features of PTC, vascular or capsular invasion and propensity 
for metastasis via the blood stream (Figure 1). It mostly affects 40-60 years old 
patients (Kondo et al. 2006). 
PDC are rare neoplasms characterized by a partial loss of differentiation 
and less favorable prognosis in comparison with WDTC. Diagnostic criteria for 
PDC include the presence of a solid-trabecular-insular pattern of growth, absence 
of the nuclear features typical of PTC and the presence of at least one of these 
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features: convoluted nuclei, high mitotic rate, and tumor necrosis (Volante et al. 
2010) (Figure 1). 
ATC is the most aggressive thyroid tumor, and it is described among the 
most lethal human malignancies, with a median survival from diagnosis of ~3-6 
months (Perri et al. 2011). ATC is characterized by admixture of spindle 
pleomorphic giant and epithelioid cells (Figure 1). Clinically, these tumors usually 
present during the 6th to 7th decade of life as a rapidly enlarging neck mass that 
extends locally, compressing the adjacent structures and tends to disseminate both 
to regional nodes and to distant sites, including lung, pleura, bone and brain. 
Current treatment of ATC has often only palliative purposes, particularly relief of 
airway compression, having little impact on patient’s survival (Smallridge and 
Copland 2010). 
Parafollicular C cell-derived medullary thyroid carcinoma (MTC) accounts 
for a small proportion (~5% of cases) of thyroid malignancies (Xing 2013). MTC 
is sporadic in ~75% of cases, and in the others it is a component of the autosomal 
dominant cancer syndrome known as “multiple endocrine neoplasia type 2” 
(MEN2) that includes: MEN2A (~80% of cases), MEN2B and familial MTC 
(FMTC) (Waguespack et al. 2011). MEN2-associated hereditary MTC is typically 
bilateral and multicentric and it is usually preceded by multifocal C-cell 
hyperplasia (CCH). In MEN2A, MTC is associated with pheochromocytoma, 
parathyroid hyperplasia and, rarely, cutaneous lichen amyloidosis (CLA) and 
Hirschsprung’s disease. In MEN2B, MTC is associated with pheochromocytoma, 
multiple ganglioneuromas of the lips and gastrointestinal tract and marfanoid body 
habitus. Total thyroidectomy is recommended. Clinical recurrence in the neck or 
in mediastinum is a common problem for MTC patients (Leboulleux et al. 2004, 
Cote and Gagel 2003). 
 11 
1.1.2 Genetics alterations in follicular thyroid cell derived tumors 
 
Similar to other cancer types, thyroid cancer initiation and progression 
occurs through a gradual accumulation of various genetic and epigenetic 
alterations, including activating and inactivating somatic mutation, alteration in 
gene expression patterns, microRNA (miRNA) dysregulation and aberrant gene 
methylation (Nikiforov and Nikiforova 2011). Thyroid cancer represents a type of 
neoplasia in which critical genes are frequently mutated via two distinct molecular 
mechanisms: point mutation or chromosomal rearrangement (Table 1). 
 
 
Table 1. Genetic alterations in follicular thyroid cell derived tumors. 
 
Tumor type Molecular lesion and approximate prevalence (%) 
PTC 
 
-RET/PTC rearrangements (10-20%) 
-NTRK1 rearrangements (<5%) 
-BRAF point mutation (45%) 
-RAS point mutation (10-20%) 
 
FTC 
 
-PAX8/PPARγ rearrangements (> 60%) 
-RAS point mutation (30-45%) 
-PIK3CA mutation (<10%) 
-PTEN mutation (<10%) 
 
PDC 
 
-RAS point mutation (20-40%) 
-PI3KCA point mutation or amplification (5-10%) 
-TP53 point mutation (15-30%) 
-CTNNB1 point mutation (25%) 
-BRAF point mutation (10-20%) 
- AKT point mutation (5-10%) 
 
ATC 
 
-TP53 point mutation (70-80%) 
-BRAF point mutation (25%) 
-RAS point mutation (20-30%) 
-CTNNB1 point mutation (60-65%) 
-PI3KCA point mutation (15-25%) 
- AKT point mutation (15%) 
-PTEN mutation (10-20%) 
-ALK point mutation (10%) 
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Genetic alterations in PTC 
 
Over 70% of PTC features genetic alterations causing activation of the 
MAPK pathway (Mitogen-Activated Protein Kinases) (Kondo et al. 2006). PTC is 
characterized by mutations of various MAPK components, including 
rearrangements of the RET (REarranged during Transfection) tyrosine kinase 
receptor, or more rarely NTRK1 (neurotrophic receptor-tyrosine kinase), or 
activation of BRAF (B-type RAF family kinase) (Table 1). 
In the thyroid gland, RET is normally expressed at high levels in 
parafollicular C-cells, but not in follicular cells. RET is a proto-oncogene encoding 
a cell membrane receptor tyrosine kinase (RTK) with four cadherin-related motifs 
in the extracellular domain, and it is located on chromosome 10q11.2 (Santoro et 
al. 2006). RET-PTC is a chromosomal rearrangement found in PTC, and occurs as 
a consequence of genetic recombination between the 3’ tyrosine kinase portion of 
RET and the 5’ portion of a partner genes (Santoro et al. 1994). The rearrangement 
results in ligand-independent dimerization and constitutive tyrosine kinase activity 
of RET which leads to chronic stimulation of MAPK signaling. There are more 
than 10 types of RET rearrangements, as determined by the types of partner genes. 
Two of the most common types of rearrangements are RET/PTC1 and RET/PTC3, 
in which RET is fused to either CCDC6 (Colied-Coil Domain Containing 6) (also 
known as H4) or NCOA4 (Nuclear Receptor Coactivator 4) (also known as ELE1 
or RFG), respectively (Rabes et al. 2000; Santoro et al. 2000; Klugbauer et al. 
1998). Both of these rearrangements are paracentric intrachromosomal inversion, 
and fusion partners reside on the long arm of chromosome 10 (Pierotti et al. 1992; 
Minoletti et al. 1994). Spatial contiguity of RET and the partner gene in the 
nucleus is a structural basis for the formation of RET-PTC rearrangement 
(Nikiforova et al. 2000). RET rearrangements are found in 10-20% of PTC, but the 
prevalence is significantly higher in patients with a history of accidental or 
therapeutic radiation exposure. RET/PTC1 is more frequently associated with 
classic PTCs and with the diffuse sclerosing variant; conversely, RET/PTC3 is 
more common in the solid variant and in PTC associated to ionizing radiations 
(Thomas et al. 1999). 
Chromosomal rearrangements involving another receptor tyrosine kinase 
gene NTRK1 also occur in PTC. The NTRK1 gene resides on chromosome 1q22 
and can be fused to at least three different partner genes located on the same or 
different chromosomes (Radice et al. 1991; Greco et al. 1992; Miranda et al. 
1994). Rearrangement of the NTRK1 genes occurs in ~5% of PTC (Musholt et al. 
2000). 
BRAF is a serine-threonine kinase belonging to the RAF family (ARAF, 
BRAF, CRAF) that is translocated to the cell membrane after being bound and 
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activated by RAS, resulting in intracellular activation of the MAPK signaling 
pathway (Davies et al. 2002). Among the RAF family members, BRAF appears to 
have the highest basal kinase activity and is the most potent activator of the 
MAPK pathway. In thyroid cancer, BRAF can be activated by point mutations, 
small in-frame deletions or insertions or by chromosomal rearrangement. The most 
common oncogenic mutation in BRAF is the replacement of valine 600 with a 
glutamic acid (V600E) caused by a thymine to adenosine substitution at nucleotide 
position 1799. BRAF V600E kinase function is ∼500 fold more active with respect 
to the wild type protein. BRAF mutation represents the most common genetic 
event in PTC, occurring in ∼45% of all cases (Xing 2007; Ciampi and Nikiforov 
2005), and in particular V600E constitutes ∼98-99% of all BRAF mutations found 
in thyroid cancer. V600E mutation has been observed in melanoma (∼80%), and in 
other tumors (∼0-18%), including colorectal (∼5%) and lung cancer (∼1-3%) 
(Namba et al. 2003).  
BRAF mutations correlate with aggressive tumor behavior, tumor 
recurrence, decreased radioiodine concentration ability, failure to treat recurrent 
disease. Other BRAF mutations are the K601E point mutation, small in-frame 
insertions or deletions around codon 600, and AKAP9/BRAF rearrangement. The 
rearrangement is a paracentric inversion of chromosome 7q that leads to the fusion 
between BRAF protein kinase domain and the AKAP9 (A Kinase (PRKA) Anchor 
Protein (yotiao) 9) gene. This rearrangement occurs in ionizing-radiation-induced 
PTC in 1-2% of cases. (Ciampi et al. 2005). Finally, point mutation or gene 
amplification of PI3KCA (phosphatidylinositol-3 kinase catalytic domain) has 
been reported in a small fraction of PTC (Wu et al. 2005).  
Overall, the genetic alterations of RET, BRAF and NTRK1 rarely overlap in 
the same tumor and in particular RET/PTC and BRAF alterations are mutually 
exclusive in PTC, suggesting that mutations at more than one of these sites are 
unlikely to confer additional biological advantage, a fact that is consistent with the 
overlap of the signaling pathways of these oncoproteins (Kimura et al. 2003; 
Soares et al. 2003; Frattini et al. 2004). 
 
 
Genetic alterations in FTC 
 
FTC may develop through at least two different pathways, involving either 
RAS or PPAR γ (peroxisome proliferation activated receptor γ). The human RAS 
gene family includes HRAS, KRAS and NRAS. These genes encode intracellular G-
proteins, thereby propagating signals from cell receptor tyrosine kinases and G-
coupled receptors along the MAPK, PI3K/AKT (v-Akt murine Thymoma viral 
oncogene) and other signaling pathways (Bhaijee and Nikiforov 2011). Activating 
point mutations in RAS genes are common in human tumors and typically affect 
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codons 12,13 and 61. In thyroid cancer, NRAS codon 61 and HRAS codon 61 
mutations are the most common. RAS mutations are identified in ∼30-45% of FTC 
(Table 1).  
PPAR γ is a member of the steroid nuclear-hormone receptor superfamily 
that forms heterodimers with retinoid X receptor. PAX8/ PPARγ rearrangement 
results from t(2:3)(q12-13;p24-25) translocation, which leads to the fusion of 
PAX8 (paired box 8) and PPARγ occurring in up to 60% of FTC (Eberhardt et al. 
2010). PAX8/ PPARγ exerts a dominant-negative effect on the wild-type tumor 
suppressor PPARγ and also transactivates certain PAX8 responsive genes 
(Placzkowski et al. 2008). PAX8/ PPARγ rearrangement and RAS point mutations 
rarely overlap in the same tumor, which suggests that they represent distinct 
pathogenetic pathways in the development of follicular thyroid carcinomas 
(Nikiforova et al. 2003). 
 
 
Genetic alterations in PDC 
 
PDC have genetic features intermediate between WDTC and ATC 
consistent with the hypothesis of a multi-step model of thyroid carcinogenesis 
(Tallini 2011) (Figure 1). Similar to WDTC, RAS point mutations occur in ∼20-
40% of PDC (Garcia-Rostan et al. 2005; Volante et al. 2007). Similar to ATC, 
PDC features in some cases, mutations in exon 5-9 of TP53 (15-30%) or in 
PIK3CA and its downstream effector AKT or point mutations in exon 3 of 
CTNNB1 (Catenin-cadherin-associated protein Beta 1) (Ricarte-Filho et al. 2009). 
About 10-20% of PDC harbor BRAF mutation, particularly those samples with 
morphological evidence of pre-existing PTC (Begum et al. 2004). A small number 
of PDC expresses rearranged tyrosine kinase genes such as RET/PTC or NTRK1, 
however there is no association with unfavorable clinicopathological features or 
decreased survival (Santoro et al. 2002) (Table 1). 
 
 
Genetic alterations in ATC 
 
ATC may derive de novo or from pre-existing PTC or FTC (Figure 1). 
BRAF and RAS mutations are frequently found in WDTC, PDC and ATC, 
therefore, probably represent an early event in thyroid cancer progression 
(Nikiforova et al. 2003). By contrast, the RET/PTC rearrangements and the 
PAX8/PPAR γ fusion protein detected in WDTC, are not observed in ATCs 
(Nikiforov 2004). ATCs frequently have additional genetic alterations that are not 
found in WDTC and, therefore, represent a late event, which may be required to 
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initiate tumor dedifferentiation. The late events include mutations of TP53, 
CTNNB1 and PIK3CA genes. 
TP53 is a tumor suppressor gene located on chromosome 17p. TP53 is 
nuclear transcription factor that plays a key role in regulation of the cell cycle, 
DNA repair, and apoptosis (O’Neill et al. 2010). Point mutations that affect TP53 
are found in ∼70-80% of cases of ATC (Xing 2013). The mutations lead to loss of 
function of this important tumor suppressor gene. 
Another gene frequently mutated in ATC is CTNNB1, which encodes β-
catenin. β-catenin is a multifunctional protein that binds and stabilize E-cadherins 
to form the adherence junction, and it is an activator of WNT signaling pathway. 
Point mutations in exon 3 of the gene are found in up to 60-65% of ATC (Garcia-
Rostan et al. 2001). 
Thyroid cancer dedifferentiations also involves progressive accumulation 
of other mutations, in particular in gene that encode effectors of the PI3K-AKT 
pathway. They, in turn, phosphorylate substrates involved in cell growth and 
survival. PIK3CA gene located on 3q26.3 and encoding a catalytic subunit of 
PI3K, was found mutated in ∼15-25% of ATC (Xing 2013; Santarpia et al. 2008). 
AKT1 is activated in ∼15% of cases of ATC (Nikiforov and Nikiforova 2011) and 
PTEN (Phosphatase and Tensin homolog) that negatively regulates the PI3K 
pathway is mutated in ∼10-20% of ATC cases (Xing 2013).  
Recently point mutations of the ALK (anaplastic lymphoma kinase) gene 
were found in ∼10% of ATCs (Murugan and Xing 2011). ALK is a member of the 
insulin receptor sub-family of receptor tyrosine kinases (RTK) with its encoding 
gene located on the short arm of chromosome 2 (Kelleher and McDermott 2010). 
The gain-of-function mutations of ALK cause dual activation of the PI3K/AKT and 
MAP kinase pathways in ATC (Table 1). 
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1.2 The transcription factor Twist1 
1.2.1 Structures of the Twist1 gene and protein 
 
Little is known about the molecular events that lead from the highly 
curable differentiated tumors to the very aggressive ATC. Through a cDNA 
microarray analysis on different thyroid tumors in comparison to normal thyroids, 
we have isolated Twist1 transcription factor as a gene up-regulated in ATC 
(Salvatore et al. 2007). 
Twist1 was originally identified in Drosophila as one of the genes essential 
for mesoderm specification during embryo development (Simpson 1983). Two 
Twist genes exist in vertebrates, Twist1 (Twist) and Twist2 (formerly known as 
Dermo-1). The human Twist2 protein contains 160 amino-acid residues and it 
shares 68% homology with human Twist1, but Twist2 lacks a glycine-rich region 
that is present in Twist1 at N-terminus (Li et al. 1995). 
Human Twist1 gene is mapped on chromosome 7q21.2 and contains two 
exons and one intron (Wang et al. 1997) (Figure 2A). The first exon contains an 
ATG site followed by an open reading frame encoding 202 amino-acid residues. 
The open reading frame is followed by a 45-bp untranslated portion in exon 1, a 
536-bp intron and a second untranslated exon with two potential polyadenylation 
sites that are 65 and 415 bp from the 5′ end of exon 2. The molecular mass 
calculated from the amino-acid sequence of human Twist1 is ∼21 kDa, with a 
theoretical isoelectric point of ~9.6. The protein contains relatively polar amino-
acid residues in the region close to the NH2-terminus and non-polar residues at the 
COOH-terminus where the bHLH (basic helix–loop–helix) domain is located (Qin 
et al. 2011) (Figure 2B).  
Twist1 is a highly conserved transcription factor that belongs to the family 
of bHLH proteins (Thisse et al. 1987). In the classification of bHLH proteins, 
based on their tissue distribution, partner choice, DNA-binding properties and 
structural features, Twist1 falls into class B. Class B proteins are tissue-specific 
and usually form heterodimers with class A bHLH factors such as the product of 
E2 genes, which are broadly expressed (Castanon and Baylies 2002). bHLH 
proteins are structurally and functionally characterized by two amphipathic helices 
that are separated by a interhelical loop of varying length, which is important in 
maintaining the tertiary structure of the HLH moiety. A basic amino acid-rich 
region precedes the first helix and is required for DNA binding (Castanon and 
Baylies 2002). The functional importance of this domain has been emphasized by 
the isolation of mutations within this region. For example, humans carrying point 
mutations in the bHLH domain display Saethre-Chotzen syndrome (SCS), an 
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autosomal dominant inherited disease characterized by a broad spectrum of 
malformations including short stature, craniosynostoses, high forehead, ptosis, 
small ears with prominent crus, and maxillary hypoplasia with a narrow and high 
palate (El Ghouzzi et al. 1997). The ɑ-helices mediate dimerization with a second 
bHLH factor (Figure 2C), leading to the formation of a bipartite DNA-binding 
domain that specifically binds to hexanucleotide sequences (CANNTG), known as 
E-boxes. The E-boxes are found in the regulatory elements of many lineage-
specific genes. Consistently, bHLH are transcription factors acting in various 
differentiation processes, and play key roles in different developmental events like 
neurogenesis and myogenesis (Puisieux et al. 2006). 
 
 
 
 
 
Figure 2. Structure of human Twist1. A. The human-Twist1 gene comprises two exons separated 
by a unique intron. B. The human-Twist1 protein is 202 amino acids long presenting a basic helix-
loop-helix (bHLH) domain. C. Interaction of dimers of Twist1 with DNA (modified from 
Bonaventure and El Ghouzzi 2003). 
 
 
The Twist1 protein displays a very high degree of conservation among a 
broad range of species, including human, mouse, frog, Drosophila and 
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Caenorhabditis elegans, a high degree of sequence similarity in their C-terminal 
half, including the bHLH domain and a Twist box protein interaction surface and 
are more divergent in their N-terminus. 
The C-terminal part of the protein comprises the WR motif also called 
“Twist box” (Spring et al. 2000; Bialek et al. 2004). The WR motif is located 
between residues 20 and 55 C-terminal to the bHLH region. Recently it was 
demonstrated that through the Twist box, Twist1 establishes a direct interaction 
with p53 and this interaction is critical for Twist1 mediated inhibition of p53, 
suggesting that the binding via Twist box is leitmotif in the inhibition exerted by 
Twist1 on other transcription factors (Piccinin et al. 2012). 
The Twist1 protein functions as a transcription factor in the cell nucleus 
and presents two nuclear localization signal (NLS) sequence 37RKRR40 and 
73KRGKK77. Regulation of transcriptional outcome mediated by Twist1 depends 
on different mechanisms. Binding of Twist1 to E-boxes in the promoter of the 
target genes could either activate (e.g. N-cadherin, AKT2 or Gli1) or repress (e.g. 
E-cadherin) transcription (Alexander et al. 2006; Cheng et al. 2007). Twist1 can 
also influence gene expression via epigenetic mechanisms. The N-terminus of 
Twist1 can interact with p300, cAMP-response element binding protein (CREB), 
CREB-binding protein (CBP) and p300/CBP associated factor (PCAF), resulting 
in inhibition of the acetyl transferase activities of these histone remodeling 
enzymes (Hamamori et al. 1999). Since histone acetylation is usually coupled with 
transcriptional activation, the inhibition of p300, CBP and PCAF activities by 
Twist1 should repress gene expressions mediated by transcription factors that 
recruit these histone acetyltransferases.  
The C-terminus of Twist1 interacts with the DNA-binding domain of 
Runx2 to repress Runx2 function necessary for osteoblast differentiation (Bialek et 
al. 2004). These findings suggests that Twist1 not only serves as a transcription 
factor to directly regulate its target genes, but also regulates other transcription 
factor/coregulator-mediated gene expression through interaction with other 
transcriptional regulators (Figure 3). 
In addition, it was reported that Twist1 protein directly interacts with 
several other transcription factors, including MyoD, MEF2, RUNX1, PGC1-α, 
p53 and NF-κB (Nuclear Factor-KappaB) and inhibits their activities (Šošić et al. 
2003; Bialek et al. 2004; Sharabi et al. 2008; Shiota et al. 2008; Pan et al. 2009) 
(Figure 3). Furthermore, a recent paper showed that Twist1 directly negatively 
regulates formation of miRNA let-7i which (Yang et al. 2012). 
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Figure 3. Structure of the human Twist1 protein. Twist1 has the typical modular structure of 
bHLH transcriptional factor family. At the N-terminus two nuclear localization signals (NLS) are 
located. In the C-terminal region, the functional Twist box can bind Runx. The protein-protein 
interactions are delineated with black bars on top. A number of functional Ser/Thr residues allow 
post-translational modifications of Twist1 are illustrated on the bottom. (CBP, cAMP-response 
element binding protein (CREB)-binding protein; PCAF, p300/ CBP-associated factor, Runx, 
Runt-related transcription factor; E12/47, a bHLH transcription factor that form dimer with Twist1; 
MyoD, a bHLH transcription factor that regulates muscle differentiation; Id family of proteins can 
sequester the E-box transcription factor and therefore prevent formation of the dimers with Twist1 
(modified from Dobrian 2012). 
 
 
 
1.2.2 Twist1 protein phosphorylation 
 
Regulation of protein stability is an important way to control Twist1 
function. Recently, it was reported that Twist1 protein stability is largely regulated 
by MAPK-mediated phosphorylation on serine68 (S68). The S68 in Twist1 can be 
phosphorylated by p38, JNK and ERK1/2  (Extracellular signal-Regulated Kinase) 
MAPKs, and this phosphorylation prevents Twist1 protein from ubiquitination-
mediated degradation (Hong et al. 2011). Twist1 can heterodimerize with different 
transcription factors. Partner choice could also be regulated by the phosphorylation 
state of specific threonine (Thr 125) and serine (Ser 127) residues that are 
conserved in the first α-helix of the HLH domain of Twist1 protein. The 
phosphorylation state is determined by protein kinase A (PKA) and C (PKC) 
(Friulli et al. 2003) (Figure 3). Recently, AKT has also been linked to the 
phosphorylation of Twist1 at serine 42 (Vichalkovski et al. 2010).  
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1.2.3 Physiological functions of Twist1 protein 
 
Twist1, identified originally in Drosophila as a zygotic developmental 
gene, is considered crucial for the establishment of the ventral furrow, a 
prerequisite for the development of all mesoderm-derived internal organs (Thisse 
et al. 1987). The name “Twist” was given to this gene on the basis of observations 
that Drosophila embryos lacking the Twist1 gene failed to gastrulate normally, 
produced no mesoderm and died at the end of embryogenesis with a ‘twisted’ 
appearance (Simpson 1983). 
In mouse, the KO of Twist1 was shown to be embryonic lethal and die at 
E10.5-11 displaying severe defects in closure of the cephalic neural tube, deficient 
cranial mesoderm, malformed branchial arches and facial primordium, and 
retarded limb bud development (El Ghouzzi et al. 1997). Twist1 KO mice also 
present a significant increase in apoptotic cells, especially in the developing 
sclerotome (Chen and Behringer 1995). The lethality of the Twist1 knockout 
mouse led to the development of a Cre-mediated conditional knockout mouse to 
studying the regulatory functions of Twist1 post-neural crest cell migration 
(Bildsoe et al. 2009). A Twist1-null heterozygous mouse has also been developed 
that presents a Saethre-Chotzen syndrome-like (SCS) phenotype (Bourgeois et al. 
1998), thus providing an animal model for studying the SCS craniosynostosis 
phenotype. After birth, Twist1 is expressed in the adult stem cells of the 
mesenchyme (Figeac et al. 2007) and mRNA has also been detected in primary 
osteoblastic cells derived from newborn mouse (Murray et al. 1992) and in mouse 
brown and white adipocytes (Pan et al. 2009; Pettersson et al. 2010). The Twist1 
protein is also likely to be important for maintaining the immature phenotype of 
chondrocytes (Dong et al. 2007). 
The expression profile of Twist1 during human embryogenesis is 
unknown. Twist1 mRNA expression pattern was examined in various adult human 
tissues, as well as several cell lines originated from different normal human tissues 
(Wang et al. 1997). Among the human tissues analyzed, the strongest signals for 
Twist1 mRNA were observed in the placenta, a tissue containing a large fetal 
portion and a small maternal portion. In particular, strong Twist1 signals were seen 
in the fetal portion of the placenta developed from the chorionic sac, which is 
mostly derived from the mesoderm. Intermediate strength signals were seen in the 
adult heart and skeletal muscle, which are also mostly derived from the mesoderm. 
Weak signals were found in the kidney and pancreas, while no signals were 
observed in the ectoderm- derived cells in the brain and endoderm-derived cells in 
the lung and liver. Additionally, Twist1 expression is also observed in human 
white adipocytes (Pettersson et al. 2011). Twist1 expression was not observed in 
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human epithelial cells, although its mRNA was detected in both fetal and adult 
human skin fibroblasts (Wang et al. 1997). 
 
1.2.4 Role of Twist1 in human cancer 
 
Twist1 overexpression is associated with many types of aggressive tumors 
(Table 2) and in some cases correlates with poor prognosis and high or invasive 
grade/stage of the tumor  
Cancer is a complex multistep process involving genetic and epigenetic 
changes that eventually result in the activation of oncogenic pathways and/or 
inactivation of tumor suppressor signals. During cancer progression, cancer cells 
acquire a number of hallmarks that promote tumor growth and invasion (Hanahan, 
and Weinberg 2011). A crucial mechanism by which tumor cells enhance their 
invasive capacity is the dissolution of intercellular adhesions and the acquisition of 
a motile mesenchymal phenotype as part of an epithelial- to-mesenchymal 
transition (EMT). EMT is a critical mechanism of migration and invasion during 
development and in the case of cancer cells is a mechanism of increased invasion, 
metastasis, and resistance to chemotherapy. A hallmark of EMT is the functional 
loss of the E-cadherin protein encoded by the CDH1 gene (De Craene and Berx 
2013). 
Twist1 has been identified as a master regulator of EMT (Yang et al. 
2004). Twist1 down regulates epithelial markers such as E-cadherin, and up-
regulates mesenchymal markers such as N-cadherin. Repression of CDH1 gene by 
Twist1 is either direct (Vesuna et al. 2008) or mediated by SNAI1 (Smit et al. 
2009). Twist1 plays multiple roles in cancer initiation, progression and metastasis 
and. 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Table 2. Overexpression of Twist1 in human cancer (modified by Ansieau et al. 
2010). 
 
  Human cancer type Poor prognosis * 
High or invasive 
grade/stage * Reference 
Ameloblastoma  √ Feng et. al 2009 
Bladder carcinoma  √ Zhang et al. 2007 
Breast carcinoma √ √ Mironchik et al. 2005 
Cervical carcinoma √  Shibata et al. 2008 
Choroid plexus 
carcinoma 
  Hasselblatt et al. 2009 
Colon carcinoma   Ansieau et al. 2008 a,b 
Endometrial carcinoma √ √ Kyo et al. 2006 
Gastric carcinoma   Rosivatz et al. 2002 
Glioma  √ Elias et al. 2005 
Head and neck 
carcinoma 
√ √ Ou et al. 2008 
Hepatocarcinoma   Lee et al. 2006 
Kidney carcinoma   Ansieau et al. 2008 a,b 
Melanoma √ √ Hoek et al. 2004 
Nasopharyngeal 
carcinoma 
√  Song et al. 2006 
Neuroblastoma   Valsesia-Wittmann et al. 
2004 
Oesophageal squamous 
cell carcinoma 
  Yuen et al. 2007 
Ovarian carcinoma √ √ Hosono et al. 2007 
Pancreas carcinoma   Ohuchida et al. 2007 
Parathyroid carcinoma   Fendrich et al. 2009 
Pheochromocytoma   Waldmann et al. 2009 
Prostate carcinoma  √ Kwok et al. 2005 
Sarcoma   √ Maestro et al. 1999 
Thyroid carcinoma  √ Salerno et al. 2011 (attached manuscript II) 
* correlation with Twist1 overexpression 
 
 
1.2.5 Mechanisms of overexpression of Twist1 in human cancer 
 
The mechanisms leading to the aberrant ovexpression of Twist1 appear to 
be various and complex. Interestingly, stress conditions seem to control both the 
physiological and aberrant expression of Twist1. Hypoxic conditions are defined 
as potent inducers of Twist1 expression in cancer cell. Up-regulation of Twist1 by 
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HIF1α (Hypoxia Inducible Factor 1, alpha) during hypoxic conditions has 
significant implications in tumor invasion and angiogenesis (Yang et al. 2008).  
It was reported that also YB1 (Y box-binding protein I) is able to modulate 
Twist1 expression. The DNA/RNA binding protein YB1 was found to enhances 
the cap-independent translation of EMT-inducing mRNA including Twist1, 
thereby promoting growth arrest and cell dissemination (Evdokimova et al. 2009). 
In breast cancer Cheng and colleagues (2008) postulated that activated 
STAT3 transcriptionally induces Twist1 expression, which subsequently promotes 
the migration, invasion and anchorage-independent growth of breast cancer cells.  
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma is highly 
metastatic compared to other head and neck tumors. A study showed that the 
principal EBV oncoprotein, latent membrane protein 1 (LMP1), up-regulates 
Twist1 to induce EMT, suggesting the contribution of Twist1 to the highly 
metastatic nature of nasopharyngeal carcinoma (Horikawa et al. 2007) 
Furthermore, this study revealed that LMP1 regulates Twist1 through the NF-κB 
pathway. 
Moreover, it was described that Twist1 forms a negative loop with 
inflammatory cytokines, as Twist1 is transcriptionally induced by NF-κB and in 
turn binds to the TNFα (Tumor Necrosis Factor α) and IL1β promoters blocking 
NF-κB transcriptional activity (Šošić et al. 2003). 
In a recent paper it was also demonstrated that HMGA2 (high mobility 
group A2) protein in association with Smad complex directly associates with A:T-
rich sequences and promotes transcription from the Twist1 promoter (Tan et al. 
2012). 
 
 
1.2.6 Twist1 target genes 
 
Twist1 regulates gene expression as a transcriptional activator through 
binding as a homodimer or heterodimer to the E-box DNA consensus sequence. 
All the genes that present an E-box consensus sequence in the promoter are 
potentially Twist1 target genes.  
However in accordance with its important role in EMT, it was 
demonstrated that Twist1 down-regulates the epithelial marker E-cadherin and on 
the other hand up-regulates the mesenchymal marker N-cadherin (Vesuna et al. 
2008). Moreover, Twist1 directly activated the cell adhesion protein periostin 
(POSTN), involved in cancer metastasis (Oshima et al. 2002). Twist1 induces also 
PDGFRα (Platelet-derived Growth Factor Receptor α) expression, which in turn 
activates Src, to promote invadopodia formation. Invadopodia are specialized 
membrane protrusions for extracellular matrix degradation (Eckert et al. 2011). 
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Twist1 can promote cancer cell invasion and metastasis also by repressing 
the expression of TIMP1 a key inhibitor of MMPs (metalloproteinase) (Okamura 
et al. 2009). 
Direct regulation of genes involved in cancer progression has also been 
observed. AKT2 is a modulator of YB-1 function, and both are central to tumor 
proliferation (Shiota et al. 2008). Twist1 can up-regulate the proto-oncogene 
AKT2 by directly binding to its promoter (Cheng et al. 2007). Additionally, 
Twist1 directly regulated, in the presence of E12, the cyclin-dependent kinase 
inhibitor p21 (Funato et al. 2001; Murakami et al. 2008). 
Twist1 directly up-regulates Bmi1, a polycomb-group protein that 
maintains stem cell self-renewal and is frequently overexpressed in human 
cancers. Twist1 targets Bmi1 expression and works with Bmi1 to promote tumor-
initiating capability and EMT by repressing E-cadherin expression (Yang et al. 
2010). 
Twist1 can regulates gene expression indirectly by regulating microRNAs 
expression. Recent evidence has shown that Twist1 can directly activate miR-10b 
by binding to its promoter (Ma et al. 2007). Activation of miR-10b by Twist1 
leads to inhibition of translation of the homeobox D10 mRNA resulting in 
increased expression of the pro-metastatic gene RHOC (Ras Homolog family 
member C) (Ma et al. 2007). 
Recently it was reported that Twist1 cooperates with Bmi1 to suppress let-
7i expression, which results in up-regulation of NEDD9 (Neural precursor cell 
Expressed, Developmentally Down-regulated 9) and DOCK3 (Dedicator of 
Cytokinesis 3), leading to RAC1 activation and enabling mesenchymal-mode 
movement in three-dimensional environments (Yang et al. 2012). 
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 2. AIM OF THE STUDY 
 
The aim of this study (main body of dissertation and attached manuscript II) was 
to identify genes that mediate Twist1 effects in thyroid cancer cells.  
The specific aims were as follows: 
 
1.  To study the functional consequences of silencing of top up-regulated 
genes on cell proliferation and survival. 
 
2.  To study the functional consequences of silencing of top up-regulated 
genes on cell migration. 
 
3.  To study the functional consequences of silencing of top up-regulated 
genes on cell invasion. 
 
 
Besides Twist1 study, projects developed during my PhD program regarded: 
 
- Identification of AGR2, as a novel marker of PTC, involved in thyroid 
cancer cells survival, migration and invasion and in protection from 
Endoplasmic Reticulum (ER) stress (attached manuscript III). 
 
- A novel method to characterize in vivo the VEGFR-2 expression in the 
tumor vasculature of a mouse model of thyroid cancer (Tg-TRK-T1) 
(attached manuscript IV). 
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3. MATERIALS AND METHODS 
 
3.1 Cell lines 
 
Human papillary thyroid cancer cell line TPC, was obtained from M. 
Nagao (Carcinogenesis Division, National Cancer Center Research Institute, 
Tokyo, Japan). The TPC cell line was authenticated based on the unique presence 
of the RET/PTC1 rearrangement. Human anaplastic thyroid cancer cell line, 
CAL62 was purchased from DSMZ (Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH, Braunschweig, Germany). CAL62 cells were DNA 
profiled by short tandem repeat analysis in 2009 and shown to be unique and 
identical to those reported in Schweppe et al. 2008. TPC and CAL62 were grown 
in DMEM (Dulbecco's Modified Eagle Medium), supplemented with 10% FBS 
(fetal bovine serum), L-glutamine and penicillin/streptomycin. HUVEC cells were 
purchased from Lonza and cultured in EBM-2 (Endothelial Cell Basal Medium) 
medium supplemented with SingleQuot growth supplements (Lonza, Switzerland) 
up to passage 7.  
The generation of TPC-Twist1 and CAL62-shTwist1 cells is described in 
the attached manuscript II. 
 
3.2 Tissue samples 
 
Tumors and normal thyroid tissue samples for immunohistochemical 
analysis were retrieved from the files of the Pathology Department of the Hospital 
Central de Asturias (Oviedo University, Asturias, Spain) and of the Hospital 
Clinico Universitario de Santiago de Compostela (Santiago de Compostela 
University, Galicia, Spain). Tumors and normal thyroid tissue samples for RNA 
extraction and quantitative RT-PCR were retrieved from the files of the 
Department of Surgery, University of Pisa (Italy). Detailed histological analysis is 
described in the attached manuscript II.  
 
3.3 Immunohistochemistry 
The experimental procedure is discussed in detail in the attached 
manuscript II. Briefly, slides of tumor sections deparaffinized were incubated with 
a mouse monoclonal antibody against Twist1 (sc-81417, Santa Cruz 
Biotechnology, USA) and processed according to standard procedures. Cases were 
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scored as positive when unequivocal brown staining was observed in the nuclei of 
tumor cells. Immunoreactivity was expressed as the percentage of positively 
stained target cells in four intensity categories [-, no staining; +, low/weak; ++ 
moderate/distinct; +++, high/ intense staining].  
 
 
3.4 Microarray analysis  
 
300 ng purified total RNA from TPC-Twist1 cells (Twist1 mp1, Twist1 
mp2, Twist1 Cl2) and pcDNA control cells was transcribed into cDNA using 
Superscript RT (Invitrogen), in the presence of T7-oligo (dT) 24 primer, 
deoxyribonucleoside triphosphates (dNTPs), and T7 RNA polymerase promoter 
(Invitrogen). An in vitro transcription reaction was then performed to generate 
biotinylated cRNA which, after fragmentation, was used in a hybridization assay 
on Affymetrix U133 plus 2.0 GeneChip microarrays, according to manufacturer's 
protocol (GeneChip 3' ivt Express Kit, Affymetrix). The screening was conducted 
in collaboration with Aarhus Biotechnology (Aarhus, Denmark). Normalization 
was performed by global scaling and analysis of differential expression was 
performed by Microarray Suite software 5.0 (Affymetrix). The final results were 
imported into Microsoft Excel (Microsoft).  
 
 
3.5 Network and gene ontology analysis 
 
For functional analysis, the set of input genes (158 up-regulated and 221 
down-regulated genes) were uploaded into the Ingenuity Pathway Analysis (IPA) 
online tool (Ingenuity System Inc, www.ingenuity.com). IPA is a system that 
transforms large data sets into a group of relevant networks biological processes, 
and pathways, containing direct or indirect relationships between genes based on 
known interactions in the literature. IPA computes a score for each biological 
process according to the fit of the user's set of significant genes. The score 
indicates the likelihood of the genes in a biological process to cluster together due 
to random chance. 
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3.6 RNA extraction, cDNA synthesis, and quantitative real-time PCR 
 
Total RNA was isolated with the RNeasy Kit (Qiagen, Crawley, West 
Sussex, UK). The quality and concentration of the RNA was verified by the 
NanoDrop 2005 (Thermo Scientific). One µg of total RNA from each sample was 
reverse-transcribed with the QuantiTect® Reverse Transcription (Qiagen) 
according to manufacturer’s instructions. The expression level of each gene was 
measured by quantitative PCR assay, using the Universal ProbeLibray Set, Human 
(Roche). PCR reactions were performed in triplicate and fold changes were 
calculated with the formula: 2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference 
between the amplification fluorescent thresholds of the mRNA of interest and the 
mRNA of RNA polymerase 2 used as an internal reference. The primers used 
were:  
- HS6ST2 F: tgcgatcttctccaagattttc, HS6ST2 R: cgatcacggcaaataggaag; 
- CD24 F: ggctttggatttgacattgc, CD24 R: tgcttggatctggggtagat; 
- COL1A1 F: atgttcagctttgtggacctc, COL1A1 R: ctgtacgcaggtgattggtg;  
- KRT7 F: caggctgagatcgacaacatc, KRT7 R: cttggcacgagcatcctt; 
- VANGL2 F: gccagccgcttctacaac, VANGL2 R: tctccaggatccacactgc; 
- PKP2 F: tgtcagaggaaccattgcag, PKP2 R: ggttatgaagaatgcacacacaa; 
- F2RL1 F: tgctagcagcctctctctcc, F2RL1 R: aggcttcttcctttagaggatctatt; 
- LEPREL1 F: tgcagattgcttaattccttga, LEPREL1 R: ctcagggttagccacgaaaa; 
- THRB F: gggcactggtaatttggcta, THRB R: cagaaggaaatcgcagatcc; 
- ZBED2 F: gagagaagtccagagccttgc, ZBED2 R: aagcagctcaccatactccac; 
- ADAMTS5 F: taagccctggtccaaatgc, ADAMTS5 R: aggtccagcaaacagttacca; 
- ID4 F: tgcagtgcgatatgaacgac, ID4 R: gcaggatctccactttgctg; 
- RHOB F: tatgtggccgacattgagg, RHOB R: gcggtcgtagtcctcctg; 
- PDZK1 F: ccggctctgctatctcgt, PDZK1 R: tcatgtacaccccctttttacc 
- PDZK1IP1 F: gcagtcaaccacttctggtg, PDZK1IP1 R: gacggtcaggatcatgtgtg; 
- RNApol F: gcgatgagaacaagatgcaa, RNApol R: cgcaggaagacatcatcatc; 
- Twist1 F: ggctcagctacgccttctc, Twist1 R: ccttctctggaaacaatgacattct. 
 
 
3.7 RNA silencing 
 
TPC-Twist1 cells were transfected with the specific siRNA (Qiagen) in 6-
well plate in triplicate. For each transfection, 5 μl of 100 micromolar siRNA (25 
nM) were mixed with 20 μl of HiPerFect Transfection reagent (Qiagen) and 300 μl 
of Optimem medium (Invitrogen). Following 10 minutes of incubation, the 
transfection mix was delivered to each well and incubated at 37°C for 72h. 
Specific siRNAs (Qiagen) used were: siRNA HS6ST2 (SI04269020), siRNA 
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CD24 (SI04180078), siRNA COL1A1 (SI04434773), siRNA KRT7 
(SI04339776), siRNA F2RL1  (SI04435088), siRNA LEPREL1 (SI04265184), 
siRNA THRB (SI03027535), siRNA ID4 (SI00445389), siRNA RHOB 
(SI00058912), siRNA PDZK1 (SI04314723), siRNA PDZK1IP1 (SI04164587), 
and AllStars Negative Control siRNA (SI03650318). 
 
 
3.8 Trypan-Blue assay 
 
Cells were collected by trypsinization after 48h and 72h of transfection, 
stained for 10 minutes with 0.4% trypan-blue (Sigma) according to manufacturer’s 
instructions, and counted in triplicate with TC10™Automated Cell Counter (Bio-
Rad, Richmond, VA, USA). 
 
 
3.9 Wound Closure Assay 
 
A wound was induced on the confluent monolayer cells by scraping a gap 
using a micropipette tip after 48h of transfection with specific siRNA. Photographs 
were taken at 10 X magnification using phase-contrast microscopy immediately 
after wound incision and 24h later. Pixel densities in the wound areas were 
measured using the Cella software (Olympus Biosystem Gmb) and expressed as 
percentage of wound closure where 100 % is the value obtained at 24h for control 
cells. 
 
 
3.10 Transwell migration and Matrigel assay 
 
 The cells suspension  (1 × 105 cells) was resuspended in serum free culture 
medium (100 μl) and loaded onto the upper well of prehydrated polycarbonate 
membrane filter of 8 μm pore size (Costar, Cambridge, MA) coated with (invasion 
assay) or without (migration assay) 35 μg of reconstituted extracellular matrix 
(Matrigel, BD Biosciences, San Jose, CA). Medium (500 μl) that contained 2.5% 
serum was added to the lower well and cells were allowed to migrate or invade for 
24h at 37°C. Then cells were fixed with 10% glutaraldehyde solution (Sigma-
Aldrich) for 30 minutes, stained with crystal violet in 20% methanol for 30 
minutes, mounted on glass slides using mounting medium and stained with 
Hoechst (Sigma). Cell migration or invasion was quantified by counting the 
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number of stained nuclei in five individual fields in each transwell membrane, by 
fluorescence microscopy, in triplicate. 
 
 
3.11 Collagen Migration and Invasion Assay 
 
The migration into collagen matrix was evaluated with CytoSelected™ 24-
Well Cell Haptotaxis Assay (8 μm, Collagen 1-Coated, Colorimetric Format) (Cell 
Biolabs, San Diego, CA) where Collagen I was present at the bottom side of the 
insert. The invasion through collagen matrix was evaluated with CytoSelected™ 
24-Well Cell Invasion assay (Collagen 1, Colorimetric Format) (Cell Biolabs) 
where Collagen I was present at the upper side of the insert. The cells suspension 
(1 × 105 cells) was resuspended in serum free culture medium (300 μl) seeded on 
the inside of each insert and allow to migrate or invade toward 2.5% FBS for 24h. 
Migratory or invaded cells were stained and quantified at OD 560 nm after color 
extraction. 
 
 
3.12 Transendothelial Cell Migration Assay 
 
Millipore’s QCM™ Tumor Cell Transendothelial Migration Assay was 
used to analyze the ability of tumor cells to invade the endothelium. HUVEC 
(1x105 cells) were grown to confluence for 48h on cell culture inserts coated with 
fibronectin and then treated with 20 ng/ml of TNFα for 18h. The cells suspension  
(1 × 105 cells) was resuspended in serum free culture medium (250 μl) added on 
the endothelial layer and left to migrate for 24h at 37°C. Media (500 μl) that 
contained 2.5% serum was added to the lower well. Migrated cells were stained 
and color intensity was measured by OD 560 nm according to the assay 
instruction. 
 
 
3.13 Statistical analysis 
 
Data are presented as mean ± standard deviation. Two-tailed paired 
Student’s t test (normal distributions and equal variances) was used for statistical 
analysis. Differences were significant when p < 0.05. Statistical analyses were 
carried out using the GraphPad InStat software program (version 3.1a, San Diego, 
CA). 
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4. RESULTS 
 
4.1 Up-regulation of Twist1 in ATC 
 
We evaluated Twist1 expression levels by immunohistochemistry in 157 
human tissues including: 15 normal thyroids (NT), 13 PTC, 88 PDC, and 41 ATC 
samples. The data are detailed in the attached manuscript II. Twist1 was virtually 
undetectable in NT, PTC, and PDC samples. In contrast, 49% of the ATC samples 
were positive for Twist1 expression (Figure 4).  
 
 
 
Figure 4. Immunohistochemical analysis of Twist1 protein expression in normal and 
malignant thyroid tissues. Representative histological sections from NT, classical PTC, follicular 
variant PTC, PDC and ATC stained with a mouse monoclonal anti-Twist1 antibody are shown. 
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Twist1 positivity correlated with moderate/high proliferation rate assessed 
by Ki67/MIB1 immunoreactivity. Twist1 expression correlated with the 
fusocellular ATC phenotype and inversely correlated with the epithelioid ATC 
phenotype, suggesting that Twist1 is involved in mesenchymal transition of ATC 
cells (attached manuscript II). Accordingly, there was a trend toward a correlation 
between Twist1 up-regulation and lack of β-catenin staining at the plasma 
membrane (data not shown). 
To determine whether Twist1 up-regulation also occurred at the RNA 
level, we examined an independent set of ATC, PDC, PTC, and NT samples by 
quantitative RT-PCR. Twist1 mRNA was up-regulated by more than 5-fold in 
about 50% of the ATC samples (data are described in detail in the attached 
manuscript II). NT, PTC, and PDC samples on average expressed lower Twist1 
levels compared to ATC (Figure 5). 
 
 
 
 
Figure 5. Quantitative RT-PCR of Twist1 mRNA in NT, PDC and ATC snap-frozen tissue 
samples. The level of Twist1 expression in each sample was measured by comparing its 
fluorescence threshold with the average fluorescence threshold of the NT samples. 
 
Finally, silencing of Twist1 by RNA interference in ATC cells reduced cell 
migration and invasion and increased sensitivity to apoptosis. On the contrary, the 
ectopic expression of Twist1 in thyroid cells (TPC-Twist1) induced resistance to 
apoptosis and increased cell migration and invasion (data are described in detail in 
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the attached manuscript II). Thus, these data suggest that Twist1 plays a 
pleiotropic role in determining the anaplastic thyroid cancer phenotype. 
 
4.2 Identification of Twist1 target genes 
 
To determine the molecular mechanisms by which Twist1 regulates 
anaplastic thyroid cancer phenotype, we analyzed gene expression profiles in 
TPC-Twist1 cells in comparison to control cells. Total RNA extracted from three 
TPC-Twist1 stable transfectants (Twist1 mp1, Twist1 mp2 and Twist1 Cl2) was 
used to examine gene expression profile in comparison to vector control cells 
(pcDNA). The screening was conducted in collaboration with Aarhus 
Biotechnology (Aarhus, Denmark) using the human Genome U133 Plus 2.0 Array 
GeneChips (Affymetrix) containing > 47.000 gene transcripts. We analyzed only 
the genes that were changed in all the three Twist1 transfectants compared to 
vector control cells. Genes were analyzed only if the signal intensity was ≥ 50. We 
found 158 genes up-regulated (attached Table 1) and 221 down-regulated 
(attached Table 2) by more than 1.5 fold in TPC-Twist1 cells compared to control 
cells.  
We used the Ingenuity pathways Analysis (IPA) (Ingenuity Systems, 
www.ingenuity.com) to classify Twist1 target genes. Consistent with the 
biological function of Twist1 in ATC, the top three molecular and cellular bio 
functions enriched in TPC-Twist1 cells compared to vector control were: cellular 
movement, cellular growth and proliferation, cell death and survival (Figure 6). 
Other top bio functions enriched were: cancer, reproductive system disease, tissue 
development, tumor morphology (Figure 6).  
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Figure 6. Summary of IPA’s analysis. List of Top Bio Function is divided in three different 
categories: Disease and Disorders, Molecular and Cellular Function, Physiological System 
Development and Function. The number of genes and p values corresponding to each single 
function are indicated on the right side.  
 
In detail 53.6% (203/379) of the genes that changed 1.5 fold, belonged to: 
Cellular Movement, Cellular Growth and Proliferation, Cell Death and Survival. 
17.6% (67/379) belonged to other top functions (mainly to cancer) and 28.7% 
(109/379) of genes were not classified (Figure 7). 
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Figure 7. Graphic representation of IPA’s classification. The number of the genes is reported on 
y axis. 
 
 
There was no difference in the distribution in the different groups among 
up-regulated and down-regulated genes (data not shown).  
Among the top three molecular and cellular function: ~33.5% of the genes 
were common to all three categories (Cellular Growth and Proliferation/ Cell 
Death and Survival/ Cellular Movement), ~28.6% were present in two different 
categories, and ~38% of the genes was present in a single category (Figure 8). 
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Figure 8. Graphic representation of IPA’s classification. The number of the genes is reported on 
y axis.  
 
 
This work has been focused on the up-regulated genes, because more is 
known about the role of Twist1 as transcriptional activator. We studied the up-
regulated genes by ≥ 4 fold (Table 3). PDZK1IP1, up-regulated ∼3 fold, was also 
studied because it is the interacting protein of PDZK1, a gene up-regulated by 3.99 
fold (Carnero 2012) (Table 3). 
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Table 3. List of top up-regulated genes ≥ 4 fold. 
 
Gene Fold Change IPA Molecular and Cellular Bio Function 
HS6ST2 10.28 Cellular Growth and Proliferation 
CD24 8.66 Cellular Growth and Proliferation/ Cell Death and Survival/ Cellular Movement 
COL1A1 7.22 Cellular growth and Proliferation/ Cell Death and Survival/ Cellular Movement 
GFRA1 6.91 Cellular growth and Proliferation/ Cell Death and Survival/ Cellular Movement 
KRT7 5.56 Cellular growth and Proliferation/ Cellular Movement 
VANGL2 5.48 Cellular Assembly and Organization/ Cellular Function and Maintenance 
MXRA8 5.41 Cancer 
PKP2 5.33 Cellular Assembly and Organization 
F2RL1 5.31 Cellular growth and Proliferation/ Cell Death and Survival/ Cellular Movement 
LEPREL1 4.99 Cellular Growth and Proliferation 
THRB 4.88 Cellular growth and Proliferation/ Cellular Movement 
ZBED2 4.59 Not Classified 
ADAMTS5 4.36 Cancer 
ID4 4.33 Cellular growth and Proliferation/ Cell Death and Survival 
RHOB 4.13 Cellular Growth and Proliferation/ Cell Death and Survival/ Cellular Movement 
PDZK1 3.99 Cellular Growth and Proliferation/ Cell Death and Survival 
PDZK1IP1 2.90 Cellular Growth and Proliferation 
 
 
Initially, we confirmed the microarray data by performing quantitative RT-
PCR of the top 17 up-regulated genes, in the cell lines used in the screening in 
comparison to vector control cells. As shown in Figure 9, the quantitative RT-
PCR confirmed the microarray screening, albeit with some variability in the 
different Twist1 clones. The expression of MXRA8 and GFRA1 was undetectable 
by quantitative RT-PCR and thus these genes were not further studied. 
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Figure 9. Quantitative RT-PCR in TPC-Twist1 cells. Quantitative RT-PCR of the indicated 
genes in TPC-Twist1 cells in comparison to vector control cells (pcDNA mp). Values represents 
the average of triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 (***) 
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4.3 Down-regulation of the Twist1 target genes in CAL62-shTwist1 cells 
 
To further confirm that Twist1 transcriptionally regulates these genes, we 
studied whether silencing of Twist1 affected their expression levels. Thus, we 
performed quantitative RT-PCR of the top 15 up-regulated target genes in the 
ATC, CAL62 cell line stably transfected with an shTwist1 plasmid. CAL62 cell 
line presents high endogenous level of Twist1 (attached manuscript II). In CAL62-
shTwist1 cells, Twist1 mRNA was down-regulated of ∼ 2 fold (Figure 10) and 
Twist1 ablation affected several hallmarks of malignancy, including anchorage 
independent proliferation, survival, and invasion (attached manuscript II).  
 
 
 
Figure 10. Quantitative RT-PCR of Twist1 in CAL62 sh-Twist1 cells. Quantitative RT-PCR of 
Twist1 in CAL62 sh-Twist1 cells in comparison to vector control cells (shLUC mp). Values 
represents the average of triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 
(***). 
 
 
As shown in Figure 11, transfection of CAL62 with a Twist1 shRNA promoted a 
blunted expression of mRNAs of up-regulated genes respect to the control cell (p 
< 0.001).  
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Figure 11. Quantitative RT-PCR in CAL62-shTwist1 cells. Quantitative RT-PCR of the 
indicated genes in CAL62-shTwist1 cells in comparison to control. Values represents the average 
of triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 (***). 
 
4.4 Silencing of Twist1 positive targets in TPC-Twist1 cells impairs cell 
viability 
 
Of the top 15 up-regulated genes confirmed by RT-PCR, VANGL2, PKP2, 
ADAMTS5 that belong to other top functions or ZBED2 that was not classified by 
the IPA’s software (Table 3), were not further studied.  
Thus, we transiently transfected TPC-Twist1 cells with siRNA of HS6ST2, 
CD24, COL1A1, KRT7, F2RL1, LEPREL1, THRB, ID4, RHOB, PDZK1, 
PDZK1IP1 or a scrambled siRNA and examined at 48 and 72 hours post-
transfection cell viability using trypan blue assay. As shown in Figure 12A, 
transient silencing of these genes decreased cell number in TPC-Twist1 cells at 
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different time points. Silencing of COL1A1, KRT7 and PDZK1 increased also the 
cell death (in particular at 72 hours post-transfection).  
Then, we verified by quantitative RT-PCR that the specific siRNA silenced 
the corresponding gene. Transfection of siRNA of HS6ST2, CD24, COL1A1, 
KRT7, F2RL1, LEPREL1, THRB, ID4, RHOB, PDZK1 and PDZK1IP1 in TPC-
Twist1 cells efficiently down-regulated the specific gene, albeit with some 
variability (p < 0.001) (Figure 12B). 
 
 
 
 
Figure 12. Silencing of the top 11 genes impairs cell viability. A. TPC-Twist1 cells were 
transfected with indicated siRNA or scrambled siRNA; after 48 and 72 hours, cells were collected 
by trypsinization, stained for 10 min with trypan-blue and counted. B. Cells were transiently 
transfected with the indicated siRNA. After 48 and 72 hours RNA was extracted and mRNA 
expression levels were measured by quantitative RT-PCR. Results are reported as fold change in 
comparison to the scrambled control. Values represents the average of triplicate experiments ± 
standard deviations. Asterisks indicate p < 0.001 (***). 
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4.5 Silencing of HS6ST2, THRB, ID4, RHOB and PDZK1IP1 in TPC-Twist1 
cells impairs cell migration 
 
Another of the most enriched molecular and cellular functions in TPC-
Twist1 cells was cellular movement. Thus, to study whether the silencing of top 
up-regulated genes impaired the cell migration ability, we performed a wound 
closure assay. We selected HS6ST2, THRB, ID4, RHOB and PDZK1IP1 because 
silencing of these genes affected the cell viability less than the silencing of the 
other genes (Figure 12). 
A scraped wound was introduced on the confluent monolayer of TPC-
Twist1 cells transfected with specific siRNAs or scrambled siRNA, and the cell 
migration into the wound was monitored after 24 hours. Wound closure was 
measured by calculating pixel densities in the wound area using Cella software 
(Olympus Biosystem Gmb) and expressed as percentage of wound closure of 
triplicate areas ± standard deviations. TPC-Twist1 cells transfected with the 
scrambled control efficiently migrated into the wound; by contrast, cells 
transfected with HS6ST2, THRB, ID4, RHOB and PDZK1IP1 siRNA had a 
reduced migrating ability (p < 0.001) (Figure 13A). The result was particularly 
evident in TPC-Twist1 transfected with siRNA of RHOB or PDZK1IP1 (Figure 
13A). Quantitative analysis of wound closure assay is shown in Figure 13B. 
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Figure 13. Silencing of indicated genes reduces the migration ability through the wound of 
TPC-Twist1 cells. A. Cells were transfected with specific siRNA, 48h post transfection scratch 
wounds were inflicted on confluent cell monolayer and after 24h cells were photographed. B. 
Wound closure was measured by calculating pixel densities in the wound area and expressed as 
percentage of wound closure of triplicate areas ± standard deviations. Asterisks indicate p < 0.001 
(***). 
 
 
To further study the effect of the silencing of HS6ST2, THRB, ID4, RHOB 
and PDZK1IP1 on cell migration ability, we performed a transwell migration 
assay. TPC-Twist1 cells were transfected with specific siRNA or scrambled 
control, 48 hours post transfection cells were collected, counted and plated on top 
of transwell insert. The lower chambers were filled with media that contained 
2.5% serum. Cells were allowed to migrate for 24h (Figure 14A) and quantified 
by counting the number of migrated cells in three different fields (Figure 14B). 
The transwell migration assay showed that silencing of HS6ST2, THRB, ID4, 
RHOB and PDZK1IP1 reduced the number of migrated cells, and in particular the 
silencing of RHOB decreased the ability to migrate in transwell of ~49%. 
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Figure 14. Silencing of indicated genes reduces the migration ability through the transwell of 
the TPC-Twist1 cells. A. 48h post-transfection cells were seeded in upper chamber of transwells 
and allowed to migrate for 24h. The upper surface of the filter was wiped clean, and cells on the 
lower surface were stained and counted in three different fields. B. Migration ability was expressed 
as number of migrated cells. Values represents the average of triplicate experiments ± standard 
deviations. Asterisks indicate p < 0.001 (***). 
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Silencing of HS6ST2, THRB, ID4, RHOB and PDZK1IP1 in TPC-Twist1 cells 
impairs cell migration in Collagen I matrix 
 
To further investigate the migration ability of these cells, we evaluated the 
migration rate through the Collagen I matrix.  
We initially evaluated TPC-Twist1 cells ability to migrate within collagen I 
matrix. TPC-Twist1 and control cells (pcDNA), were plated onto the 
polycarbonate membrane inserts coated with Collagen I matrix at the bottom side. 
After 24 hours migrated cells on the bottom of the polycarbonate membrane were 
stained, photographed (Figure 15A) and quantified at OD 560 nm after color 
extraction (Figure 15B). As shown in Figure 15, Twist1 increased (∼2 fold) the 
ability of TPC cells to migrate into Collagen I matrix. 
 
 
 
 
 
Figure 15. Twist1 increases the ability of TPC cells to migrate in collagen I matrix. 
A. Cells were seeded onto the insert and incubated for 24h. After 24h cells were stained and 
photographed. B. Migration ability was expressed as absorbance at OD 560 nm. Values represent 
the average of triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 (***). 
 
 
Then, we studied whether the silencing of HS6ST2, THRB, ID4, RHOB and 
PDZK1IP1 affected the ability of TPC-Twist1 cells to migrate into Collagen I 
matrix. TPC-Twist1 cells were transfected with specific siRNA or scrambled 
control and after 48 hours, cells were collected, counted and plated on the insert. 
After 24 hours of incubation, cells were colored and photographed (Figure 16A) 
and quantified by measuring the absorbance at OD 560 nm (Figure 16B). 
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Figure 16. Silencing of indicated genes reduces the migration ability through the Collagen I 
matrix of the TPC-Twist1 cells. A. Forty-eight hours post-transfection cells were seeded on the 
insert coated with Collagen I matrix at the bottom side and allowed to migrate for 24h. Then, cells 
were stained and photographed. B. Migration ability was expressed as absorbance at OD 560 nm. 
Values represent the average of triplicate experiments ± standard deviations. Asterisks indicate p < 
0.001 (***). 
 
 
TPC-Twist1 cells transfected with HS6ST2, THRB, ID4, RHOB and 
PDZK1IP1 siRNA presented a decreased ability to migrate in Collagen I matrix 
compared to siRNA scrambled transfected cells. In particular the silencing of 
RHOB and PDZK1IP1 reduced the migration ability in Collagen I matrix of ~64% 
and ~62% respectively. 
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4.6 Silencing of HS6ST2, THRB, ID4, RHOB and PDZK1IP1 in TPC-Twist1 
cells impairs cell invasion  
 
We asked whether TPC-Twist1 cells were more or less able to invade the 
Collagen I matrix compare to TPC-pcDNA vector control cells. 
Thus TPC-Twist1 and TPC-pcDNA cells were plated on the membrane 
insert coated at the upper surface with a uniform layer of dried Bovine Type I 
Collagen matrix, and allowed to invade for 24 hours. Hence cells were stained 
(Figure 18 A) and quantified (Figure 18 B). As shown in the figure below, Twist1 
increased the ability of TPC cells to invade the Collagen I matrix of ∼2 fold. 
 
 
 
 
Figure 18. Twist1 increases the ability of TPC cells to invade the Collagen I matrix. 
A. TPC-Twist1 and TPC-pcDNA cells were seeded on insert and allowed to invade for 24h. B. 
Invasive ability was expressed as absorbance at OD 560 nm. Values represents the average of 
triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 (***). 
 
 
Then, TPC-Twist1 cells were transfected with HS6ST2, THRB, ID4, RHOB 
and PDZK1IP1 siRNA or with siRNA scrambled for 48 hours and then were 
plated into the chamber coated with Collagen I matrix. After 24 hours of invasion, 
cells were stained, photographed (Figure 19 A) and quantified at OD 560 nm 
(Figure 19 B). The silencing of HS6ST2, THRB, ID4, RHOB and PDZK1IP1 
reduced the ability of TPC-Twist1 cells to invade the Collagen I matrix compared 
to cells transfected with scrambled siRNA. In particular silencing of RHOB 
reduced the ability to invade the Collagen I matrix of ~32%. 
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Figure 19. Silencing of indicated genes reduces the invasion ability in Collagen I matrix of 
TPC-Twist1 cells. A. TPC-Twist1 cells were seeded in the upper chamber of transwells coated 
with Collagen I matrix and incubated for 24 hours; the upper surface of the filter was wiped clean 
and cells on the lower surface were stained and counted. B. Invasive ability was expressed as 
absorbance at OD 560 nm. Values represents the average of triplicate experiments ± standard 
deviations. Asterisks indicate p < 0.001 (***). 
 
 
Silencing of HS6ST2, THRB, ID4, RHOB and PDZK1IP1 in TPC-Twist1 cells 
impairs cell invasion in Matrigel 
 
Twist1 increased the invasion ability of TPC cells of about 5 fold in 
Matrigel (attached manuscript II). Thus, we transfected TPC-Twist1 cells with 
HS6ST2, THRB, ID4, RHOB and PDZK1IP1 siRNA or with scrambled siRNA. At 
48 hours post transfection cells were seeded into the top chamber of transwells 
coated with Matrigel. The cells were allowed to invade for 24 hours and 
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photographed (Figure 17 A). The quantification of the assay was performed by 
counting the number of invaded cells in three different fields (Figure 17 B).  
 
 
 
 
Figure 17. Silencing of indicated genes reduces the invasion ability in Matrigel of the TPC-
Twist1 cells. A. TPC-Twist1 transfected cells were seeded in the upper chamber of transwells 
coated with Matrigel and incubated for 24 hours; the upper surface of the filter was wiped clean 
and cells on the lower surface were stained and counted. B. Invasive ability was expressed as 
number of invaded cells. Values represents the average of triplicate experiments ± standard 
deviations. Asterisks indicate p < 0.001 (***). 
 
 
The TPC-Twist1 cells transfected with HS6ST2, THRB, ID4, RHOB and 
PDZK1IP1 specific siRNA presented a reduced ability to invade Matrigel 
compared to siRNA scrambled transfected cells. In particular the silencing of 
RHOB and PDZK1IP1 induced a dramatic reduction of ~86% and ~84% 
respectively, of invasion ability. 
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4.7 Silencing of HS6ST2, THRB, ID4, RHOB and PDZK1IP1 in TPC-Twist1 
cells impairs transendothelial cell migration 
 
The cell ability to penetrate into the endothelium represents another 
important aspect of tumor progression. In order to investigate this phenomenon we 
performed a transendothelial cell migration assay.  
To this aim, the endothelial cell line HUVEC, was plated and allowed to 
grow to confluence on 8 µm pore size cell culture insert coated with fibronectin. 
HUVEC cells were then activated with TNFα for 18 hours. TPC-Twist1 and 
control TPC-pcDNA cells were plated on confluent monolayer of activated 
HUVEC cells and allowed to migrate for 24 hours. After 24 hours, cells were 
stained (Figure 20 A) and quantified by measuring the absorbance at OD 560 nm 
(Figure 20 B). TPC-Twist1 cells presented an increased ability to migrate through 
endothelial cells compared to control cells. HUVEC cells did not migrate. 
 
 
 
 
Figure 20. Twist1 increased the ability of TPC cells to migrate through endothelium cells. A. 
Cells were seeded on confluent monolayer of endothelial HUVEC cells and incubated for 24h. 
After 24h cells were stained and photographed. HUVEC only was used as negative control. B. 
Quantification of the assay, migration ability was expressed as absorbance at OD 560 nm. Values 
represents the average of triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 
(***). 
 
 
Then we studied whether the silencing of HS6ST2, THRB, ID4, RHOB and 
PDZK1IP1 affected the ability to migrate through endothelial cells. 
TPC-Twist1 cells were transfected with specific siRNA for 48 hours and 
then plated on confluent monolayer of activated HUVEC cells and left to migrate 
for 24 hours. Migrated cells were stained, photographed (Figure 21 A) and 
quantified at OD 560 nm (Figure 21 B). As it is shown in figure 21, TPC-Twist1 
cells transfected with HS6ST2, THRB, ID4 and PDZK1IP1 siRNA presented a 
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modest decrease in the transendothelial cell migration ability compared to cells 
transfected with scrambled siRNA. Noteworthy, silencing of RHOB decreased this 
ability of ~35%. 
 
 
 
 
 
Figure 21. Silencing of indicated genes reduces the migration ability through endothelial cells 
of the TPC-Twist1 cells. A. Cells were seeded on confluent monolayer of endothelial HUVEC 
cells 48h post-transfection and left to migrate for 24h. Then, cells were stained and photographed. 
B. Migration ability was expressed as absorbance at OD 560 nm. Values represents the average of 
triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 (***). 
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5. DISCUSSION 
 
Thyroid cancer includes tumor types as different as well differentiated 
carcinomas that have a very good prognosis and undifferentiated carcinomas or 
ATC that are among the most aggressive human cancers and present a dismal 
prognosis. The molecular players sustaining such aggressive behavior are largely 
unknown. 
In this Dissertation, we have demonstrated that Twist1 is up-regulated in 
ATC and that silencing of Twist1 by RNA interference in ATC cells reduced cell 
migration and invasion and increased sensitivity to apoptosis. The ectopic 
expression of Twist1 in thyroid carcinoma cells induced resistance to apoptosis 
and increased cell migration and invasion (attached manuscript II).  
Although some direct and indirect targets of Twist1 have been identified, 
the exact mechanisms through which Twist1 contributes to tumorigenesis are still 
largely unknown. This Dissertation focused on the identification of Twist1 target 
genes in thyroid carcinoma cells. To this aim, we have performed a gene 
expression profile of Twist1 overexpressing cells in comparison to control cells. 
Gene signature obtained was enriched for genes involved in cellular movement, 
cellular growth and proliferation, cell death and survival consistent with the role of 
Twist1 in anaplastic thyroid cancer cells. 
We focused on the up-regulated genes because more is known about the 
role of Twist1 as transcriptional activator. The top up-regulated genes by more 
than 4 fold studied were: HS6ST2, CD24, COL1A1, KRT7, F2RL1, LEPREL1, 
THRB, ID4, RHOB, PDZK1, PDZK1IP1. 
HS6ST2 is a member of the heparan sulfate (HS) sulfotransferase gene 
family. Heparan sulfate proteoglycans are ubiquitous components of the cell 
surface, extracellular matrix, and basement membranes, and interact with various 
ligands to influence cell growth, differentiation, adhesion, and migration. HS6ST2, 
catalyze the transfer of sulfate to HS (Song et al. 2011). 
CD24 is a glycosylphosphatidylinositol-anchored membrane protein with a 
small protein core and a high level of glycosylation. It is overexpressed in many 
human carcinomas and is correlated with poor prognosis. CD24 is a marker for 
pancreatic and ovarian cancer stem cells, whereas breast cancer stem cells are 
negative for CD24. CD24 has been shown to recruit adhesion molecules to lipid 
rafts, thereby contributing to tumor cell migration, dissemination and metastasis 
(Bretz et al. 2012).  
COL1A1 encodes the pro-alpha1 chains of type I collagen whose triple 
helix comprises two alpha1 chains and one alpha2 chain (Speakman 1968). 
KRT7 is a member of the keratin gene family. The type II cytokeratins 
consist of basic or neutral proteins which are arranged in pairs of heterotypic 
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keratin chains coexpressed during differentiation of simple and stratified epithelial 
tissues (Harbaum et al. 2011). 
F2RL1, also known as PAR2, is a member of the large family of 7-
transmembrane-region receptors that couple to guanosine-nucleotide-binding 
proteins. F2RL1 is also a member of the protease-activated receptor family (Zhang 
et al. 2012). 
LEPREL1 encodes a member of the prolyl 3-hydroxylase subfamily of 2-
oxo-glutarate-dependent dioxygenases. These enzymes play a critical role in 
collagen chain assembly, stability and cross-linking by catalyzing post-
translational 3-hydroxylation of proline residues (Fernandes et al. 2011).  
THRB is a nuclear hormone receptor for triiodothyronine. It is one of the 
several receptors for thyroid hormone, and has been shown to mediate the 
biological activities of thyroid hormone (Kim and Cheng 2012). 
ID proteins (ID-1 to 4) are dominant negative regulators of basic helix-
loop-helix transcription factors. They play a key role during development, 
preventing cell differentiation while inducing cell proliferation. They are poorly 
expressed in adult life but can be reactivated in tumorigenesis. Several evidences 
indicate that ID proteins are associated with loss of differentiation, unrestricted 
proliferation and neoangiogenesis in diverse human cancers (Dell’Orso et al. 
2010).  
RHOB is a member of the Ras superfamily small GTPases. Overexpression 
of RHO GTPases in human tumors often correlates with a poor prognosis. 
Furthermore, coordinated RHO GTPase signaling is considered to be part of 
mechanism underlying tumor cell invasion (Street et al. 2011).  
PDZK1 is a member of the Na+/H+ exchanger regulatory family (NHERF) 
and is a multi-PDZ domain containing protein, possessing four PDZ domains. 
These domains facilitate the interaction of PDZK1 with a range of binding partners 
(Birrane et al. 2013).  
PDZK1IP1 (interacting protein PDZK1) is a small 17 kDa non-
glycosylated membrane protein overexpressed in a great variety of human 
carcinomas. Immunohistochemical analysis of PDZK1IP1 during cancer 
progression shows, at least in prostate and ovarian carcinomas, that overexpression 
of the protein strongly correlates with tumoral progression. Moreover, it was 
described that PDZK1IP1 promoter is activated by different oncogenes (Guijarro 
et al. 2007).  
The data presented in this dissertation showed that Twist1 effects on 
thyroid cancer cell survival are mediated by COL1A1, KRT7 and PDZK1 target 
genes, while Twist1 effects on thyroid cancer cell migration and invasion are 
mediated by HS6ST2, THRB, ID4, RHOB and PDZK1IP1 genes with a prominent 
effect mediated by RHOB.  
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Further studies are on going in our laboratory to test the expression levels 
of the 11 identified Twist1 target genes in thyroid carcinoma samples in 
comparison to normal thyroids. We will correlate target genes expression with 
Twist1 levels. Based on the results obtained, we will further perform western blot 
and immunohistochemistry studies to clarify the role of these genes in thyroid 
carcinogenesis.  
We are currently verifying whether Twist1 binds to the promoter of the 
identified genes. Possible binding sites for Twist1 are E-box (5’-CANNTG-3’) 
sequence motif. In the promoter of all 11 up-regulated genes we have found 
several E-box sequences. We are performing chromatin immunoprecipitation to 
formally prove that these genes are direct Twist1 targets. 
Identification of genes downstream transcription factors is important for 
clinical translation of basic research. Directly inhibiting the transcription factors is 
currently difficult, as targeting large binding interfaces is not amenable to small-
molecule inhibition. Instead, downstream targets of these transcription factors 
could be more realistic for therapeutic intervention. 
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Gene Title Gene Symbol Fold Change SD
Chromosomal 
Loca9on
Cellular 
Growth and 
Prolifera9on
Cell Death 
and 
Survival
Cellular 
Movement
Other 
func9ons
Not 
Classiﬁed
heparan sulfate 6‐O‐
sulfotransferase 2 HS6ST2 10,28173122 0,351188458 chrXq26.2 X
CD24 molecule CD24 8,662800421 1,817507451 chr6q21 X X X
collagen, type I, alpha 1 COL1A1 7,222289403 1,410673598 chr17q21.33 X X X
GDNF family receptor alpha 1 GFRA1 6,919557528 0,608276253 chr10q26 X X X
keraPn 7 KRT7 5,567294029 0,8326664 chr12q12‐q13 X X
vang‐like 2 (van gogh, 
Drosophila) VANGL2 5,480655757 0,305505046 chr1q22‐q23 X
matrix‐remodelling associated 
8  MXRA8 5,415015976 0,577350269 chr1p36.33 X
plakophilin 2 PKP2 5,339337988 0,873689495 chr12p11 X
coagulaPon factor II 
(thrombin) receptor‐like 1 F2RL1 5,312989839 0,953939201 chr5q13 X X X
leprecan‐like 1 LEPREL1 4,994543441 0,472581563 chr3q28 X
thyroid hormone receptor, 
beta (erythroblasPc leukemia 
viral (v‐erb‐a) oncogene 
homolog 2, avian) THRB 4,883874803 0,871779789 chr3p24.2 X X
zinc ﬁnger, BED‐type 
containing 2 ZBED2 4,597610544 0,655743852 chr3q13.13 X
ADAM metallopepPdase with 
thrombospondin type 1 moPf, 
5 (aggrecanase‐2) ADAMTS5 4,369317144 0,850490055 chr21q21.3 X
inhibitor of DNA binding 4, 
dominant negaPve helix‐loop‐
helix protein ID4 4,336721203 0,264575131 chr6p22‐p21 X X
ras homolog gene family, 
member B RHOB 4,135412309 0,611010093 chr2p24 X X X
PDZ domain containing 1 PDZK1 3,993886633 0,550757055 chr1q21 X X
netrin 4 NTN4 3,979515052 0,75055535 chr12q22‐q23 X X X
papilin, proteoglycan‐like 
sulfated glycoprotein PAPLN 3,94748841 0,702376917 chr14q24.2 X
Supplemental Table 1: Genes upregulated by Twist1 by ≥1.5 fold
cytochrome P450, family 24, 
subfamily A, polypepPde 1 CYP24A1 3,895790353 0,971253486 chr20q13 X
ﬁlaggrin FLG 3,72986228 0,692820323 chr1q21.3 X
NUAK family, SNF1‐like kinase, 
2 NUAK2 3,644961964 0,519615242 chr1q32.1 X X
coiled‐coil domain containing 
80 CCDC80 3,585786458 0,86216781 chr3q13.2 X
transforming growth factor, 
beta‐induced, 68kDa TGFBI 3,504545129 0,2 chr5q31 X X X
Suppression of tumorigenicity 
7 like ST7L 3,453420992 0,871779789 chr1p13.2 X
prostaglandin I2 (prostacyclin) 
synthase PTGIS 3,43195669 0,776745347 chr20q13.13 X
transgelin TAGLN 3,405866218 1,006644591 chr11q23.2 X
mal, T‐cell diﬀerenPaPon 
protein 2 MAL2 3,381182308 0,519615242 chr8q23 X
EGF‐like repeats and discoidin I‐
like domains 3 EDIL3 3,288688661 0,635085296 chr5q14 X X
tumor‐associated calcium 
signal transducer 1 TACSTD1 3,241226113 0,953939201 chr2p21 X X
death‐associated protein 
kinase 1 DAPK1 3,211787362 0,6244998 chr9q34.1 X
LIM and cysteine‐rich domains 
1 LMCD1 3,202603619 0,461880215 chr3p26‐p24 X
WAS protein family, member 3 WASF3 3,116089412 0,585946528 chr13q12 X
microphthalmia‐associated 
transcripPon factor MITF 2,945811369 0,854400375 chr3p14.2‐p14.1 X X X
phospholipase C, beta 4 PLCB4 2,936408568 0,793725393 chr20p12 X
ADAM metallopepPdase with 
thrombospondin type 1 moPf, 
1 ADAMTS1 2,930214545 0,781024968 chr21q21.2 X X X
chromosome 10 open reading 
frame 65 HOGA1 2,924178087 0,611010093 chr10q24.1 X
PDZK1 interacPng protein 1 PDZK1IP1 2,901835211 0,577350269 chr1p33 X
inositol(myo)‐1(or 4)‐
monophosphatase 2 IMPA2 2,835027268 0,550757055 chr18p11.2 X
doublecorPn domain 
containing 2 DCDC2 2,765568919 0,642910051 chr6p22.1 X
Cbp/p300‐interacPng 
transacPvator, with Glu/Asp‐
rich carboxy‐terminal domain, 
2 CITED2 2,717517969 0,86216781 chr6q23.3 X X X
homolog of rat pragma of 
Rnd2 PRAGMIN 2,645044724 0,56862407 chr8p23.1 X
myosin, light chain kinase MYLK 2,580367042 0,642910051 chr3q21 X X X
thrombospondin 1 THBS1 2,470516694 0,4163332 chr15q15 X X X
Kv channel interacPng protein 
1 KCNIP1 2,446433025 0,608276253 chr5q35.1 X
argininosuccinate synthetase 1 ASS1 2,429964151 0,702376917 chr9q34.1 X
O‐6‐methylguanine‐DNA 
methyltransferase MGMT 2,419540831 0,4163332 chr10q26 X X
endothelial PAS domain 
protein 1 EPAS1 2,36398258 0,435889894 chr2p21‐p16 X X X
syncoilin, intermediate 
ﬁlament 1 SYNC1 2,361554172 0,585946528 chr1p34.3‐p33 X
alpha‐kinase 2 ALPK2 2,336479509 0,513160144 chr18q21.31 X
ring ﬁnger 144B RNF144B 2,28151547 0,503322296 chr6p22.3 X
apolipoprotein L domain 
containing 1 APOLD1 2,267236721 0,702376917 chr12p13.1 X
ribokinase RBKS 2,2545217 0,404145188 chr2p23.3 X
cystaPn E/M CST6 2,2545217 0,404145188 chr11q13 X X
SRY (sex determining region Y)‐
box 4 SOX4 2,247681135 0,556776436 chr6p22.3 X X
GLIS family zinc ﬁnger 3 GLIS3 2,246526787 0,529150262 chr9p24.2 X
ATPase, class II, type 9A ATP9A 2,246526787 0,529150262 chr20q13.2 X
melanoma cell adhesion 
molecule MCAM 2,24373728 0,519615242 chr11q23.3 X X X
RAB40B, member RAS 
oncogene family RAB40B 2,237691725 0,351188458 chr17q25.3 X
growth arrest‐speciﬁc 6 GAS6 2,216209577 0,251661148 chr13q34 X X X
shroom family member 3 SHROOM3 2,205673738 0,435889894 chr4q21.1 X
transducin‐like enhancer of 
split 4 (E(sp1) homolog, 
Drosophila) TLE4 2,204871835 0,550757055 chr9q21.31 X
secreted phosphoprotein 1 
(osteoponPn, bone 
sialoprotein I, early T‐
lymphocyte acPvaPon 1) SPP1 2,173953455 0,642910051 chr4q21‐q25 X
immediate early response 5‐
like IER5L 2,168360602 0,264575131 chr9q34.11 X
tubulin, alpha 1a TUBA1A 2,148548898 0,550757055 chr12q12‐q14.3 X X
uncoupling protein 2 
(mitochondrial, proton carrier) UCP2 2,103543126 0,404145188 chr11q13 X X X
collagen, type IV, alpha 1 COL4A1 2,09569795 0,057735027 chr13q34 X X X
small nuclear RNA acPvaPng 
complex, polypepPde 1, 43kDa SNAPC1 2,093480906 0,519615242 chr14q22 X
odz, odd Oz/ten‐m homolog 2 
(Drosophila) ODZ2 2,057218164 0,550757055 chr5q34‐q35.1 X X
UDP‐glucose ceramide 
glucosyltransferase UGCG 2,057218164 0,550757055 chr9q31 X
prickle homolog 1 (Drosophila) PRICKLE1 2,051577463 0,4 chr12q12 X
suppressor of cytokine 
signaling 2 SOCS2 2,004667006 0,550757055 chr12q X X X
interleukin 11 IL11 2,003204303 0,1
chr19q13.3‐
q13.4 X X X
tufelin 1 TUFT1 1,962675136 0,404145188 chr1q21 X
mixed lineage kinase 4 KIAA1804 1,95883413 0,404145188 chr1q42 X
enabled homolog (Drosophila) ENAH 1,95855963 0,115470054 chr1q42.12 X
PRKC, apoptosis, WT1, 
regulator PAWR 1,95571516 0,529150262 chr12q21 X X
PHD ﬁnger protein 17 PHF17 1,951719066 0,37859389 chr4q26‐q27 X
family with sequence similarity 
83, member H FAM83H 1,942631582 0,321455025 chr8q24.3 X
arresPn domain containing 3 ARRDC3 1,941529905 0,5 chr5q14.3 X X
Bardet‐Biedl syndrome 10 BBS10 1,931443504 0,458257569 chr12q21.2 X
keraPn 80 KRT80 1,914189457 0,4 chr12q13.13 X
transmembrane, prostate 
androgen induced RNA TMEPAI 1,90636884 0,360555128
chr20q13.31‐
q13.33 X X
progesterone receptor 
membrane component 2 PGRMC2 1,903870091 0,360555128 chr4q26 X
myosin, light chain 9, 
regulatory MYL9 1,900435804 0,346410162 chr20q11.23 X
phospholipase C, epsilon 1 PLCE1 1,887667543 0,264575131 chr10q23 X X
transducin‐like enhancer of 
split 1 (E(sp1) homolog, 
Drosophila) TLE1 1,872534505 0,404145188 chr9q21.32 X
ﬁbroblast growth factor 2 
(basic) FGF2 1,867503395 0,37859389 chr4q26‐q27 X X X
RNA binding moPf, single 
stranded interacPng protein RBMS3 1,861009508 0,513160144 chr3p24‐p23 X
glutaminase GLS 1,859225418 0,351188458 chr2q32‐q34 X
Zinc ﬁnger protein 84 ZNF84 1,851404801 0,305505046 chr12q24.33 X
zinc ﬁnger protein 91 ZNF91 1,841776492 0,251661148 chr19p13.1‐p12 X
Rho guanine nucleoPde 
exchange factor (GEF) 5 ARHGEF5 1,836384281 0,2081666 chr7q33‐q35 X
RegulaPng synapPc membrane 
exocytosis 2 RIMS2 1,833669061 0,4163332 chr8q22.3 X
heterogeneous nuclear 
ribonucleoprotein A3 HNRPA3 1,831240653 0,404145188 chr2q31.2 X
GLI‐Kruppel family member 
GLI2 GLI2 1,827656868 0,404145188 chr2q14 X X X
LIM domain and acPn binding 
1 LIMA1 1,817570466 0,351188458 chr12q13 X
transmembrane emp24 
domain traﬃcking protein 2 TMED2 1,812539356 0,321455025 chr12q24.31 X
FOS‐like anPgen 2 FOSL2 1,80210051 0,458257569 chr2p23.3 X X X
hepaPPs A virus cellular 
receptor 1 HAVCR1 1,800121539 0,251661148 chr5q33.2 X
KIAA0802 KIAA0802 1,798202369 0,458257569 chr18p11.22 X
par‐3 parPPoning defecPve 3 
homolog (C. elegans) PARD3 1,797518837 0,230940108
chr10p11.22‐
p11.21 X
SMAD family member 7 SMAD7 1,778705022 0,360555128 chr18q21.1 X X X
kalirin, RhoGEF kinase KALRN 1,778705022 0,360555128 chr3q21.1‐q21.2 X
eukaryoPc translaPon 
elongaPon factor 1 alpha 1 EEF1A1 1,776276614 0,346410162 chr6q14.1 X X
Cysteine rich transmembrane 
BMP regulator 1 (chordin‐like) CRIM1 1,776276614 0,346410162 chr2p21 X X
protease, serine, 23 PRSS23 1,776276614 0,346410162 chr11q14.1 X
unc‐51‐like kinase 2 (C. 
elegans) ULK2 1,765837768 0,472581563 chr17p11.2 X
angiomoPn like 2 AMOTL2 1,763571984 0,461880215 chr3q21‐q22 X
collagen, type XVIII, alpha 1 COL18A1 1,743890634 0,1 chr21q22.3 X X X
placenta‐speciﬁc 8 PLAC8 1,743714804 0,404145188 chr4q21.22 X X
heat shock 22kDa protein 8 HSPB8 1,724993353 0,288675135 chr12q24.23 X X
guanine nucleoPde binding 
protein (G protein), gamma 4 GNG4 1,71843823 0,251661148 chr1q42.3 X
UDP‐N‐acetyl‐alpha‐D‐
galactosamine:polypepPde N‐
acetylgalactosaminyltransferas
e 4 (GalNAc‐T4) GALNT4 1,708607945 0,404145188 chr12q21.3‐q22 X
WW and C2 domain containing 
1 WWC1 1,707627892 0,152752523 chr5q35.1 X
heterogeneous nuclear 
ribonucleoprotein R HNRNPR 1,702235682 0,057735027 chr1p36.12 X
F11 receptor F11R 1,699070132 0,37859389 chr1q21.2‐q21.3 X X
galecPn‐related protein HSPC159 1,69585321 0,351188458 chr2p14 X
Fucosyltransferase 1 
(galactoside 2‐alpha‐L‐
fucosyltransferase, H blood 
group) FUT1 1,69585321 0,351188458 chr19q13.3 X
thioredoxin reductase 2 TXNRD2 1,68141923 0,458257569 chr22q11.21 X X X
KIT ligand KITLG 1,68141923 0,458257569 chr12q22 X
dual speciﬁcity phosphatase 
16 DUSP16 1,677144378 0,230940108 chr12p13 X
RAB11 family interacPng 
protein 1 (class I) RAB11FIP1 1,677144378 0,230940108 chr8p11.22 X
inhibitor of DNA binding 1, 
dominant negaPve helix‐loop‐
helix protein ID1 1,677039394 0,435889894 chr20q11 X X X
family with sequence similarity 
115, member A FAM115A 1,677039394 0,435889894 chr7q35 X X X
cylindromatosis (turban tumor 
syndrome) CYLD 1,673793557 0,2081666 chr16q12.1 X X X
B‐cell CLL/lymphoma 2 BCL2 1,673793557 0,2081666
chr18q21.33|18
q21.3 X X X
cleavage and polyadenylaPon 
speciﬁc factor 6, 68kDa CPSF6 1,673793557 0,2081666 chr12q15 X
tumor necrosis factor, alpha‐
induced protein 2 TNFAIP2 1,66639871 0,4 chr14q32 X
prenylcysteine oxidase 1 PCYOX1 1,657324683 0,346410162 chr2p13.3 X
NUAK family, SNF1‐like kinase, 
1 NUAK1 1,648004234 0,3 chr12q23.3 X X
armadillo repeat containing, X‐
linked 3 ARMCX3 1,648004234 0,3
chrXq21.33‐
q22.2 X X
pleiomorphic adenoma gene‐
like 1 PLAGL1 1,645470844 0,461880215 chr6q24‐q25 X X
zinc ﬁnger protein 395 ZNF395 1,643310043 0,264575131 chr8p21.1 X
vesicle‐associated membrane 
protein 3 (cellubrevin) VAMP3 1,643310043 0,264575131 chr1p36.23 X
mitochondrial ribosomal 
protein L30 MRPL30 1,632499705 0,173205081 chr2q11.2 X
zinc ﬁnger protein 260 ZNF260 1,630135968 0,404145188 chr19q13.12 X
myristoylated alanine‐rich 
protein kinase C substrate MARCKS 1,627107495 0,1 chr6q22.2 X
Ribosomal protein L37 RPL37 1,624504793 1,05367E‐08 chr5p13 X
phosphoribosyl pyrophosphate 
synthetase 1 PRPS1 1,611741492 0,305505046 chrXq21.32‐q24 X
nephroblastoma 
overexpressed gene NOV 1,600570055 0,230940108 chr8q24.1 X X X
ROD1 regulator of 
diﬀerenPaPon 1 (S. pombe) ROD1 1,598665371 0,2081666 chr9q32 X
programmed cell death 6 
interacPng protein PDCD6IP 1,598665371 0,2081666 chr3p22.3 X
CDC14 cell division cycle 14 
homolog B (S. cerevisiae) CDC14B 1,598665371 0,2081666 chr9q22.33 X
nucleosome assembly protein 
1‐like 1 NAP1L1 1,596301634 0,4163332 chr12q21.2 X
zinc ﬁnger protein 558 ZNF558 1,593273161 0,152752523 chr19p13.2 X
lysophosphaPdylcholine 
acyltransferase 2 LPCAT2 1,582286993 0,351188458 chr16q12.2 X
glucosamine (N‐acetyl)‐6‐
sulfatase (Sanﬁlippo disease 
IIID) GNS 1,56709682 0,251661148 chr12q14 X
arginine vasopressin‐induced 1 AVPI1 1,56170461 0,2081666 chr10q24.2 X
KIAA1600 KIAA1600 1,557010418 0,152752523 chr10q25.3 X
deleted in liver cancer 1 DLC1 1,554407716 0,115470054 chr8p22 X X X
mex‐3 homolog D (C. elegans) MEX3D 1,548452659 0,360555128 chr19p13.3 X
dopey family member 2 DOPEY2 1,533262485 0,264575131 chr21q22.2 X
ubiquiPn‐conjugaPng enzyme 
E2H (UBC8 homolog, yeast) UBE2H 1,532250111 0,264575131 chr7q32 X
cysteine‐rich, angiogenic 
inducer, 61 CYR61 1,525441868 0,2 chr1p31‐p22 X X X
collagen, type IV, alpha 2 COL4A2 1,525441868 0,2 chr13q34 X X X
protein‐L‐isoaspartate (D‐
aspartate) O‐
methyltransferase domain 
containing 1 PCMTD1 1,518144974 0,1 chr8q11.23 X
keraPn 81 KRT81 1,518144974 0,1 chr12q13 X
acPn binding LIM protein 1 ABLIM1 1,501693935 0,288675135 chr10q25 X
Gene Title Gene Symbol Fold Change SD
Chromosomal 
Loca9on
Cellular 
Growth and 
Prolifera9on
Cell Death 
and 
Survival
Cellular 
Movement
Other 
func9ons
Not 
Classiﬁed
peroxisomal biogenesis factor 
5‐like PEX5L ‐32,00208893 3,247049943 chr3q26.33 X
NADPH oxidase, EF‐hand 
calcium binding domain 5 NOX5 ‐25,62317608 2,821937868 chr15q23 X
hydroxysteroid (11‐beta) 
dehydrogenase 1 HSD11B1 ‐24,5629411 2,214347157 chr1q32‐q41 X
protocadherin 7 PCDH7 ‐23,26581277 2,571640203 chr4p15 X
interleukin 13 receptor, alpha 
2 IL13RA2 ‐23,05602193 2,653927907 chrXq13.1‐q28 X X
granzyme A (granzyme 1, 
cytotoxic T‐lymphocyte‐
associated serine esterase 3) GZMA ‐19,474627 1,365039682 chr5q11‐q12 X
Rho GTPase acPvaPng protein 
9 ARHGAP9 ‐15,03306137 1,855622088 chr12q14 X
interleukin 1, beta IL1B ‐13,13285389 2,107921567 chr2q14 X X X
hematopoiePc cell‐speciﬁc Lyn 
substrate 1 HCLS1 ‐12,83846002 2,025668614 chr3q13 X X X
G protein‐coupled receptor 65 GPR65 ‐11,24875416 1,44222051 chr14q31‐q32.1 X
FAT tumor suppressor 
homolog 3 (Drosophila) FAT3 ‐9,696293796 2,023198787 chr11q14.3 X
solute carrier family 22 
(organic caPon transporter), 
member 18 anPsense SLC22A18AS ‐9,626602845 1,644181661 chr11p15.5 X
BCL2‐related protein A1 BCL2A1 ‐9,266625608 1,662327685 chr15q24.3 X X
linker for acPvaPon of T cells 
family, member 2 LAT2 ‐8,215015976 1,40118997 chr7q11.23 X
serpin pepPdase inhibitor, 
clade D (heparin cofactor), 
member 1 SERPIND1 ‐8,148234742 1,607275127
chr22q11.2|22q
11.21 X
heat shock 70kDa protein 1A HSPA1A ‐7,849436164 1,473091986 chr6p21.3 X X X
Supplemental Table 2: Genes downregulated by Twist1 by ≥1.5 fold
myeloma overexpressed gene 
(in a subset of t(11;14) posiPve 
mulPple myelomas) MYEOV ‐7,781161268 0,680685929 chr11q13 X
gap juncPon protein, beta 2, 
26kDa GJB2 ‐7,678658707 1,703917056 chr13q11‐q12 X X X
protease, serine, 3 
(mesotrypsin) PRSS3 ‐7,638278029 1,258305739 chr9p11.2 X
growth hormone receptor GHR ‐7,38077076 1,006644591 chr5p13‐p12 X X
interleukin 1, alpha IL1A ‐7,078349034 1,106044002 chr2q14 X X X
synaptotagmin‐like 3 SYTL3 ‐6,859924827 1,473091986 chr6q25.3 X
vanin 1 VNN1 ‐6,593199654 0,916515139 chr6q23‐q24 X
SLAIN moPf family, member 1 SLAIN1 ‐6,301788353 1,053565375 chr13q22.3 X
keraPn 15 KRT15 ‐6,145492176 1,135781669 chr17q21.2 X
baculoviral IAP repeat‐
containing 3 BIRC3 ‐6,133066583 1,27410099 chr11q22 X X
podoplanin PDPN ‐6,117213292 1,30511813 chr1p36.21 X X
Pssue factor pathway inhibitor 
2 TFPI2 ‐6,022029743 1,386842938 chr7q22 X X X
chemokine (C‐X‐C moPf) ligand 
3 CXCL3 ‐5,685529409 0,680685929 chr4q21 X X X
interleukin 7 IL7 ‐5,619632538 0,971253486 chr8q12‐q13 X X X
phosphaPdylinositol 3,4,5‐
trisphosphate‐dependent RAC 
exchanger 1 PREX1 ‐5,467587256 1,115048579 chr20q13.13 X
epithelial membrane protein 1 EMP1 ‐5,466602544 1,703917056 chr12p12.3 X X
sorbin and SH3 domain 
containing 1 SORBS1 ‐5,363523592 1,27410099
chr10q23.3‐
q24.1 X
neurotrimin HNT ‐5,311194879 1,011599394 chr11q25 X
absent in melanoma 1 AIM1 ‐5,183017519 1,078579312 chr6q21 X
signal‐regulatory protein beta 
1 SIRPB1 ‐5,17400814 1,2489996 chr20p13 X
thrombomodulin THBD ‐5,131473598 0,37859389 chr20p11.2 X X
Rho GDP dissociaPon inhibitor 
(GDI) beta ARHGDIB ‐4,985514301 1,153256259 chr12p12.3 X X
G0/G1switch 2 G0S2 ‐4,876670142 1,18462371 chr1q32.2‐q41 X
solute carrier family 7 (caPonic 
amino acid transporter, y+ 
system), member 7 SLC7A7 ‐4,806772314 0,850490055 chr14q11.2 X
carbohydrate (keratan sulfate 
Gal‐6) sulfotransferase 1 CHST1 ‐4,765182973 1,289702808
chr11p11.2‐
p11.1 X
metastasis suppressor 1 MTSS1 ‐4,707740182 0,602771377 chr8p22 X
olfactomedin‐like 2B OLFML2B ‐4,608607945 0,404145188 chr1q23.3 X
lysosomal associated 
mulPspanning membrane 
protein 5 LAPTM5 ‐4,546080177 1,18462371 chr1p34 X
ChaC, caPon transport 
regulator homolog 1 (E. coli) CHAC1 ‐4,48800712 0,953939201 chr15q15.1 X
WD repeat domain 16 WDR16 ‐4,464309867 0,529150262 chr17p13.1 X
N‐deacetylase/N‐
sulfotransferase (heparan 
glucosaminyl) 2 NDST2 ‐4,44771527 1,115048579 chr10q22 X
potassium channel 
tetramerisaPon domain 
containing 12 KCTD12 ‐4,345765045 0,929157324 chr13q22.3 X
WD repeat domain 66 WDR66 ‐4,310515196 1,113552873 chr12q24.31 X
frizzled homolog 8 
(Drosophila) FZD8 ‐4,264582737 0,945163125 chr10p11.21 X
Friend leukemia virus 
integraPon 1 FLI1 ‐4,181212521 0,953939201
chr11q24.1‐
q24.3 X X
stanniocalcin 1 STC1 ‐4,119437063 1,00166528 chr8p21‐p11.2 X X X
neuromedin U NMU ‐4,040514615 0,493288286 chr4q12 X
sine oculis binding protein 
homolog (Drosophila) SOBP ‐4,039766071 0,793725393 chr6q21 X
secretory leukocyte pepPdase 
inhibitor SLPI ‐4,039766071 0,793725393 chr20q12 X X X
FOS‐like anPgen 1 FOSL1 ‐4,025425219 0,665832812 chr11q13 X X X
HOP homeobox HOPX ‐4,000069042 0,754983444 chr4q11‐q12 X
roundabout homolog 4, magic 
roundabout (Drosophila) ROBO4 ‐3,99855086 0,602771377 chr11q24.2 X
interleukin 27 receptor, alpha IL27RA ‐3,976064992 0,7 chr19p13.11 X X X
protein tyrosine phosphatase, 
receptor type, N polypepPde 2 PTPRN2 ‐3,940633834 0,655743852 chr7q36 X
interleukin 7 receptor IL7R ‐3,931569838 0,850490055 chr5p13 X X
coronin, acPn binding protein, 
2B CORO2B ‐3,902653924 1,069267662 chr15q23 X
sprouty homolog 4 
(Drosophila) SPRY4 ‐3,88679978 0,838649708 chr5q31.3 X
pentraxin‐related gene, rapidly 
induced by IL‐1 beta PTX3 ‐3,847033709 0,642910051 chr3q25 X X
sema domain, immunoglobulin 
domain (Ig), transmembrane 
domain (TM) and short 
cytoplasmic domain, 
(semaphorin) 4B SEMA4B ‐3,834270139 0,776745347 chr15q25 X
glycine dehydrogenase 
(decarboxylaPng) GLDC ‐3,818011156 0,602771377 chr9p22 X
cysPn 1 CYS1 ‐3,805593339 0,56862407 chr2p25.1 X
cortacPn CTTN ‐3,765607731 1,040833 chr11q13 X X
leucine rich repeat neuronal 3 LRRN3 ‐3,624993353 0,321455025 chr7q31.1 X
spen homolog, transcripPonal 
regulator (Drosophila) SPEN ‐3,612935374 0,964365076
chr1p36.33‐
p36.11 X
v‐maf musculoaponeuroPc 
ﬁbrosarcoma oncogene 
homolog F (avian) MAFF ‐3,608241183 0,953939201 chr22q13.1 X
methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 2‐like MTHFD2L ‐3,591563779 0,850490055 chr4q13.3 X
Solute carrier family 20 
(phosphate transporter), 
member 1 SLC20A1 ‐3,446013344 0,305505046 chr2q11‐q14 X X
coiled‐coil domain containing 4 CCDC4 ‐3,436091026 0,550757055 chr4p13 X
laminin, gamma 2 LAMC2 ‐3,420203012 0,8326664 chr1q25‐q31 X
six transmembrane epithelial 
anPgen of the prostate 1 STEAP1 ‐3,368923358 0,6 chr7q21 X
G protein‐coupled receptor 92 GPR92 ‐3,3138468 0,458257569 chr12p13.31 X
nuclear receptor interacPng 
protein 3 NRIP3 ‐3,29952912 0,665832812 chr11p15.3 X
ATP synthase mitochondrial F1 
complex assembly factor 2 ATPAF2 ‐3,209763044 0,611010093 chr17p11.2 X
Rho GTPase acPvaPng protein 
22 ARHGAP22 ‐3,181882232 0,550757055 chr10q11.22 X X
transmembrane protein 163 TMEM163 ‐3,180937097 0,721110255 chr2q21.3 X
calmin (calponin‐like, 
transmembrane) CLMN ‐3,165679684 0,493288286 chr14q32.13 X
phytoceramidase, alkaline PHCA ‐3,155785481 0,814452782 chr11q13.5 X
high mobility group AT‐hook 1 HMGA1 ‐3,14486116 0,655743852 chr6p21 X X X
tumor necrosis factor (TNF 
superfamily, member 2) TNF ‐3,139665967 0,4163332 chr6p21.3 X X X
caPon channel, sperm 
associated 1 CATSPER1 ‐3,129743648 0,608276253 chr11q12.1 X
leupaxin LPXN ‐3,103904226 0,556776436 chr11q12.1 X
ras‐related C3 botulinum toxin 
substrate 2 (rho family, small 
GTP binding protein Rac2) RAC2 ‐3,070069891 0,458257569 chr22q13.1 X X X
cystaPn F (leukocystaPn) CST7 ‐3,064677681 0,435889894 chr20p11.21 X
C‐type lecPn domain family 11, 
member A CLEC11A ‐3,040406025 0,346410162 chr19q13.3 X X X
CD44 molecule (Indian blood 
group) CD44 ‐2,954288755 0,577350269 chr11p13 X X X
dedicator of cytokinesis 4 DOCK4 ‐2,925812237 0,692820323 chr7q31.1 X X
cytochrome P450, family 2, 
subfamily J, polypepPde 2 CYP2J2 ‐2,922882828 0,493288286 chr1p31.3‐p31.2 X X X
glycerophosphodiester 
phosphodiesterase domain 
containing 5 GDPD5 ‐2,892167463 0,404145188
chr11q13.4‐
q13.5 X
fumarylacetoacetate hydrolase 
(fumarylacetoacetase) FAH ‐2,891815279 0,6244998 chr15q23‐q25 X X
cyclin D1 CCND1 ‐2,887121087 0,608276253 chr11q13 X X X
eukaryoPc translaPon 
iniPaPon factor 3, subunit M EIF3M ‐2,881357125 0,351188458 chr11p13 X
coiled‐coil and C2 domain 
containing 2A CC2D2A ‐2,862655829 0,251661148 chr4p15.33 X
kynureninase (L‐kynurenine 
hydrolase) KYNU ‐2,860910353 0,723417814 chr2q22.2 X
interleukin‐1 receptor‐
associated kinase 2 IRAK2 ‐2,831443504 0,458257569 chr3p25.3 X
arresPn, beta 1 ARRB1 ‐2,831443504 0,458257569 chr11q13 X X X
EH‐domain containing 1 EHD1 ‐2,831443504 0,458257569 chr11q13 X X
SPC24, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) SPC24 ‐2,829027446 0,665832812 chr19p13.2 X
axin 2 (conducPn, axil) AXIN2 ‐2,814189457 0,4 chr17q23‐q24 X X
UDP‐N‐acetyl‐alpha‐D‐
galactosamine:polypepPde N‐
acetylgalactosaminyltransferas
e 12 (GalNAc‐T12) GALNT12 ‐2,804474836 0,776745347 chr9q22.33 X
Protocadherin alpha cluster PCDHA ‐2,803870091 0,360555128 chr5q31 X
serine/threonine kinase 17b STK17B ‐2,803870091 0,360555128 chr2q32.3 X X
microtubule associated 
serine/threonine kinase family 
member 4 MAST4 ‐2,79812252 0,757187779 chr5q12.3 X
Tetraspanin 18 TSPAN18 ‐2,793059753 0,3 chr11p11.2 X
tumor necrosis factor (ligand) 
superfamily, member 9 TNFSF9 ‐2,76654162 0,503322296 chr19p13.3 X X X
FERM domain containing 4A FRMD4A ‐2,759244726 0,472581563 chr10p13 X
EGF, latrophilin and seven 
transmembrane domain 
containing 1 ELTD1 ‐2,755051535 0,665832812 chr1p33‐p32 X
sorPng nexin 8 SNX8 ‐2,739201172 0,404145188 chr7p22.2 X
tribbles homolog 3 
(Drosophila) TRIB3 ‐2,733220637 0,781024968 chr20p13‐p12.2 X
anPgen p97 (melanoma 
associated) idenPﬁed by 
monoclonal anPbodies 133.2 
and 96.5 MFI2 ‐2,721217201 0,585946528 chr3q28‐q29 X
glucuronidase, beta 
pseudogene 1 GUSBP1 ‐2,694067418 0,115470054 chr5q13.2 X
unc‐5 homolog B (C. elegans) UNC5B ‐2,68964865 0,493288286 chr10q22.1 X X X
cytochrome P450, family 2, 
subfamily R, polypepPde 1 CYP2R1 ‐2,667002394 0,4163332 chr11p15.2 X
AHNAK nucleoprotein AHNAK ‐2,64587269 0,321455025 chr11q12.2 X
progesPn and adipoQ receptor 
family member VIII PAQR8 ‐2,62186864 0,152752523 chr6p12.1 X
adaptor‐related protein 
complex 1, sigma 2 subunit AP1S2 ‐2,60210051 0,458257569 chrXp22.2 X
oligonucleoPde/oligosaccharid
e‐binding fold containing 1 OBFC1 ‐2,597406319 0,435889894 chr10q24.33 X
UDP‐GlcNAc:betaGal beta‐1,3‐
N‐
acetylglucosaminyltransferase‐
like 1 B3GNTL1 ‐2,576373606 0,360555128 chr17q25.3 X
zinc ﬁnger CCCH‐type 
containing 12C ZC3H12C ‐2,576276614 0,346410162 chr11q22.3 X
SH3‐domain binding protein 5 
(BTK‐associated) SH3BP5 ‐2,557579098 0,550757055 chr3p24.3 X
abhydrolase domain 
containing 2 ABHD2 ‐2,557579098 0,550757055 chr15q26.1 X
adenylate kinase 5 AK5 ‐2,549669862 0,173205081 chr1p31 X
glycine‐N‐acyltransferase‐like 1 GLYATL1 ‐2,543890634 0,1 chr11q12.1 X
Rho GTPase acPvaPng protein 
18 ARHGAP18 ‐2,513585774 0,404145188 chr6q22.33 X
OTU domain, ubiquiPn 
aldehyde binding 2 OTUB2 ‐2,509108946 0,4163332 chr14q32.13 X
RAB38, member RAS oncogene 
family RAB38 ‐2,444207062 0,37859389 chr11q14 X
ventricular zone expressed PH 
domain homolog 1 (zebraﬁsh) VEPH1 ‐2,420203012 0,305505046 chr3q24‐q25 X
dysbindin (dystrobrevin 
binding protein 1) domain 
containing 2 /// SYS1‐DBNDD2
DBNDD2 /// SYS1‐
DBNDD2 ‐2,407126891 0,2081666 chr20q13.12 X
carbonyl reductase 4 CBR4 ‐2,377039394 0,435889894 chr4q32.3 X
pleckstrin homology‐like 
domain, family A, member 1 PHLDA1 ‐2,377039394 0,435889894 chr12q15 X X
dihydropyrimidinase‐like 3 DPYSL3 ‐2,377039394 0,435889894 chr5q32 X X
popeye domain containing 3 POPDC3 ‐2,36639871 0,4 chr6q21 X
oxysterol binding protein‐like 6 OSBPL6 ‐2,359590467 0,360555128 chr2q31‐q32.1 X
UV radiaPon resistance 
associated gene UVRAG ‐2,348004234 0,3 chr11q13.5 X
serpin pepPdase inhibitor, 
clade A (alpha‐1 
anPproteinase, anPtrypsin), 
member 1 SERPINA1 ‐2,342225007 0,264575131 chr14q32.1 X X X
osteoclast associated, 
immunoglobulin‐like receptor OSCAR ‐2,334928113 0,2 chr19q13.42 X
reelin RELN ‐2,327107495 0,1 chr7q22 X
rho/rac guanine nucleoPde 
exchange factor (GEF) 2 ARHGEF2 ‐2,314251562 0,472581563 chr1q21‐q22 X
CDC42 eﬀector protein (Rho 
GTPase binding) 4 CDC42EP4 ‐2,292422799 0,37859389 chr17q24‐q25 X
ERO1‐like beta (S. cerevisiae) ERO1LB ‐2,278408159 0,305505046 chr1q42.2‐q43 X
diﬀerenPally expressed in 
FDCP 6 homolog (mouse) DEF6 ‐2,265332037 0,2081666
chr6p21.33‐
p21.1 X X
proteasome (prosome, 
macropain) subunit, beta type, 
9 (large mulPfuncPonal 
pepPdase 2) PSMB9 ‐2,259939827 0,152752523 chr6p21.3 X
CD82 molecule CD82 ‐2,249349678 0,493288286 chr11p11.2 X X X
protein kinase (cAMP‐
dependent, catalyPc) inhibitor 
alpha PKIA ‐2,229634967 0,4163332 chr8q21.12 X
family with sequence similarity 
131, member A FAM131A ‐2,229634967 0,4163332 chr3q27.1 X
centaurin, delta 2 CENTD2 ‐2,215620327 0,351188458 chr11q13.4 X
citron (rho‐interacPng, 
serine/threonine kinase 21) CIT ‐2,211240491 0,321455025 chr12q24 X X X
jun dimerizaPon protein 2 JDP2 ‐2,207238396 0,305505046 chr14q24.3 X X
HIV‐1 Tat interacPve protein 2, 
30kDa HTATIP2 ‐2,204448889 0,288675135 chr11p15.1 X X
integrin‐linked kinase ILK ‐2,200430153 0,251661148
chr11p15.5‐
p15.4 X X X
nuclear factor of kappa light 
polypepPde gene enhancer in 
B‐cells inhibitor, alpha NFKBIA ‐2,200430153 0,251661148 chr14q13 X X X
endothelin converPng enzyme 
1 ECE1 ‐2,200430153 0,251661148 chr1p36.1 X
t‐complex 11 (mouse)‐like 1 TCP11L1 ‐2,195037943 0,2081666 chr11p13 X
transforming growth factor 
beta regulator 1 TBRG1 ‐2,195037943 0,2081666 chr11q24.2 X
zinc ﬁnger protein 91 homolog 
(mouse) ZFP91 ‐2,148452659 0,360555128 chr11q12 X
ﬁbrillin 2 (congenital 
contractural arachnodactyly) FBN2 ‐2,148452659 0,360555128 chr5q23‐q31 X X
extra spindle pole bodies 
homolog 1 (S. cerevisiae) ESPL1 ‐2,137642321 0,3 chr12q X X
tumor necrosis factor receptor 
superfamily, member 11a, 
NFKB acPvator TNFRSF11A ‐2,137642321 0,3 chr18q22.1 X X
family with sequence similarity 
149, member A FAM149A ‐2,133262485 0,264575131 chr4q35.2 X
faoy acid desaturase 1 FADS1 ‐2,132250111 0,264575131
chr11q12.2‐
q13.1 X
amyloid beta (A4) precursor‐
like protein 2 APLP2 ‐2,132250111 0,264575131
chr11q23‐
q25|11q24 X
hydroxymethylbilane synthase HMBS ‐2,125441868 0,2 chr11q23.3 X
CD40 molecule, TNF receptor 
superfamily member 5 CD40 ‐2,122839165 0,173205081 chr20q12‐q13.2 X X X
moesin MSN ‐2,076826968 0,173205081 chrXq11.2‐q12 X X
deformed epidermal 
autoregulatory factor 1 
(Drosophila) DEAF1 ‐2,070474653 0,305505046 chr11p15.5 X
LysM, putaPve pepPdoglycan‐
binding, domain containing 2 LYSMD2 ‐2,070474653 0,305505046 chr15q21.2 X
cysteinyl‐tRNA synthetase CARS ‐2,022735422 0,4163332 chr11p15.5 X
solute carrier family 39 (zinc 
transporter), member 8 SLC39A8 ‐2,020762942 0,404145188 chr4q22‐q24 X
6‐pyruvoyltetrahydropterin 
synthase PTS ‐2,001838683 0,305505046
chr11q22.3‐
q23.3 X
CHK1 checkpoint homolog (S. 
pombe) CHEK1 ‐1,99923598 0,288675135 chr11q24‐q24 X X
transmembrane protein 41B TMEM41B ‐1,995486367 0,251661148 chr11p15.4 X
Cas‐Br‐M (murine) ecotropic 
retroviral transforming 
sequence CBL ‐1,995486367 0,251661148 chr11q23.3 X X X
ring ﬁnger and FYVE‐like 
domain containing 1 RFFL ‐1,995486367 0,251661148 chr17q12 X
ring ﬁnger protein 26 RNF26 ‐1,993372316 0,230940108 chr11q23 X
transmembrane protein 179B TMEM179B ‐1,993372316 0,230940108 chr11q12.3 X
TRAF‐interacPng protein with 
a forkhead‐associated domain TIFA ‐1,993372316 0,230940108 chr4q25 X
interferon induced 
transmembrane protein 2 (1‐
8D) IFITM2 ‐1,990455258 0,2081666 chr11p15.5 X
HIRA interacPng protein 3 HIRIP3 ‐1,990455258 0,2081666 chr16p11.2 X
proteasome (prosome, 
macropain) 26S subunit, non‐
ATPase, 13 PSMD13 ‐1,990455258 0,2081666 chr11p15.5 X
apolipoprotein B mRNA ediPng 
enzyme, catalyPc polypepPde‐
like 3B APOBEC3B ‐1,986075422 0,152752523
chr22q13.1‐
q13.2 X
ribosomal protein S6 kinase, 
90kDa, polypepPde 5 RPS6KA5 ‐1,986075422 0,152752523 chr14q31‐q32.1 X X X
centaurin, delta 3 CENTD3 ‐1,986075422 0,152752523 chr5q31.3 X X
myosin phosphatase‐Rho 
interacPng protein M‐RIP ‐1,986075422 0,152752523 chr17p11.2 X
paired‐like homeodomain 1 PITX1 ‐1,98138123 0,057735027 chr5q31 X
mulPple C2 domains, 
transmembrane 2 MCTP2 ‐1,98138123 0,057735027 chr15q26.2 X
mitogen‐acPvated protein 
kinase kinase kinase kinase 4 MAP4K4 ‐1,930584484 0,264575131 chr2q11.2‐q12 X X
Rho GTPase acPvaPng protein 
5 ARHGAP5 ‐1,930584484 0,264575131 chr14q12 X X
transmembrane emp24‐like 
traﬃcking protein 10 (yeast) TMED10 ‐1,930584484 0,264575131 chr14q24.3 X
TMEM9 domain family, 
member B TMEM9B ‐1,923287589 0,2 chr11p15.3 X
ﬁbroblast growth factor 
(acidic) intracellular binding 
protein FIBP ‐1,921173538 0,173205081 chr11q13.1 X
WD repeat domain 33 WDR33 ‐1,921173538 0,173205081 chr2q14.3 X
mediator complex subunit 19 MED19 ‐1,920859182 0,173205081 chr11q12.1 X
DIX domain containing 1 DIXDC1 ‐1,916479347 0,1 ‐‐‐ X
coiled‐coil domain containing 
15 CCDC15 ‐1,916479347 0,1 chr11q24.2 X
dehydrogenase/reductase 
(SDR family) member 1 DHRS1 ‐1,916479347 0,1 chr14q12 X
ATP binding domain 4 ATPBD4 ‐1,914213562 0 chr15q14 X
cannabinoid receptor 
interacPng protein 1 CNRIP1 ‐1,862472237 0,251661148 chr2p14 X
CD59 molecule, complement 
regulatory protein CD59 ‐1,862472237 0,251661148 chr11p13 X X X
ribonucleoPde reductase M1 
polypepPde RRM1 ‐1,862472237 0,251661148 chr11p15.5 X X
CDK2‐associated protein 2 CDK2AP2 ‐1,853691514 0,152752523 chr11q13 X
twinﬁlin, acPn‐binding protein, 
homolog 2 (Drosophila) TWF2 ‐1,851577463 0,115470054 chr3p21.1 X
ataxia telangiectasia mutated ATM ‐1,849311679 0,057735027 chr11q22‐q23 X X X
Sin3A‐associated protein, 
30kDa SAP30 ‐1,792876161 0,2081666 chr4q34.1 X
poly(A) polymerase alpha PAPOLA ‐1,78878963 0,152752523 chr14q32.31 X
calcium/calmodulin‐
dependent protein kinase IV CAMK4 ‐1,78878963 0,152752523 chr5q21.3 X X X
peroxiredoxin 5 PRDX5 ‐1,78878963 0,152752523 chr11q13 X
glucosidase, alpha; neutral AB GANAB ‐1,786523846 0,115470054 chr11q12.3 X
traﬃcking protein parPcle 
complex 4 TRAPPC4 ‐1,725708493 0,173205081 chr11q23.3 X
protein phosphatase 2 
(formerly 2A), regulatory 
subunit B'', gamma PPP2R3C ‐1,721621962 0,1 chr14q13.2 X
growth arrest‐speciﬁc 2 like 1 GAS2L1 ‐1,721621962 0,1 chr22q12.2 X
coﬁlin 1 (non‐muscle) CFL1 ‐1,665186445 0,2081666 chr11q13 X X X
microsomal glutathione S‐
transferase 2 MGST2 ‐1,65883413 0,115470054 chr4q28.3 X
metastasis associated lung 
adenocarcinoma transcript 1 
(non‐protein coding) MALAT1 ‐1,656720078 0,057735027 chr11q13.1 X
cyclic AMP phosphoprotein, 19 
kD ARPP‐19 ‐1,533116893 0,1 chr15q21.2 X
calmodulin 1 (phosphorylase 
kinase, delta) CALM1 ‐1,533116893 0,1 chr14q24‐q31 X X
epithelial membrane protein 3 EMP3 ‐1,533116893 0,1 chr19q13.3 X X
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Context: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human tumors; it is
characterized by chemoresistance, local invasion, and distant metastases. ATC is invariably fatal.
Objective: The aim was to study the role of TWIST1, a basic helix-loop-helix transcription factor,
in ATC.
Design: Expression of TWIST1 was studied by immunohistochemistry and real-time PCR in normal
thyroids and well-differentiated, poorly differentiated, and ATC. The function of TWIST1 was
studied by RNA interference in ATC cells and by ectopic expression in well-differentiated thyroid
carcinoma cells.
Results: ATCs up-regulate TWIST1 with respect to normal thyroids as well as to poorly and well-
differentiated thyroid carcinomas.KnockdownofTWIST1byRNA interference inATCcells reduced
cellmigrationand invasionand increased sensitivity toapoptosis. Theectopic expressionof TWIST1
in thyroid cells induced resistance to apoptosis and increased cell migration and invasion.
Conclusions: TWIST1 plays a key role in determining malignant features of the anaplastic pheno-
type in vitro. (J Clin Endocrinol Metab 96: 0000–0000, 2011)
Thyroid neoplasms include a broad spectrum of histo-types, ranging from benign adenomas to differenti-
ated papillary and follicular, poorly differentiated, and
rapidly growing anaplastic carcinomas (1, 2). Papillary
thyroid carcinoma (PTC) far outnumbers the other mor-
phological subtypes and is characterized, in general, by an
indolentphenotypewitha10-yr survival rateofup to90%
(1, 2). Poorly differentiated carcinomas (PDC) include a
heterogeneous group of neoplasms with morphological
features and clinical characteristics intermediate between
those of well-differentiated and anaplastic carcinomas (1,
2). Anaplastic thyroid carcinomas (ATC) represent less
than2%ofall thyroid cancersbut are responsible formore
than 50% of thyroid cancer mortality, with a mean sur-
vival time from diagnosis of 4–12 months (3). ATC is
highly invasive, and themajority of ATCpatients die from
suffocation due to locoregional disease extension or be-
cause of overwhelmingdistantmetastatic disease. Surgical
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treatment, radiotherapy, and chemotherapy, based pri-
marily on doxorubicin and cisplatin, show little efficacy in
ATC patients (3, 4). ATC cells feature a highly mitogenic
and motile phenotype and epithelial-mesenchymal tran-
sitionandare refractory toapoptotic cell death (3, 4).ATC
features genetic lesions that are typical of a well-differen-
tiated carcinoma, namely BRAF or RAS point mutations.
Only a few genetic lesions have been identified exclusively
in ATC, i.e. p53, PI3KCA, or -catenin mutations (5–8).
Therefore, the molecular mechanisms driving the estab-
lishment of the highly aggressive anaplastic phenotype are
still largely unknown (2–5).
We have recently identified, through a cDNAmicroar-
ray analysis, a gene expression signature that is associated
with the highly proliferative and aneuploid ATC pheno-
type (9). Among the genes highly up-regulated in ATC vs.
normal tissue and PTC, we have isolated TWIST1.
TWIST1 is a highly conserved basic helix-loop-helix tran-
scription factor that plays a key role in mesodermal, myo-
blast, and osteoblast differentiation (10, 11). Mutational
inactivation of TWIST1 is responsible for the Saethre-
Chotzen syndrome, an autosomal dominant disorder
characterized by premature fusion of the cranial sutures,
skull deformations, limb abnormalities, and facial dys-
morphism (12). TWIST1 plays an important role in the
development and progression of human cancer. TWIST1
overexpression is reported in many human tumors, in-
cluding rhabdomyosarcoma, glioma, melanoma, breast,
gastric, and prostate carcinomas (13, 14). Elevated
TWIST1 protein levels are associated with advanced tu-
mor stage and poor prognosis in several cancer types (14,
15). TWIST1 promotes epithelial-mesenchymal transition
(16, 17). TWIST1 gene amplification is associated with re-
sistance to chemotherapeutic agents (18, 19). Finally,
TWIST1 inhibits premature senescence in cancer cells (20).
Here we report that TWIST1 plays a key role in the
ATC phenotype in vitro and suggest that it may mediate
chemoresistance of ATC cells.
Materials and Methods
Reagents
Staurosporine and cisplatin were obtained from Sigma-
Aldrich (St. Louis, MO).
Cell cultures
Human cell lines (S11N, P5 4N, 8505C, CAL62, SW1736,
OCUT-2, ACT-1, TPC-1, BCPAP) (21–23), rat cell lines (PC
RET/PTC1, PCRET/PTC3, PC v-HRAS, PC-BRAF-V600E, PC-
TRK-T1, PC v-RAF, PC v-MOS, PC E1A, and PC E1A-v-RAF)
(24, 25), and culture conditions are detailed in the Supplemental
Data (publishedonTheEndocrine Society’s JournalsOnlineweb
site at http://jcem.endojournals.org).
Tissue samples
Tumors and normal thyroid (NT) tissue samples for immu-
nohistochemical analysis were retrieved from the files of the Pa-
thologyDepartment of theHospital Central deAsturias (Oviedo
University, Asturias, Spain) and of the Hospital Clinico Univer-
sitario de Santiago deCompostela (Santiago deCompostelaUni-
versity, Galicia, Spain). Tumors andNT tissue samples for RNA
extractionandquantitativeRT-PCRwere retrieved fromthe files
of the Department of Surgery, University of Pisa (Pisa, Italy).
Case selection was based on the histological findings and on the
availability of adequate material for RNA extraction. All histo-
logical diagnoses were reviewed by two blinded pathologists
(G.G.-R. and C.D.) according to the latest recommendations
about diagnostic features of PTC, PDC, and ATC (26–28). PDC
were defined as malignant tumors of follicular cells displaying
predominant solid/trabecular/insular growth patterns, high-
grade features such asmitoses (more than three to fivemitoses
10 high power field) and/or necrosis and convoluted nuclei, with
or without concurrent differentiated components of the follicu-
lar or papillary type. ATC were defined as tumors displaying
admixtures of spindle, pleomorphic giant, and epithelioid cells;
high mitotic activity; extensive coagulative necrosis with irreg-
ular borders; and infiltration of vascular walls often accompa-
nied by obliteration of the vascular lumina. After microscopic
examinationof exhaustively sampled specimens, 32 tumorswere
classified as PTC, 93 as PDC, and 56 as ATC. Processing of
samples and of patient information proceeded in agreementwith
review board-approved protocols.
Immunohistochemistry
Formalin-fixed and paraffin-embedded 3- to 5-m-thick tu-
mor sections were deparaffinized, placed in a solution of abso-
lute methanol and 0.3% hydrogen peroxide for 30 min, and
treated with blocking serum for 20 min. The slides were incu-
bated with mouse monoclonal antibodies against TWIST1 (sc-
81417; Santa Cruz Biotechnology, Santa Cruz, CA) and pro-
cessed according to standard procedures. Negative controls by
omitting the primary antibody were included in the assay. Cases
were scored as positive when unequivocal brown staining was
observed in the nuclei of tumor cells. Immunoreactivity was ex-
pressed as the percentage of positively stained target cells in four
intensity categories (, no staining; , low/weak; , moder-
ate/distinct; , high/ intense). Twist1 score values were in-
dependently assigned by two blinded investigators (G.G.-R. and
C.D.), and a consensus was reached on all scores used for
computation.
RNA extraction and expression studies
Total RNA was isolated with the RNeasy Kit (QIAGEN,
Crawley, West Sussex, UK). The quality of the RNAs was ver-
ified by the 2100 Bioanalyzer (Agilent Technologies, Wald-
bronn, Germany); only samples with an RNA integrity number
value above 7were used for further analysis. Real-time PCRwas
performed as detailed in the Supplemental Data: for the calcu-
lation of expression fold changes, sample 1 represented each
single tumor sample, and sample 2was the average of all (n22)
NTs.Microarraymethods are also reported in the Supplemental
Data.
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Protein studies
Immunoblotting was carried out according to standard pro-
cedures. Anti-TWIST1 (sc-81417) and anti-p53 (Pab 240)
monoclonal antibodies were from Santa Cruz Biotechnology;
monoclonal anti--tubulin antibody was from Sigma-Aldrich;
anti-cleaved (Asp175) caspase-3 p17 and p19 fragments poly-
clonal (5A1) antibody was from Cell Signaling Technology, Inc.
(Beverly, MA). Secondary antimouse and antirabbit antibodies
coupled to horseradish peroxidase were from Santa Cruz
Biotechnology.
RNA silencing
Small inhibitor duplex RNA targeting TWIST1 (no. 3, 5, and
7) and the scrambled control [nonspecific small interfering RNA
(siRNA) duplex containing the same nucleotides but in irregular
sequence] have been described previously (16) and were chem-
ically synthesized by Sigma-Aldrich. Based on its higher silencing
efficiency, TWIST1 siRNA 3 (hereafter referred to as TWIST1
siRNA) was selected and used throughout the paper. The day of
transfection, 1105 cellswere incubatedwith50nMsiRNAand
electroporated usingMicroPorator (MP-100, Digital Bio; Euro-
clone,Milan, Italy) according to themanufacturer’s instructions.
Cellswere harvested 24, 48, and72hafter transfection, counted,
and analyzed for protein expression.Methods used to determine
cell viability, motility, and invasion are detailed in the Supple-
mental Data.
TWIST1 transfection
The pcDNA 3-TWIST1 vector is described elsewhere (29).
TPC-1 cellswere transfectedbyusing theLipofectamineReagent
(Invitrogen, Carlsbad, CA) according to the instructions of the
manufacturer. Two days later, G418 (Invitrogen) was added at
a concentration of 1.2 mg/ml. Two mass populations of several
clones and three independent cell clones were isolated, ex-
panded, and screened for TWIST1 expression by Western blot
and RT-PCR analysis. One mass population and two cell clones
transfectedwith the control pcDNA3 vectorwere expanded. To
generate stable shRNA (short hairpin RNA)-expressing cell line,
CAL62 cells were transfected with shTWIST1 and shLUC vec-
tors (20) by using the Lipofectamine reagent (Invitrogen) ac-
cording to the instructions of the manufacturer. Two days later,
puromycin (Invitrogen) was added at a concentration of 0.5 mg/
ml. Mass populations and several cell clones were isolated, ex-
panded, and screened for TWIST1 knockdown byWestern blot
and RT-PCR analysis. Methods used to determine cell viability,
motility, and invasion are detailed in the Supplemental Data.
Statistical analysis
Statistical analyses were carried out using the GraphPad In-
Stat softwareprogram(version3.06.3;GraphPadSoftware, Inc.,
San Diego, CA). All P values were two-sided, and differences
were significant when P  0.05.
Results
Up-regulation of TWIST1 in ATC
We evaluated TWIST1 expression levels by immuno-
histochemistry in 157 human tissues including: 15NT, 13
PTC, 88 PDC, and 41 ATC samples. Representative im-
munohistochemical staining is shown in Fig. 1A, and the
entire dataset is reported inTable 1.TWIST1was virtually
undetectable in NT, PTC, and PDC samples. In contrast,
49% of the ATC samples (20 of 41) were positive for
TWIST1 expression. Positivity ranged between at least 5
and nomore than 25% () to at least 60% () of cells
(Fig. 1A and Table 1); no staining was observed in the
absence of the primary antibody (data not shown).
TWIST1 positivity correlated with moderate/high prolif-
eration rate assessed by Ki67/MIB1 immunoreactivity
(Freeman-Haltonextensionof theFisher exactprobability
test, P 0.048) (Supplemental Table 1). There was also a
trend for a significant association with up-regulation of
the cell cycle regulated minichromosome maintenance 5
protein (Freeman-Halton extension of the Fisher exact
probability test, P  0.11) (data not shown). TWIST1
expression correlated with the fusocellular ATC pheno-
type and inversely correlated with the epithelioid ATC
phenotype (2 test, P  0.0002; Freeman-Halton exten-
sion of the Fisher exact probability test, P 0.0001) (Sup-
plemental Table 1), suggesting that TWIST1 is involved in
mesenchymal transition of ATC cells. Accordingly, there
was a trend toward a correlation between TWIST1 up-
regulation and lack of -catenin staining at the plasma
membrane (Freeman-Halton extension of the Fisher exact
probability test, P  0.119) (data not shown). Finally,
TWIST1 positivity correlated with p53 positivity (Free-
man-Halton extension of the Fisher exact probability test,
P  0.030) (Supplemental Table 1).
To determine whether TWIST1 up-regulation also oc-
curred at the RNA level, we examined an independent set
ofATC (n 15), PDC (n 4), PTC (n 19), andNT (n
22) samples byquantitativeRT-PCR.As shown inFig. 1B,
TWIST1 mRNAwas up-regulated by more than 5-fold in
about 50% (seven of 15) of the ATC samples, with values
greater than10-fold in13%(twoof15)of them.NT,PTC,
and PDC samples expressed lower TWIST1 levels com-
pared with ATC (P  0.001) (Fig. 1B).
In vertebrates, there are two TWIST genes, TWIST1 and
TWIST2 (also known as Dermo1), and their encoded pro-
teins showan identity in thebasichelix-loop-helixdomainof
more than 90% (20). Therefore, we alsomeasured TWIST2
expression by quantitative RT-PCR in thyroid tissue
samples. TWIST2 was overexpressed in some cases, but
at a lower extentwith respect to TWIST1 (Supplemental
Fig. 1). Indeed, TWIST2was up-regulated bymore than
2-fold in only about half of the ATC samples (four of
nine), with values greater than 5-fold in only one of nine
ATC samples. No PTC sample up-regulated TWIST2
(Supplemental Fig. 1A).
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Up-regulation of TWIST1 in thyroid cancer cell
lines
We analyzed TWIST1 expression in cultured human
thyroid cells. To this aim, we used primary cultures of NT
follicular cells (P5 4N and S11N) and a panel of PTC
(TPC-1, NIM, BCPAP) and ATC (ACT-1, OCUT-2,
8505C, SW1736, CAL62) cell lines.Western blot analysis
showedup-regulation of a band at approximately 26 kDa,
which corresponded to the TWIST1 protein only in the
ATC cell lines OCUT-2, 8505C, and CAL62 (Fig. 1C).
TWIST1 expression was lower in the other ATC cells
and in all the PTC cell lines analyzed, whereas it was
undetectable in NT cells (Fig. 1C). RT-PCR analysis
confirmed the Western blot results (data not shown).
Finally, CAL62 and BCPAP also up-regulated TWIST2
mRNA by more than 2-fold with respect to NT cells
(Supplemental Fig. 1B).
To confirm TWIST1 expression in a model cell sys-
tem and to start exploring whether TWIST1 up-regu-
lation correlated with loss of differentiation or with an
aggressive tumor phenotype, we used a panel of rat thy-
roid follicular Fischer rat-derived thyroid follicular cell
TABLE 1. TWIST1 expression in thyroid samples
(n  157)
Tissue
TWIST1 positivity, % of positive samples
(positive/total samples)
NT 0% (0/15)
PTC 0% (0/13)
PDC 0% (0/88)
ATC 49% (20/41)  17% (7/41)
 15% (6/41)
 17% (7/41)
, 5 to 25% of positive cells; , 25 to 60% of positive cells;
, 60% of positive cells.
FIG. 1. Expression of TWIST1 in thyroid tissue samples and in cell lines. A, Immunohistochemical analysis of TWIST1 protein expression in normal
and malignant thyroid tissues. Representative histological sections from NT (20 magnification), classical PTC (CL-PTC; 10 magnification),
follicular variant PTC (FV-PTC; 20 magnification), PDC (4 magnification), and ATC (20 and 4 magnification) stained with a mouse
monoclonal anti-TWIST1 antibody are shown. The NT, CL-PTC, FV-PTC, and PDC sections were negative for TWIST1, whereas the two ATC cases
featured high/intense immunoreactivity levels (, e.g. 60% of cells); in particular, the ATC sample at 20 magnification showed 65% of
positive cells, whereas the ATC at 4 magnification showed 85% of positive cells. B, Quantitative RT-PCR of TWIST1 mRNA in NT (n  22), PTC
(n  19), PDC (n  4) and ATC (n  15) snap-frozen tissue samples. The level of TWIST1 expression in each sample was measured by comparing
its fluorescence threshold with the average fluorescence threshold of the NT samples. The average results of triplicate samples are plotted. C, NT
follicular cells (P5 4N and S11N), PTC (TPC-1, NIM, and BCPAP), and ATC (ACT- 1, OCUT-2, 8505C, SW1736, and CAL62) cell lines were analyzed
by immunoblot using a mouse monoclonal anti-TWIST1 antibody. Anti -tubulin monoclonal antibody was used as a control for equal protein
loading. D, Immunoblot of TWIST1 expression in rat thyroid PC cells expressing the indicated oncogenes. ***, P  0.001.
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line PC CI 3 (PC) cells adoptively expressing various
oncogenes (PC-RET/PTC1, PC-RET/PTC3, PC-v-HRAS,
PC-TRK-T1, PC-v-RAF, PC-BRAF V600E, PC-E1A,
PC-E1A-v-RAF, and PC-v-MOS). Although the expres-
sion of v-MOS and of the E1A/v-RAF combination en-
abled PC cells to grow in semisolid medium and to in-
duce tumors in athymicmice, the expression of the RET/
PTC1/3,HRAS, TRK,RAF (v-RAF and BRAF) and E1A
oncogenes only caused loss of differentiation without
fostering a tumorigenic phenotype (24, 25). Figure 1D
shows that TWIST1 was only expressed in the PC cells
transformed by v-MOS, and at lower levels by E1A 
v-RAF. Therefore, TWIST1 up-regulation correlated
with malignant phenotype rather than loss of differen-
tiation of rat thyroid cells.
Knockdown of TWIST1 induces apoptosis of ATC
cells
We evaluated the effects of TWIST1 ablation in ATC
cells by RNA interference. We initially tested, byWestern
blot in CAL62 cells, the efficiency of TWIST1 ablation
using three different siRNA (no. 3, 5, and7) (16). TWIST1
FIG. 2. Effects of TWIST1 knockdown in ATC cells. A, CAL62, 8505C, and OCUT-2 cells were transfected with TWIST1 siRNA or with scrambled
siRNA. Cells were harvested at different time points, and protein lysates were subjected to immunoblotting with the indicated antibodies. B,
CAL62, 8505C, and OCUT-2 cells were transfected with TWIST1 siRNA or with scrambled siRNA and counted at different time points. Values
represent the average of triplicate experiments  95% confidence intervals. C, CAL62 and 8505C cells were transfected with TWIST1 siRNA or
with scrambled siRNA. Cells were harvested at different time points, and protein lysates were subjected to immunoblotting with the indicated
antibodies. D, The indicated cell lines were transfected with TWIST1 siRNA or scrambled siRNA; after 48 and 72 h, cells were collected by
trypsinization, stained for 10 min with trypan blue, and counted in triplicate. The percentage of trypan blue excluding cells compared with cells
transfected with siRNA scrambled is reported  SD. ***, P  0.001.
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siRNA 3 (hereafter named TWIST1 siRNA) reduced
TWIST1 protein levels of about 60% (Fig. 2A) and there-
fore was selected for further experiments, whereas the
other two siRNAs (5 and 7) were less effective, with
siRNA 5 being practically devoid of any effect and siRNA
7 depleting TWIST1 protein by less than 30% (Supple-
mental Fig. 2).
We knocked down TWIST1 by transient siRNA
TWIST1 transfection in CAL62, 8505C, and OCUT-2
cells. As shown in Fig. 2A, a TWIST siRNA silenced the
TWIST1protein starting at 24hafter transfection, and the
effect lasted up to 72 h, whereas a scrambled siRNA con-
trol had no effect (Fig. 2A). Thus, cells were transfected
with TWIST1 siRNA or with scrambled siRNA and
counted at different time points (24, 48, and 72 h) (Fig.
2B). Seventy-two hours after transfection, CAL62 cells
transfected with scrambled siRNA numbered 259 103,
whereas those transfectedwithTWIST1 siRNAnumbered
81  103 (P 0.0008); 8505C cells transfected with
scrambled siRNA numbered 679  103, whereas those
transfected with TWIST1 siRNA numbered 351  103
(P  0.0001); OCUT-2 cells transfected with scrambled
siRNA numbered 278  103, and those transfected with
TWIST1 siRNA numbered 176 103 (P
0.0009) (Fig. 2B). It should be noted that
CAL62, but not 8505C and OCUT-2, ex-
pressed detectable levels of TWIST2 (Sup-
plemental Fig. 1B). Thus, it is feasible, be-
cause of the high degree of homology
between TWIST1 and TWIST2, that the ef-
fects of TWIST1 siRNAobserved inCAL62
cells were due to the combined inhibition of
TWIST1 andTWIST2. Accordingly, at 24 h
after siRNA transfection, TWIST2 mRNA
was down-regulated by 1.8-fold in CAL62
(data not shown).
At 48 and 72 h, siRNATWIST1 induced
cell apoptosis of CAL62 and 8505C cells as
measured by immunoblot with an antibody
for the cleaved products of caspase 3 (Fig.
2C). Accordingly, the percentages of trypan
blue excluding (viable) cells, of CAL62
transfected with TWIST1 siRNA 48 and
72h after transfection,were of 69 and32%,
respectively, with respect to scrambled con-
trol, confirming that TWIST1 depletion re-
duced thyroid cancer cell viability (P 
0.001) (Fig. 2D).
Because TWIST1 has been associated
with premature senescence of cancer cells
(20), we performed a senescence-associated
-galactosidase (SA--gal) stainingassayon
siRNA TWIST1-treated cells. Seventy-two
hours after transfection with TWIST1 siRNA, the per-
centage of SA--gal-positive cells was 1.3%, whereas it
was 0.7% in scrambled siRNA transfected cells. As a pos-
itive control, the percentage of SA--gal-positive cells was
38% in normal human diploid fibroblasts treated with
Etoposide (Sigma-Aldrich) (data not shown). Thus, al-
though significant, senescence induced by TWIST1
knockdown involved only a minor fraction of ATC cells.
Knockdown of TWIST1 impairs cell migration and
invasion of ATC cells
Weevaluated themigration (by awound-healing assay)
and invasion (by a Matrigel invasion assay) ability of
TWIST1 siRNA-transfected cells compared with scram-
bled siRNA-transfected cells. As shown in Fig. 3A, 8505C
and OCUT-2 cells transfected with the scrambled control
efficiently migrated into the wound; in contrast, cells
transfected with TWIST1 siRNA had a greatly reduced
migrating ability (P  0.001). Furthermore, cells trans-
fected with TWIST1 siRNA had a reduced ability to in-
vade Matrigel compared with control cells (P  0.001)
(Fig. 3B).
FIG. 3. Effects of TWIST1 knockdown on ATC cell migration and invasion. A, Cells were
transfected with TWIST1 siRNA or scrambled siRNA; a scraped wound was introduced,
and cell migration into the wound was monitored at 24 h. B, Wound closure was
measured by calculating pixel densities in the wound area and expressed as percentage
of wound closure of triplicate areas  SD. C, Cells were transfected with TWIST1 siRNA
or scrambled siRNA; after transfection, cells were seeded in the upper chamber of
transwells and incubated for 12 h; the upper surface of the filter was wiped clean, and
cells on the lower surface were stained and counted. Invasive ability was expressed as
number of invaded cells. Values represent the average of triplicate experiments  SD.
***, P  0.001.
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Effects of stable silencing of TWIST1 in CAL62 cells
We stably transfected CAL62 cells with an shTWIST1
plasmid or with shLUC control (20). After antibiotic se-
lection, cells were screened by Western blot for TWIST1
expression. Amass population (mp) (shTWIST1mp)with
a TWIST1 knockdown of approximately 52% was used
for further study (Supplemental Fig. 3A). Consistent with
data obtained upon transient TWIST1 silencing (Fig. 2),
shTWIST1 mp cells showed decreased migration and in-
vasion abilitywith respect to shLUC-transfected cells (P
0.001) (Supplemental Fig. 3, B–D). To address effects of
TWIST1 knockdown on chemosensitivity, cells were
treated with cisplatin (200 or 1000 nM) or staurosporine
(300or 500nM) and counted at 24h.Upon treatmentwith
cisplatin (1000 nM) or staurosporine (300–500 nM),
shTWIST1 mp cells had a decreased viability compared
with control cells (P  0.001) (Supplemental Fig. 3E).
Finally, the number of colonies formed
in semisolid medium (soft agar) was
also reduced by 2-fold compared with
the shLUCmp control (P 0.05) (Sup-
plemental Fig. 3F). Thus, TWIST1 ab-
lation in vitro affected several hall-
marks of malignancy of CAL62 cells,
including anchorage-independent pro-
liferation, survival, and invasion.
Ectopic TWIST1 promotes cell
migration and invasion of PTC
cells
PTC cells, TPC-1, which have low
endogenous levels of TWIST1, were
transfected with a TWIST1-express-
ing plasmid (pcDNA-TWIST1) or
with the empty vector (pcDNA).Mass
populations and cell clones were se-
lected in G418 (1.2 mg/ml). TWIST1
expression was increased (4- to 13-
fold) in all the cell lines transfected
with TWIST1 comparedwith the con-
trols (Fig. 4A). Growth rate was sim-
ilar in TWIST1- and vector-trans-
fected control cell lines (data not
shown). Therefore, we studied cell
migration using thewound closure as-
say. As shown in Fig. 4, B and C, mi-
gration rate was higher in TWIST1-
transfected cells than in control cells
(P  0.05). We next seeded TWIST1-
transfected and control cells into the
top chamber of transwells and evalu-
ated their ability to invade Matrigel.
TPC-1 cells had basal levels of inva-
siveness, and TWIST1 overexpression further increased
this ability by 4- to 6-fold (P  0.001) (Fig. 4D). Thus,
TWIST1 stimulated cell motility and invasion, although
wound closure and Matrigel invasion extent were not
directly proportional to the TWIST1 expression levels
(Fig. 4). These findings suggest that the TWIST1 ex-
pression level is not the only molecular determinant of
thyroid cancer cell invasive phenotype.
Ectopic TWIST1 protects PTC cells from apoptosis
We treated TPC-1 cells transfected with TWIST1 or
control vector with different concentrations of cisplatin
(200, 1000, and 2000 nM) and counted cell number at
24 h. As shown in Fig. 5A, cell viability was higher in
TWIST1-transfected than in control cells upon treat-
ment with the highest drug dose (P  0.05). Moreover,
FIG. 4. Effects of TWIST1 overexpression on TPC-1 cell migration and invasion. A, Expression
levels of TWIST1 in TPC-1-transfected cells. After G418 selection, cells were lysed and blotted
with the indicated antibodies. B, A scraped wound was placed on the confluent monolayer of
TPC-1 transfected with TWIST1 or the empty vector, and the cell migration into the wound
was monitored at 24 h. Arrows indicate the site of wound closure. C, Wound closure was
measured by calculating pixel densities in the wound area and expressed as percentage of
wound closure of triplicate areas  SD. D, Cells were seeded in the upper chamber of
transwells and incubated for 12 h; the upper surface of the filter was wiped clean, and cells
on the lower surface were stained and counted. Invasive ability was expressed as number of
invaded cells. Values represent the average of triplicate experiments  SD. *, P  0.05;
**, P  0.01; and ***, P  0.001.
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the amount of caspase 3 cleaved product was lower in
TWIST1-transfected than in control cells (Fig. 5B).
Finally, we searched an Affymetrix microarray-based
data set for genes that were previously reported to be
TWIST1 targets and related to cell cycle and apoptosis
control (30). TWIST1-overexpressing cells (TPC-1
TWIST1 mp1, TWIST1 mp2, and TWIST1 Cl2) up-reg-
ulated (P 0.05), with respect to pcDNAmp control, the
expression of AKT2 (average fold change  SD, 2  0.5)
and BCL-2 (average fold change  SD, 1.67  0.2),
whereas they down-regulated the expression of p21CIP/
WAF1 (average fold change  SD, 0.7  0.3). TWIST1
overexpression, instead, did not significantly change the
expression of p14ARF, BAX, and TIMP1 in our system
(data not shown).
Discussion
Thyroid cancer includes tumor types as different as well-
differentiated carcinomas that have a very good prognosis
and undifferentiated carcinomas or ATC that are among
the most aggressive human cancers. As yet, the molecular
players sustaining such different behavior are largely un-
known. Here, we demonstrate that TWIST1 is up-regu-
lated in ATC samples. Overall TWIST1 up-regulation in
ATC is more prominent at the RNA than at the protein
level. It is possible that TWIST1 overexpression is affected
not only at the transcriptional level but also at the post-
transcriptional level. TWIST1 up-regulation was associ-
ated with mitotic index, as determined by Ki67/MIB1.
However, the fact that TWIST1 did not influence cell pro-
liferation in cultured cells suggests that it is not directly
involved in controlling cell proliferation. In ATC samples,
TWIST1 positivity also correlated with markers of mes-
enchymal transition (fusocellular phenotype) and malig-
nancy (p53 positivity); however, correlation with p53 ex-
pression was not demonstrated in cultured thyroid cancer
cells because TWIST1-positive (OCUT-2, 8505C, and
CAL62) and TWIST1-negative (TPC-1, BCPAP, NIM,
ACT-1,SW1736)cellsbothhadeitherhigh (8505C,ACT-1)
or low/undetectable (CAL62, OCUT-2, TPC-1, BCPAP,
NIM, SW1736) p53 expression (Supplemental Fig. 4).
In vitro cellular models confirmed the role of
TWIST1 in determining the ATC phenotype and iden-
tified the ATC features that were sustained by TWIST1
up-regulation. TWIST1 up-regulation did not correlate
with loss of differentiation; indeed, it did not occur in
PC cells that lost differentiation secondary to the
expression of various oncogenes. Rather, TWIST1
overexpression correlated with a malignant phenotype
being present in tumorigenic PC-v-MOS and PC-
E1Av-RAF cells (24). Moreover, TWIST1 expression
was necessary to counteract spontaneous ATC cell ap-
optosis and to sustain the invasive andmotile phenotype
of ATC cells. Accordingly, when overexpressed in PTC
cells, TWIST1 promoted cell migration and protected
cells from apoptosis. Given the high homology between
TWIST1 and -2, the TWIST siRNA also targeted
TWIST2 (1.8-fold), albeit at lower levels than TWIST1
(2.5-fold). Thus, it is possible that at least in CAL62
cells effects were due to the combined inhibition of
TWIST1 and TWIST2.
TWIST1 expression is responsive to Wnt-1 (31),
IGF-I (32), and nuclear factor B (NF-B) signaling
(33). Elements of the Wnt pathway, particularly
CTNNB1 (the gene coding -catenin), were found to be
mutated in PDC and ATC (34). Moreover, NF-B is ac-
tivated in human thyroid cancer cells, in particular inATC
(35). Therefore, both the Wnt-1/-catenin and NF-B
pathways are good candidates as mediators of TWIST1
up-regulation in ATC.
Up-regulation of TWIST1 is associated with cellular
resistance to anticancer drugs such as cisplatin, taxol, and
vincristine in various types of cancers (18, 19, 36). Here,
we show that TWIST1 overexpression protected thyroid
FIG. 5. Effects of TWIST1 overexpression on TPC-1 cell apoptosis. A,
The cells were treated with increasing doses of cisplatin and counted
24 h after treatment. Data are shown as percentage of inhibition of
cell viability. Values represent the average of three independent
experiments  SD. *, P  0.05; **, P  0.01; and ***, P  0.001. B,
The indicated cell lines were treated with increasing doses of cisplatin,
lysed, and blotted with the indicated antibodies.
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cancer cells from cell death induced by cisplatin and stau-
rosporine. This suggests that TWIST1may be exploited as
a molecular marker of the response of thyroid cancer to
chemotherapy.
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Supplemental Methods 
Cell cultures-Normal thyroid primary S11N cells were provided by H. Zitzelsberger 
(Department of Radiation Cytogenetics, Neuherberg, Germany) and P5 4N cells were provided 
by F. Curcio (Università di Udine, Udine, Italia) in 2003. 8505C and CAL62 cells were 
purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig, Germany) in 2006. SW1736 cells were obtained from N.E. Heldin (University 
Hospital, Uppsala, Sweden) in 2005. OCUT-2 and ACT-1 cells were provided by N. Onoda 
(Osaka University of Medicine, Osaka, Japan) in 2005. TPC-1 cells were obtained from M. 
Nagao (Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan) in 
1990. NIM cells were obtained from J. Fagin (Memorial Sloan Kettering Cancer Center, New 
York, NY) in 1993. BCPAP cells were obtained from N. Fabien (CNRS, Oullins, France) in 
1994. 8505C, SW1736 and CAL62 cells were DNA profiled by short tandem repeat analysis in 
2009 and shown to be unique and identical to those reported in Schweppe et al., 2008 (1, 2). 
The BCPAP cell line was genotyped as reported elsewhere Schweppe et al., 2008 (1). The TPC-
1 cell line was identified based on the unique presence of the RET/PTC1 rearrangement. S11N 
cells were grown in RPMI (Invitrogen, Groningen, The Netherlands) containing 20% fetal 
bovine serum; P5 4N were grown as previously described (3). The thyroid cancer cell lines were 
grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) containing 10% fetal 
bovine serum. 
TWIST1 transcription factor in thyroid tumour progression 
JCEM 10-1182 v2 
 
 2 
The Fischer rat-derived differentiated thyroid follicular cell line PC Cl 3 (hereafter 
named “PC”) was grown in Coon’s modified Ham F12 medium supplemented with 5% calf 
serum and a mixture of six hormones (6H): thyrotropin (10mU/ml), hydrocortisone (10nM), 
insulin (10µg/ml), apo-transferrin (5µg/ml), somatostatin (10ng/ml), and glycyl-histidyl-lysine 
(10ng/ml) (Sigma-Aldrich, St. Louis, MO). PC adoptively expressing several oncogenes (PC 
RET/PTC1, PC RET/PTC3, PC v-HRAS, PC-BRAF-V600E, PC-TRK-T1, PC v-RAF, PC v-
MOS, PC E1A and PC E1A-v-RAF) have been described previously and cultured in the same 
medium as PC but without the 6H (4, 5). 
 
Cell culture methods- For cell viability determination, cells were collected by trypsinization, 
stained for 10 min with 0.4% trypan-blue (Sigma) according to manufacturer’s instructions, and 
counted in triplicate.  
For senescence-Associated-β-galactosidase staining, CAL62 (2x105) cells were 
transfected with TWIST1 siRNA or with scrambled control. Seventy-two h after transfection, 
the cells were washed twice with PBS, fixed with 2% formaldehyde and 0.2% glutaraldehyde in 
PBS, and washed twice in PBS. Then, cells were stained overnight in X-gal staining solution [1 
mg/ml X-gal, 40 mM citric acid/sodium phosphate (pH 6.0), 5 mM potassium ferricyanide, 5 
mM potassium ferrocyanide, 150 mM NaCl, 2 mM MgCl2] and stained cells were counted. 
Positive control was represented by normal human diploid fibroblasts IMR-90 treated with 
Etoposide 20 µM for 24 h. 
Cell invasion was examined using a reconstituted extracellular matrix (Matrigel, BD 
Biosciences, San Jose, CA). The cell suspension (1 x 105 cells per well) was added to the upper 
chamber of transwell cell culture chambers on a prehydrated polycarbonate membrane filter of 
8-µm pore size (Costar, Cambridge, MA) coated with 35 µg of Matrigel (BD Biosciences). The 
lower chamber was filled with 2.5% medium. After 12-h incubation at 37°C, non-migrating 
cells on the upper side of the filter were wiped-off. Invading cells were mounted on glass slides 
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using mounting medium and stained with Hoechst (Sigma). Cell migration was quantified by 
counting the number of stained nuclei in five individual fields in each Transwell membrane, by 
fluorescence microscopy, in triplicate.  
For wound closure, a wound was induced on the confluent monolayer cells by scraping 
a gap using a micropipette tip. Photographs were taken at 100 X magnification using phase-
contrast microscopy immediately after wound incision and 24 h later. Pixel densities in the 
wound areas were measured using the Cella software (Olympus Biosystem Gmb) and expressed 
as percentage of wound closure where 100% is the value obtained at 10h for control cells. 
For growth in semisolid medium, colony formation ability of CAL62 shLUC mp and 
CAL62 shTWIST1 mp cells was examined by soft agar assay. Briefly, 7 ml of FBS 
supplemented medium containing 0.5% noble agar were added to 60-mm cell culture dish and 
allowed to solidify (base agar). Next, 2x104 cells were mixed with 1.5 ml of FBS supplemented 
medium containing 0.83% noble agar and added to the top of base agar. The cells were then 
cultured for 14 days at 37°C under 5% carbon dioxide and colonies were counted. 
 
RNA extraction and expression studies - Total RNA was isolated with the RNeasy Kit (Qiagen, 
Crawley, West Sussex, UK). The quality of the RNAs was verified by the 2100 Bioanalyzer 
(Agilent Technologies, Waldbronn, Germany); only samples with RNA integrity number (RIN) 
value > 7 were used for further analysis. One µg of RNA from each sample was reverse-
transcribed with the QuantiTect® Reverse Transcription (Qiagen). For quantitative RT-PCR, we 
used the Human ProbeLibrayTM system (Exiqon, Denmark). TWIST1 primer sequences were: 
TWIST1 -F: 5’-GGC TCA GCT ACG CCT TCT C-3’ 
TWIST1 -R: 5’- CCT TCT CTG GAA ACA ATG ACA TCT-3’ 
PCR reactions were performed in triplicate and fold changes were calculated with the formula: 
2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference between the amplification fluorescent 
thresholds of the mRNA of interest and the mRNA of RNA polymerase 2 used as an internal 
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reference. Sample 1 represented each single tumor sample and sample 2 was the average of all 
(n. 22) normal thyroids.  
For microarrays, 10 µg purified total RNA from 3 TWIST1 TPC-1 transfectants 
(TWIST1 mp1, TWIST1 mp2, TWIST1 Cl2) and pcDNAmp2 control was transcribed into 
cDNA using Superscript RT (Invitrogen), in the presence of T7-oligo(dT)24 primer, 
deoxyribonucleoside  triphosphates (dNTPs), and T7 RNA polymerase promoter (Invitrogen). 
An in vitro transcription reaction was then performed to generate biotinylated cRNA which, 
after fragmentation, was used in a hybridization assay on Affymetrix U133 plus 2.0 GeneChip 
microarrays, according to manufacturer’s protocol (GeneChip 3' IVT Express Kit, Affymetrix). 
Normalization was performed by global scaling and analysis of differential expression was 
performed by Microarray Suite software 5.0 (Affymetrix). The final results were imported into 
Microsoft Excel (Microsoft). 
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Supplemental Results 
 
 
Figure 1: A: Quantitative RT-PCR of TWIST2 mRNA in NT (n=22), PTC (n= 19), and ATC 
(n=9) snap-frozen tissue samples. The level of TWIST2 expression in each sample was 
measured by comparing its fluorescence threshold with the average fluorescence threshold of 
the 22 NT samples. The average results of triplicate samples are plotted. B: Quantitative RT-
PCR of TWIST2 mRNA in normal human thyroid follicular cells (S11N), PTC (TPC-1, BCPAP 
and NIM) and ATC (8505C, SW1736, OCUT-2 CAL62, ACT- 1) cell lines. The level of 
TWIST2 expression in each sample was measured by comparing its fluorescence threshold with 
the fluorescence threshold of the human thyroid follicular cells (S11N). The average results of 
triplicate samples ± SD are plotted. 
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Figure 2: CAL62 were transfected with two different small inhibitor duplex RNA targeting 
TWIST1 (#5, #7) and the scrambled control. Cells were harvested 48 h after transfection, and 
analyzed for TWIST1 protein expression. Tubulin was used for normalization. 
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Figure 3: A Expression levels of TWIST1 and Tubulin in CAL62 cells transfected with 
shLUC or shTWIST1; B: A scraped wound was placed on the confluent monolayer of CAL62 
transfected with shTWIST1 or shLUC and the cell migration into the wound was monitored at 
the indicated time points. C: Wound closure was measured by calculating pixel densities in the 
wound area and expressed as percentage of wound closure of triplicate areas ± SD. D: CAL62 
transfected with shTWIST1or shLUC (1x105) were seeded in the upper chamber of transwells 
and incubated for 12 h; the upper surface of the filter was wiped clean and cells on the lower 
surface were stained and counted. Invasive ability is expressed as number of invaded cells. 
Values represent the average of triplicate experiments ± SD. E: The cells were treated with 
increasing doses of Cisplatin or Staurosporine and counted after 24 h. The percentage of 
viability inhibition is shown: values represent the average of three independent experiments ± 
SD. F: CAL62 shLUC mp and CAL62 shTWIST1 mp cells were seeded in soft agar. Total 
number of colonies were counted after 14 days: values represent the average of three 
independent experiments ± SD. Asterisks indicate p < 0.05 (*), p < 0.01 (**) and p < 0.001 
(***). 
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Figure 4: Expression levels of p53 in human thyroid cell lines. Cells were lysed and 
blotted with the indicated antibodies. 
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Table 1: Clinico-pathological features of anaplastic thyroid carcinoma and TWIST1 
expression. 
 
Features TWIST1 negative (n=21) TWIST1 positive (n=20) p-value 
        
Phenotype       
Epithelioid (n=19) 76% (16/21) 15% (3/20) 0.0001 
Mixed (n=7) 9% (2/21) 25% (5/20)   
Fusocellular (n=15) 15% (3/21) 60% (12/20)   
        
Ki67/MIB1 expression       
+++ (n=9) 10% (2/21) 35% (7/20) 0.048 
++ (n=16) 33% (7/21) 45% (9/20)   
+ (n=15) 52% (11/21) 20% (4/20)  
Negative (n=1) 5% (1/21) 0% (0/20)   
        
p53 expression       
+++ (n=14) 19% (4/21) 50% (10/20) 0.030 
++ (n=10) 33% (7/21) 15% (3/20)   
+ (n=5) 5% (1/21) 20% (4/20)   
Negative (n=12) 43% (9/21) 15% (3/20)   
 
+: ≥5–≤25% of positive cells 
++: >25–<60%  of positive cells 
+++:≥60% of positive cells 
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Abstract 
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Through a cDNA microarray 
analysis, we have isolated Anterior gradient protein 2 (AGR2) as a gene upregulated in PTC. AGR2 is a 
disulfide isomerase overexpressed in several human carcinomas and recently linked to endoplasmic 
reticulum (ER) stress. We demonstrated by real-time PCR and immunohistochemistry that PTC 
overexpressed AGR2 respect to normal thyroid tissues. Knockdown of AGR2 induced apoptosis and 
decreased migration and invasion of PTC cells. Ectopic expression of AGR2 in non-transformed human 
thyroid cells increased cell migration and invasion and protected cells from ER stress induced by 
Bortezomib. Thus, AGR2 is a novel marker of PTC and plays a role in thyroid cancer cell survival, 
migration, invasion and protection from ER stress.  
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1. Introduction 
 
Thyroid carcinoma is the most common endocrine neoplasm and is increasing in incidence (Siegel et al., 
2012). Most thyroid carcinoma arises from thyroid follicular cells. These include papillary thyroid carcinoma 
(PTC) (which accounts for 80% of all thyroid tumors) and follicular thyroid carcinoma (FTC) 
(approximately 15% of thyroid tumors) as well as the less common anaplastic thyroid carcinoma (Nikiforov 
and Nikiforova 2011; Kondo et al., 2006). PTC is a well-differentiated slow growing and treatable tumor. 
The tumor is usually removed by surgery and treated by iodine 131 radiation therapy, however, a few PTC 
carriers develop recurrences and distant metastases (Nikiforov and Nikiforova 2011; Kondo et al., 2006).  
To look for genes potentially involved in the neoplastic transformation of the thyroid gland, we conducted a 
cDNA microarray screening of different thyroid tumors (Salvatore et al., 2007). Among the genes highly 
upregulated in PTC, we focused on Anterior gradient protein 2 (AGR2). AGR2, also known as hAG-2 or 
Gob-4, is the human orthologue of the Xenopus laevis protein, XAG-2. In the frog embryo, XAG-2 induces 
cement gland differentiation (Aberger et al., 1998; Komiya et al., 1999).  
Subsequent studies have shown a significant function for AGR2 in a range of biological pathways including 
cell migration and cellular transformation (Brychtova et al., 2011). AGR2 protein is upregulated in several 
human carcinoma, including breast, pancreatic, ovarian, esophageal, lung and prostate cancers, and is 
associated with a metastatic phenotype and poor prognosis (Barraclough et al., 2009; Zhang JS et al., 2005). 
Many studies revealed that overexpression or suppression of AGR2, in different cancer model systems, can 
affect cell proliferation, invasion and survival, metastasis and tumor growth (Chevet et al, 2012).  
Recently, AGR2 has been shown to have structural characteristics of the protein disulfide isomerase (PDI) 
family, including a carboxy-terminal endoplasmic reticulum (ER) retention signal KTEL and a single 
thioredoxin-like domain with a CXXS motif (Persson et al., 2005). PDI proteins catalyze formation, 
reduction, and isomerization of disulfide bonds, thereby facilitating the maturation of proteins in the ER and 
ensure correct folding and multimerization of proteins targeted for the secretory pathway. During 
tumorigenesis, the high proliferation rate of cancer cells requires increased activities of ER protein folding, 
assembly, and transport, a condition that can induce ER stress. Importantly, AGR2 knock out mice had 
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elevated endoplasmic reticulum (ER) stress (Zhao et al., 2010). AGR2 expression is induced by ER stress, 
and siRNA knockdown of AGR2 increases ER stress response (Zhao et al., 2010; Higa et al., 2011). 
Furthermore, AGR2 localizes in the ER of normal intestinal epithelial cells and is essential for in vivo 
production of mucus (Park SW et al., 2009). Indeed, AGR2 mediates processing of the intestinal mucin 
MUC2 through formation of mixed disulfide bonds (Park SW et al., 2009).  
In this work, we analyze the expression of AGR2 in PTC and its functional consequences. 
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2. Materials and methods 
 
2.1 Tissue samples – Tumors (n= 39) and normal (n=25) thyroid tissue samples for immunohistochemical 
analysis were retrieved from the Pathology Department of the Istituto Pascale, Naples, Italy. In addition, 
RNA from frozen tissues of 10 PTC cases and 10 normal matched thyroid controls was obtained from the 
Chernobyl Tissue Bank (http://www.chernobyltissuebank.com) (Thomas, 2012). Fifty PTC and 50 normal 
thyroid tissues used in the DNA array were obtained from Imperial College London, London, UK. In all 
cases, the respective institutional review boards approved the study protocols. The samples were classified 
according to the diagnostic criteria required for the identification of PTC (Hedinger et al., 1989).  
 
2.2. Immunohistochemical staining - Sections of paraffin-embedded samples were stained with hematoxylin 
and eosin for histological examination to ensure that the samples fulfilled the diagnostic criteria (Hedinger et 
al., 1989). For immunohistochemistry analysis, 2 µm paraffin sections were deparaffinised and then placed in 
a solution of absolute methanol and 0.3% hydrogen peroxide for 30 minutes and then washed in phosphate 
buffered saline (PBS) before immunoperoxidase staining. The slides were then incubated overnight at 4°C in 
a humidified chamber with mouse monoclonal antibody against AGR2 (PO1, Abnova, Taipei City, Taiwan) 
diluted 1:100 in PBS. The slides were subsequently incubated with biotinylated goat anti-mouse IgG for 20 
minutes (Vectostain ABC kits, Vector Laboratories) and then with premixed reagent ABC (Vector) for 20 
minutes. The immunostaining was performed by incubating the slides in diaminobenzidine (DAB, DAKO) 
solution containing 0.06 mM DAB and 2 mM hydrogen peroxide in 0.05% PBS, pH 7.6, for 5 minutes, and 
after chromogen development, the slides were washed, dehydrated with alcohol and xylene and mounted 
with coverslips using a permanent mounting medium (Permount). Micrographs were taken on Kodak 
Ektachrome film with a photo Zeiss system. Negative controls were performed in each case by incubating 
tissue slides with secondary antibody only. The expression of AGR2 was categorized as positive (staining of 
≥10% of the tumor cells) and negative (staining of <10% of the tumor cells). The staining intensity of 
positive cells was further graded in: score 1 (10-50% of positive cells), score 2 (51-75% of positive cells) and 
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score 3 (76-100% of positive cells). Score values were independently assigned by two blinded investigators 
(G.C. and M.M.) and a consensus was reached on all scores used for computation.  
 
2.3. Cell cultures- Human papillary thyroid cancer cell line TPC-1, was obtained from M. Nagao 
(Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan). The TPC-1 cell 
line was identified based on the unique presence of the RET/PTC1 rearrangement. Nthy-ori 3-1 cells 
are non transformed human thyrocytes immortalized by the Large T of SV40 and were obtained from 
the European Tissue Culture collection (Sigma Aldrich, St. Louis, MO, USA). Nthy-ori 3-1 cell line 
was grown in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal 
bovine serum (FBS), L-glutamine and penicillin/streptomycin (Invitrogen, Carlsbad, California, USA). 
TPC-1 cell line was grown Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS), L-glutamine and penicillin/streptomycin (Invitrogen).  
Bortezomib was obtained from Millenium (Cambridge, MA, USA). 
 
2.5 Cell viability - For cell viability determination, cells were collected by trypsinization stained for 10 
minutes with 0.4% trypan-blue (Sigma Aldrich) according to manufacturer’s instructions, and counted in 
triplicate. 
 
2.6 Chemoinvasion - Cell invasion was examined using a reconstituted extracellular matrix (Matrigel, BD 
Biosciences, San Jose, CA). The cell suspension (1 x 105 cells per well) was added to the upper chamber of 
transwell cell culture chambers on a prehydrated polycarbonate membrane filter of 8-µm pore size (Costar, 
Cambridge, MA) coated with 35 µg of Matrigel (BD Biosciences). The lower chamber was filled with 10% 
medium. After incubation at 37° C, non-migrating cells on the upper side of the filter were wiped-off. 
Invading cells were mounted on glass slides using mounting medium and stained with Hoechst (Sigma 
Aldrich). Cell migration was quantified by counting the number of stained nuclei in five individual fields in 
each transwell membrane, by fluorescence microscopy, in duplicate.  
 
2.7 Wound closure assay - A wound was introduced on the confluent monolayer cells using a micropipette 
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tip. Photographs were taken at 40 X magnification using phase-contrast microscopy immediately after 
wound incision and at different time-points. Wound closure was measured by calculating pixel densities in 
the wound area by Cella software (Olympus Biosystem Gmb, Hamburg, Germany) and expressed as 
percentage of wound closure of triplicate areas ± SD. 
 
2.8 RNA silencing - Pools of 4 small inhibitor duplex RNAs (ON-TARGETplus siRNA SMARTpool) 
targeting human AGR2 (# L-003626-00), and a non-targeting pool (ON-TARGETplus Non-Targeting Pool) 
control (#D 001810-10-20) were purchased from Dharmacon RNAi Technologies (Dharmacon Inc., 
Chicago, IL, USA). Cells were grown under standard conditions. The day before transfection, 1 x 105 TPC-1 
cells were plated in 60-mm dishes in complete medium without antibiotics and electroporated using 
MicroPorator (MP-100, Digital Bio, Euroclone, Milan, Italy) according to the manufacturer’s instructions. 
Cells were harvested 48 and 72 hours after transfection, counted and analyzed for protein expression.  
 
2.9. Protein studies - Immunoblotting was carried out according to standard procedures. Anti-AGR2 (PO1) 
monoclonal antibody was from Abnova (Taipei City, Taiwan); anti-GADD153 (B-3, sc-7351) monoclonal 
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin monoclonal antibody 
was from Sigma-Aldrich. Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish peroxidase 
were from Santa Cruz Biotechnology.  
 
2.10. Generation of stable AGR2 transfectants - cDNA containing the complete coding sequence of human 
AGR2 was produced by reverse transcription of RNA from HT29 colon adenocarcinoma cells (American 
Type Culture Collection, Rockville, MD, USA) using the following primers:  
AGR2 Cl For.:5’-ATCCTCGAGCGATCATGGAGAAAATTCCA-3’;  
AGR2 Cl Rev.: 5’-ATCGGATCCCAATTCAGTCTTCAGCAA-3’ (annealing temperature: 60°C).  
AGR2 cDNA was cloned into pcDNA3.1 (hereafter named pcDNA) (Invitrogen) by using BamHI and Xho1 
restriction enzymes and verified by sequencing.  
A point mutation in AGR2 that changed the cysteine at aminoacid position 81 to serine (C→S) was 
introduced in the pCDNA-AGR2 plasmid by the Stratagene QuikChange site-directed mutagenesis kit 
Role of AGR2 in papillary thyroid carcinoma 
 
 8 
(Agilent Technologies, Inc. Life Sciences and Chemical Analysis Group, Santa Clara, CA, USA).  
The following oligonucleotides were used:  
AGR2 C81S For: 5’- CATCACTTGGATGAGTCCCCACACAGTCAAGC-3’;   
AGR2 C81S Rev: 5’- GCTTGACTGTGTGGGGACTCATCCAAGTGATG-3’ (annealing temperature: 
55°C). 
The Nthy-ori 3-1 and TPC-1 cells were transfected with pcDNA-AGR2, pcDNA-AGR2 (C→S) or the empty 
vector (pcDNA) using the Lipofectamine Reagent (Invitrogen) according to the instructions of the 
manufacturer. Two days later, G418 (Invitrogen) was added at a concentration of 0.3 mg/ml (Nthy-ori 3-1) 
or at a concentration of 1.2 mg/ml (TPC-1). Several clones and mass populations of transfectants were 
isolated, expanded and screened for AGR2 expression by Western blot. 
 
2.11. RNA extraction and expression studies - Total RNA was isolated with the RNeasy Kit (Qiagen, 
Crawley, West Sussex, UK). The quality of the RNAs was verified by the 2100 Bioanalyzer (Agilent 
Technologies, Waldbronn, Germany); only samples with RNA integrity number (RIN) value > 7 were used 
for further analysis. One µg of RNA from each sample was reverse-transcribed with the QuantiTect® Reverse 
Transcription (Qiagen).  
 
2.12. Semi-quantitative RT-PCR- Semiquantitative RT-PCR was applied to study AGR2 expression in PTC 
samples and normal thyroid matched control; amplimers and annealing temperatures were as follows: 
AGR2 F: CTG GCCAGAGATACCACAGTC;  
AGR2 R: AGTTGGTCACCCCAACCTC (annealing temperature: 60°C). 
β-actin mRNA was used as housekeeping gene; β-actin amplimers and annealing temperatures were as 
follows: 
β-Actin F: TGCGTGACATTAAGGAGAAG;   
β-Actin R: GCTCGTAGCTCTTCTCCA (annealing temperature: 60°C). 
PCR were performed in triplicates, PCR products were subjected to agarose gel electrophoresis and signal 
intensity was analyzed with the Phosphorimager (Typhoon 8600, Amersham Pharmacia Biotech) interfaced 
with the ImageQuant software.  
Role of AGR2 in papillary thyroid carcinoma 
 
 9 
 
2.13. Xbp1 spilicing assay- Xbp1 splicing was measured by semi-quantitative RT-PCR using the following 
specific primers: 
Xbp1s. For: 5’- AAACAGAGTAGCAGCTCAGACTGC-3’; 
Xbp1s. Rev: 5’- CCTTCTGGGTAGACCTCTGGGAG-3’ (annealing temperature: 64°C); flanking the 
splicing site yielding PCR product sizes of 164 and 138 bp, Xbp1u (unspliced) and Xbp1s (spliced) 
respectively. Products were resolved on 2.5% agarose gels and band intensity was determined 
densitometrically with the ImageJ software. 
 
2.14. Statistical analysis- Data are presented as mean ± standard deviations. Mann–Whitney U test or 
Student t unpaired tests were used. P values were 2-sided throughout, and P < 0.05 was considered 
statistically significant. Statistical analyses were carried out using the Graph Pad InStat software program 
(version 3.1a, La Jolla, CA, USA).
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3. Results 
 
3.1. AGR2 is upregulated in human PTC samples 
We measured AGR2 expression by immunohistochemistry with an anti-AGR2 monoclonal antibody in 64 
thyroid samples including 25 normal thyroid (NT) samples and 39 PTC samples. Representative 
immunohistochemical staining is shown in Figure 1A, and the entire dataset is reported in Table 1. AGR2 
was expressed at low levels in normal thyroid glands (Fig. 1A, inset 1). In contrast, a large fraction (∼ 71%) 
of PTC samples (PTC classical papillary variant: 23 out of 28 samples; PTC follicular variant: 5 out of 11 
samples), were positive for AGR2 expression in more than 75% (3+) of the cells, and positivity was confined 
to tumor cells (Table 1 and Figure 1A, inset 2). No staining was observed in the absence of the primary 
antibody (Figure 1A, inset 3). Normal colon mucosa was used as positive control (Figure 1A, inset 4).  
To obtain an additional assessment of AGR2 upregulation and to determine whether upregulation occurred 
also at RNA level, we verified AGR2 expression levels in a DNA array dataset of 50 normal human thyroid 
(NT) samples and 50 PTC samples. As shown in Figure 1B, PTC samples showed significantly increased 
AGR2 levels compared to normal thyroid tissues (P=0.000000365). The data was further confirmed by semi-
quantitative RT-PCR analysis in an independent set of PTC samples. Nine out of ten PTC samples analyzed 
expressed elevated AGR2 mRNA levels compared to the matched normal thyroid tissues (Figure 1C).  
 
3.2. Knockdown of AGR2 induces apoptosis of TPC-1 cells 
We evaluated the effects of AGR2 ablation in TPC-1 cells by RNA interference. TPC-1 cells were 
transfected with AGR2 siRNA or with scrambled siRNA, counted and lysed at different time points. At 48 
and 72 hours after transfection AGR2 siRNA reduced AGR2 protein levels respectively of about 56% and 
96% (Fig. 2A). Forty-eight hours after transfection TPC-1 cells transfected with scrambled siRNA numbered 
192 x 103, whereas those transfected with AGR2 siRNA numbered 146 x 103 (P=0.0492). Seventy–two 
hours after transfection, TPC-1 cells transfected with scrambled siRNA numbered 413 x 103, whereas those 
transfected with AGR2 siRNA numbered 279 x 103 (P=0.0045) (Fig. 2B). Accordingly, the percentages of 
trypan blue excluding (viable) cells, of TPC-1 transfected with AGR2 siRNA, 48 and 72 hours post 
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transfection, were of 77% and 33% of scrambled control respectively, confirming that AGR2 depletion 
reduced thyroid cancer cell viability (P<0.0001) (Figure 2C).  
 
3.3. Knockdown of AGR2 reduces migration and invasion of TPC-1 cells 
We evaluated the migration (by a wound-healing assay) and invasion (by a Matrigel invasion assay) ability 
of AGR2 siRNA-transfected cells. A scraped wound was introduced on the confluent monolayer of TPC-1 
cells transfected with AGR2 siRNA or scrambled siRNA. Figure 2D and E shows that TPC-1 transfected 
with the scrambled control efficiently migrated into the wound; in contrast, cells transfected with AGR2 
siRNA had a reduced migrating ability both at 12 hours (P<0.0001) and at 24 hours (P<0.0001). Moreover, 
cells transfected with AGR2 siRNA showed a reduced ability to invade Matrigel compared to control cells 
(P<0.0001) (Fig. 2F and G). 
 
3.4. Ectopic AGR2 promotes migration and invasion of Nthy-ori 3-1 cells 
We transfected the non-transformed thyroid cells, Nthy-ori 3-1, which do not express AGR2, with an AGR2-
expressing plasmid (pcDNA-AGR2), or with an AGR2-mutant plasmid (pcDNA-AGR2 C→S), or with the 
empty vector (pcDNA). The cysteine 81 to serine mutation (C→S) in the thioredoxin domain of AGR2 
ablates the catalytic activity of AGR2 (24). Several cell clones and mass populations of Nthy-ori 3-1 cells 
transfected with the different plasmids, were selected in G418. One mass population of AGR2, one mass 
population of AGR2 (C→S) and one mass population of vector (pcDNA) control transfected cells were 
selected for further studies (Fig. 3A). Nthy-ori 3-1 AGR2, AGR2 (C→S) and pcDNA cells show comparable 
growth rates (Fig. 3B). Then, we studied cell migration using the wound closure assay. A scraped wound was 
introduced on the confluent monolayer of Nthy-ori 3-1 transfected with AGR2, AGR2 (C→S) or the empty 
vector (pcDNA), and the cell migration into the wound was monitored after 9 and 12 hours. As shown in 
Figure 3C and D, migration rate was higher in AGR2-transfected cells compared to control vector (pcDNA) 
cells at 9 hours (P<0.0001) and at 12 hours (P< 0.0001) and compared to AGR2 (C→S) cells at 9 hours (P= 
0.0006) and at 12 hours (P< 0.0001). We next seeded AGR2, AGR2 (C→S) cells and vector control 
(pcDNA) cells into the top chamber of transwells and evaluated their ability to invade Matrigel. AGR2 
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overexpression increased the invasive ability of Nthy-ori 3-1 cells in comparison to vector control (pcDNA) 
cells (P< 0.0001) and in comparison to AGR2 (C→S) cells (P< 0.0001) (Fig. 3E and F). 
 
3.5. Ectopic AGR2 promotes cell migration and invasion of TPC-1 cells  
To confirm these findings, we overexpressed AGR2 in TPC-1 cells. Cells were transfected with AGR2 
(pcDNA-AGR2), with AGR2-mutant plasmid (pcDNA AGR2 C→S) or with the empty vector (pcDNA). 
Mass populations were selected in G418 (Supplemental Figure 1A). Growth rate was similar in TPC-1-
AGR2, AGR2 (C→S) and control (pcDNA) cell lines (Supplemental Figure 1B). Then, we studied cell 
migration using the wound closure assay. As shown in Supplemental Figure 1C migration rate was higher in 
TPC-1 AGR2 cells compared to AGR2 (C→S) cells (P<0.0001) and compared to vector control (pcDNA) 
cells (P<0.0001). We next seeded TPC-1 AGR2, AGR2 (C→S) and pcDNA control cells into the top 
chamber of transwells and evaluated their ability to invade Matrigel. TPC-1 cells had a basal level of 
invasiveness, AGR2 overexpression further increased this ability in comparison to TPC-1 AGR2 (C→S) 
cells (P<0.0001) and to control vector (pcDNA) cells (P<0.0001) (Supplemental Figure 1D).  
 
3.6. AGR2 protects non transformed thyroid Nthy-ori 3-1 cells from endoplasmic reticulum stress 
AGR2 is a disulfide isomerase on the basis of its CXXS motif, and has a role in the endoplasmic reticulum 
(ER) stress response (Fritzsche et al., 2006 b). Thus, we studied the effects of AGR2 ectopic expression in 
the ER stress pathway upon treatment with Bortezomib. Bortezomib is a potent and selective inhibitor of the 
proteasome that causes an accumulation of unfolded proteins in the ER (Mujtaba and Dou, 2011; Mitsiades 
et al., 2006). Nthy-ori 3-1 cells transfected with AGR2, AGR2 (C→S) or vector (pcDNA) were treated for 
24 hours with Bortezomib 100 nM. After treatment, cells were stained with trypan-blue and counted. As 
shown in Figure 4A overexpression of AGR2 in Nthy-ori 3-1 cells treated with Bortezomib increased cell 
viability in comparison to overexpression of AGR2 (C→S) (P= 0.0002) and to control (pcDNA) (P= 
0.0006). Trypan blue excluding cells were 50%, 73% and 45% respectively in Nthy-ori 3-1 pcDNA, AGR2 
and AGR2 (C→S) cells treated with Bortezomib. 
Then, we examined the expression levels of members of the UPR pathways, in particular of Chop (also 
named GADD153) and of the spliced form of X box-binding protein 1 (Xbp1s). GADD153 and Xbp1s are 
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well-characterized biomarkers of ER stress (Ma and Hendershot, 2004; Moenner et al., 2007). Then, we 
determined by Western blot the expression level of GADD153 (Chop) in Nthy-ori 3-1 AGR2, AGR2 (C→S) 
or empty vector (pcDNA) cells treated with Bortezomib (100 nM) for 24 hours. As shown in Figure 4B a 
reduced increase in the amount of GADD153 protein upon Bortezomib treatment was detected in Nthy-ori 3-
1 AGR2 cells compared to pcDNA of ∼ 13 fold (P< 0.0001) and compared to AGR2 (C→S) cells of ∼ 13 
fold (P<0.0001). These data indicate that AGR2 ectopic expression protects non-transformed thyroid cells 
from ER stress induced by Bortezomib.  
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4. Discussion 
 
AGR2 is a protein disulfide isomerase that is overexpressed in several human carcinoma and can stimulate 
cancer cell proliferation, invasion, survival and metastasis.  
In the present study, we demonstrated that AGR2 is a novel marker of papillary thyroid carcinoma (PTC). 
Further, we investigated the functional role of AGR2 using gain and loss-of-function approaches. 
Knockdown of AGR2 in papillary thyroid carcinoma cells induced cell death, decreased cell migration and 
invasion. On the other hand, forced AGR2 expression in non-transformed thyroid, Nthy-ori 3-1 cells, which 
are endogenously deficient of AGR2, resulted in increased cell migration and invasion and protection from 
ER stress. 
The endoplasmic reticulum (ER) is the cell organelle where secretory and membrane proteins are 
synthesized and folded. Proteins that fail to fold properly are retained in the ER and their accumulation may 
constitute a form of stress to the cell. Several signaling pathways, collectively known as unfolded protein 
response (UPR), have evolved to detect the accumulation of misfolded proteins in the ER and activate a 
cellular response that attempts to maintain homeostasis. (Ma and Hendershot 2004; Moenner et al., 2007).  
Increased expression of the UPR components, including Xbp1 and GADD153 have been detected in breast 
cancer, gastric tumors, and esophageal adenocarcinomas (Ma and Hendershot 2004; Moenner et al., 2007). 
In this context, our hypothesis is that AGR2 is a protein upregulated by PTC cells to cope with the ER stress. 
As shown for other ER resident proteins (Ma and Hendershot 2004; Moenner et al., 2007), increased AGR2 
expression could enhance ER folding capacity and allow cancer cells to cope with increased protein 
production and secretion, participating in cancer aggressiveness. Further, the expression of PDI proteins and 
ER chaperones has also been correlated with cancer invasion and metastasis in several tumor types (Lovat et 
al., 2008; Goplen et al., 2006) and here we provide similar evidence for AGR2 in PTC. 
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Legend to Figures 
 
Figure 1: AGR2 expression in human thyroid tissue samples.  
A) Representative images of normal thyroid (NT) (inset 1), papillary thyroid carcinoma (PTC) (inset 2), 
normal colon sample (inset 4) (used as positive control) stained with a mouse monoclonal anti-AGR2 
antibody, are presented. PTC shows a strong immunoreactivity for AGR2, while NT is negative. Inset 3, 
shows a PTC sample incubated only with secondary antibody. Photos were taken at 200x magnification. B) 
Expression of AGR2 in DNA array of 50 normal thyroid (NT) samples and 50 PTC. The box plot for AGR2 
shows a significant upregulation of this gene in tumor tissues. C) Semiquantitative RT-PCR showing 
increased levels of AGR2 in PTC samples in comparison to matched normal thyroids control. Human β-actin 
mRNA levels were used for normalization. 
 
Figure 2: Effects of AGR2 knockdown on TPC-1 cell growth, migration and invasion. 
A) TPC-1 cells were transfected with AGR2 siRNA or with scrambled siRNA. Cells were harvested at 
different time points and protein lysates were subjected to immunoblotting with the indicated antibodies. B) 
TPC-1 cells were transfected with AGR2 siRNA or with scrambled siRNA and counted at different time 
points. Values represent the average of triplicate experiments ± standard deviations. C) TPC-1 cells were 
transfected with AGR2 siRNA or with scrambled siRNA; after 48 and 72 hours cells were collected by 
trypsinization, stained for 10 minutes with trypan-blue and counted in triplicate. The percentage of trypan 
blue excluding cells compared to cells transfected with scrambled siRNA is reported ± standard deviations. 
D) TPC-1 cells were transfected with AGR2 siRNA or with scrambled siRNA, after 48 hours a wound was 
introduced and cell migration into the wound was monitored at 12 and 24 hours. E) Wound closure was 
measured by calculating pixel densities in the wound area and expressed as percentage of wound closure of 
triplicate areas ± standard deviations. F) TPC-1 cells were transfected with AGR2 siRNA or with scrambled 
siRNA; 48 hours after transfection, cells were seeded in the upper chamber of transwells and incubated for 
24 hours; the upper surface of the filter was wiped clean and cells on the lower surface were stained with 
0.1% crystal violet photographed and counted. This figure is representative of three independent 
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experiments. G) Invasive ability is expressed as number of invaded cells. Values represent the average of 
triplicate experiments ± standard deviations. Asterisks indicate P < 0.05 (*), P <0.01 (**) and P < 0.001 
(***).  
 
Figure 3: Effects of AGR2 ectopic expression on non-transformed thyroid, Nthy-ori 3-1, cell growth, 
migration and invasion. 
A) Expression levels of AGR2 and AGR2 (C→S) in transfected Nthy-ori 3-1 cells: after G418 selection, 
cells were lysed and blotted with the indicated antibodies. B) Nthy-ori 3-1 cells transfected with AGR2, 
AGR2 (C→S) or empty vector (pcDNA) were plated and counted at different time points. Values represent 
the average of triplicate experiments ± standard deviations. C) A wound was introduced on confluent 
monolayer of Nthy-ori 3-1 cells transfected with AGR2, AGR2 (C→S) and vector control (pcDNA) and 
wound closure was monitored at 9 and 12 hours time points. D) Wound closure was measured by calculating 
pixel densities in the wound area and expressed as percentage of wound closure of triplicate areas ± standard 
deviations. E) Nthy-ori 3-1 cells transfected with AGR2, AGR2 (C→S) or the empty vector (pcDNA) were 
seeded in the upper chamber of transwells and incubated for 24 hours; the upper surface of the filter was 
wiped clean and cells on the lower surface were stained and counted. F) Invasive ability was expressed as 
number of invaded cells. Values represent the average of triplicate experiments ± standard deviations. 
Asterisks indicate P < 0.001 (***). 
 
Figure 4: Effects of Bortezomib in non transformed thyroid Nthy-ori 3-1 cells ectopically expressing 
AGR2. 
A) Nthy-ori 3-1 cells transfected with AGR2, AGR2 (C→S) or with the empty vector (pcDNA) were treated 
for 24 hours with Bortezomib 100 nM. After treatment cells were collected by trypsinization, stained for 10 
minutes with trypan-blue and counted in triplicate. The percentage of trypan blue excluding cells is reported 
± standard deviations. Asterisks indicate P < 0.001 (***). B) Nthy-ori 3-1 cells transfected with AGR2, 
AGR2 (C→S) or with the empty vector (pcDNA) were treated for 24 hours with Bortezomib 100 nM. After 
treatment cells were lysed, and protein lysates were subjected to immunoblotting with the indicated 
antibodies.  
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Table 1: AGR2 expression in thyroid samples (n=64) 
 
 
AGR2 (score**) 
Negative Positive Tissue* 
Number  
of sample 
0 1+ 2+ 3+ 
NT 25 4 21   
28 (PTC CV) 1 2 2 23 PTC  
11 (PTC FV) 2 1 3 5 
 
 
* NT= normal thyroid; PTC CV= papillary thyroid carcinoma, classical variant; PTC FV= papillary thyroid 
carcinoma, follicular variant 
 
**    
0 = <10% of positive cells     
1 = 10-50% of positive cells       
2 = 51-75% of positive cells       
3 = 76-100% of positive cells      
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Supplemental Figure 1: Effects of AGR2 ectopic expression on TPC-1 cell growth, 
migration and invasion. 
Expression levels of transfected AGR2 and AGR2 (C→S) in TPC-1 cells: after G418 selection, 
cells were lysed and blotted with the indicated antibodies. B) TPC-1 cells transfected with AGR2, 
AGR2 (C→S) or empty vector (pcDNA) were plated and counted at different time points. Values 
represent the average of triplicate experiments ± standard deviations. C) A wound was introduced 
on confluent monolayer of TPC-1 cells transfected with AGR2, AGR2 (C→S) and vector control 
(pcDNA) and wound closure was monitored at 24 hours time point. D) TPC-1 cells transfected 
with AGR2, AGR2 (C→S) or the empty vector (pcDNA), were seeded in the upper chamber of 
  2 
transwells and incubated for 24 hours; the upper surface of the filter was wiped clean and cells on 
the lower surface were stained and counted. 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ABSTRACT
To evaluate whether Contrast Enhanced Ultrasund (CEUS) with microbubbles (MBs) targeted to VEGFR-2
is able to characterize in vivo the VEGFR-2 expression in the tumor vasculature of a mouse model of thyroid 
cancer (Tg-TRK-T1).
Animal protocol was approved by Institutional committee on Laboratory Animal Care. Contrast-enhanced 
ultrasound imaging with MBs targeted with an anti-VEGFR-2 monoclonal antibody (UCAVEGFR-2) and 
isotype control antibody (UCAIgG) was performed in 7 mice with thyroid carcinoma, 5 mice with hyperplasia 
or benign thyroid nodules and 4 mice with normal thyroid. After ultrasonography, the tumor samples were 
harvested for histological examination and VEGFR-2 expression was tested by immunohistochemistry.
The Video intensity difference (VID) caused by backscatter of the retained UCAVEGFR-2 was significantly 
higher in mice harboring thyroid tumors compared to mice with normal thyroids (P < 0.01) and to mice 
harboring benign nodules (P < 0.01). No statistically significant differences of VID were observed in the 
group of mice carrying benign nodules compared to mice with normal thyroids. Moreover in thyroid tumors 
VID of retained VEGFR-2-targeted UCA was significantly higher than that of control UCAIgG (p<0.05). 
Results of immunohistochemical analysis confirmed VEGFR-2 overexpression. The magnitude of the 
molecular ultrasonographic signal from a VEGFR-2-targeted UCA retained by tissue correlates with 
VEGFR-2 expression determined by immunohistochemistry (rho 0.793, P=0.0003).
We demonstrated that CEUS with UCAVEGFR-2 might be used for in vivo non invasive detection and 
quantification of VEGFR-2 expression in thyroid cancer in mice, and to differentiate benign from malignant 
thyroid nodules.
 4 
INTRODUCTION
Angiogenesis is a critical determinant of tumor growth and invasion (1,2) and successful application of novel 
therapies that target tumor vasculature will require selection of susceptible tumors and precise evaluation of 
early treatment response. Vascular endothelial growth factor and its main receptor vascular endothelial 
growth factor receptor 2 (VEGFR-2), are overexpressed on tumor vascular endothelial cells and have been 
identified as targets for antiangiogenic drugs (3-6). 
Endocrine glands are well vascularised and the structure of their vessels (fenestration of epithelium) 
facilitates the exchange of various substances, including hormones (7). The amount of VEGFR-2 in the 
thyroid gland is greater in the parenchymal and nodular goiter compared to healthy subjects (8). In patients 
with Graves’ s disease (9-10), the constant stimulation of thyroid tissue by TSH receptor (TRAb), not only 
increased the production of thyroid hormones, but also enhanced angiogenesis, leading to an increase in 
thyroid vascularity (7). 
Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland. At the molecular 
level PTC is characterized by genetic alterations of components of the mitogen-activated protein kinase 
(MAPK) pathway (11). These include structural chromosome rearrangements affecting NTRK1 (TRK-T1) 
tyrosine kinase receptor that undergo in-frame recombination with various partner genes (12). Specifically, 
the TRK-T1 oncogene results from a paracentric inversion of chromosome 1q25 that fuses the 5’ end of the 
TPR (Translocated Promoter Region) to the 3’ end of NTRK1 genes generating the constitutively active and 
oncogenic kinase NTRK1 (12). Transgenic mice featuring the thyroid-specific expression of TRK-T1 under 
the transcriptional control of the thyroid-specific bovine thyroglobulin (Tg) promoter were generated 
previously (13). Twenty-three % of TRK- !"#$%&"'(")*&"+","#'-./0")-1",23"'("#$%&"4","#'-./0"1&5&6'7&1"
thyroid nodules characterized by malignant features, such as the proliferation of follicular epithelial cells 
containing scant cytoplasm, mitotic figures and papillae with fibrovascular stalks (13,14). 
In papillary thyroid carcinoma, increased VEGFR-2 expression correlates with an increased cancer cell 
proliferation assessed by Ki-67 index, with increased thyroid tumor size (15-16) and with poor prognosis 
(16-19). The thyroid cancer cells of primary tumors taken from patients with metastases had an higher 
VEGFR-2 expression compared to cells taken from primary tumors of patients without metastases (15-16). 
 5 
These observations have been suggested to be clinically useful in identifying patients who are more prone to 
develop metastases.
Recently, tumor angiogenesis imaging in vivo has been noninvasively explored using contrast enhanced 
ultrasound (CEUS) with microbubbles (MBs) .)8*&.&1".'"9v:3 integrin, endoglin, and VEGFR2 (20-24).  
This technique is rapidly emerging as a noninvasive and quantitative molecular imaging modality that 
combines the advantages of high spatial resolution, real-time imaging, and lack of ionizing radiation and may 
be particularly advantageous in clinical oncology because VEGFR-2 has been implicated as marker of 
metastatic potential and poor prognosis in certain tumors (25-27).
Microbubbles are gas-filled echogenic US contrast agents that can be targeted to specific molecular markers 
by means of the attachment of appropriate ligands to the surface of the MBs. A specific characteristic of 
MBs is their relatively large size, which prevents them from leaking into
the extravascular space. This property can be exploited for imaging by targeting the MBs to disease 
processes reflected on the vascular endothelial cells lining the luminal surface of
capillaries and vessels, such as inflammation and angiogenesis. When these functionalized MBs are injected 
intravenously, they distribute throughout the whole body and attach at tissue sites expressing the targeted 
molecular marker, leading to a local increase of the US imaging signal. This approach allows the exclusive 
visualization of molecular markers of angiogenesis expressed on tumor vascular endothelial cells, have a 
potential clinical translation in future and should improve the ability to detect, diagnose stage, select 
appropriate treatments, and determine prognosis in patients with thyroid pathologies. 
To our knowledge, no study has addressed the potential of targeted CEUS imaging for assessment of thyroid 
tumor angiogenesis in vivo by using MBs targeted to VEGFR-2.
This study aimed to investigate whether targeted CEUS allows noninvasive assessment of VEGFR-2
expression on tumor vascular endothelium in Tg-TRK-T1 mice, a murine model of thyroid cancer. We also 
investigated whether the evaluation of expression levels of VEGFR2 in vivo can differentiate benign from 
malignant nodules of the thyroid.
MATERIALS AND METHODS
 6 
Animal Model
Animal studies were performed in accordance with National Institutes of Health (NIH) recommendations and 
Animal Research Advisory Committee (ARAC) procedure (27) and the approval of the Italian Institutional 
animal research committee (Institutional Animal and Care Committee of the University of Naples “Federico 
II” and the Italian Ministry of Health). All animal procedures in this study were conducted by a veterinarian 
and conformed to all regulations protecting animals used for research purposes, including national guidelines 
(D.L. 27 Gennaio 1992, 116 Suppl. G.U 40 18 Febbraio 1992. Direttiva CEE n.609/86) as well as the 
protocols recommended by Workamn et al. (28). 
Tg-TRK-T1 transgenic mice have been previously described (13). From 2010 to 2011, thyroid Ultrasound
was performed in 16 Tg-TRK-T1 transgenic mice model of thyroid carcinogenesis (26). Body weight range 
of animals was 29-32 gr, equally distributed among male (n=9) and female (n=7). Mice were examined every 
six months and were sacrificed immediately after the last ultrasound scanning. At the time of the necroscopy, 
the age range of mice was 12-15 months. 
High frequency ultrasound with targeted contrast enhanced imaging
A Vevo 770 microimaging system (Visualsonics, Toronto, Ontario, Canada) with a single element probe, 
center frequency of 40-MHz was used for all the examinations. The transducer has an active face of 3 mm, a 
lateral resolution of 68.2 µm, axial resolution of 38.5 µm, focal length of 6 mm, mechanical index 0.14, 
transmit power 50%, and a dynamic range 52 dB (29-30). Precise and repeatable control over the position of 
the two-dimensional image plane was obtained with a rail system (Vevo Integrated Rail System II; 
Visualsonics).  Mice were anesthetized using 1.5–2% isoflurane vaporized in oxygen (2Lt/min) on a heated 
stage, with constant monitoring of their body temperature, using physiological monitoring platform (31). 
Hairs were removed from the area of interest (neck and the high thorax) with a depilatory cream to obtain a 
direct contact of the ultrasound gel to the skin of the animal minimizing ultrasound attenuation. A 
prewarmed gel was used to provide a coupling medium for the transducer. Real-time imaging was performed 
as previously described (32).  The transducer focal zone was placed at the center of the thyroid gland and 
nodules, when they were present. All nodules were measured in three planes, and images were recorded to 
document nodule location and orientation. Each examination lasted for about 30 min. All ultrasonographic 
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assessments were performed by the same trained sonographer (A.G.)  that was not aware of the tumor type 
and of type of MBs administered to mice.
Contrast-enhanced Agent Preparation and Injection
The Ultrasound Contrast Agent (UCA) MicroMarker (VisualSonics, Inc, Toronto, Ontario, Canada), 
specifically designed for high frequency ultrasonography, was prepared and targeted according to 
manufacturer guidelines. These MBs have a mean diameter of 1.5 µm (range, 1–2 µm) and contain 
approximately 7600 molecules of streptavidin per square micrometer chemically attached to the 
phospholipid shell of the MBs via a polyethylene glycol spacer. (22). The contrast agent preparation protocol 
was designed to achieve optimal saturation of the microbubble surface with a maximal amount of antibodies 
while minimizing the amount of free non conjugated antibodies in the solution. A vial of the dry UCA 
containing 9.2 x 108 dry streptavidin-coated MBs was re-suspended in 1.2 mL of sterile saline. Then, either 
<=">*"'("?$'.$-@6).&1")-.$-mouse VEGFR-2 antibodies (clone Avas12a1; eBioscience, San Diego,) or a 
biotinylated immunoglobulin G (IgG) isotype control (eBioscience, Inc, San Diego, CA) were added per vial 
of contrast agent to produce either a VEGFR-2-targeted (UCAVEGFR-2) and a control UCA (UCAIgG) by using 
biotin-streptavidin interactions, resulting in approximately 6000 ligands per square micrometer of surface
area (22).  All mice were injected with two boluses of both the UCAVEGFR-2 and UCAIgG via a tail vein 
(injection time, 2 seconds). Each bolus containing 3.8 x 10
7
MBs in 0.02 mL of saline and was followed by a 
0.02 mL saline flush.
To allow MBs to clear from previous injections, we waited at least 30 minutes between different bolus 
injections.
Image Acquisition and Quantification
The system was set at 50% transmit power, resulting in a mechanical index of 0.14 (manufacturer 
specification). Images were acquired at a 20-Hz frame rate. The data were log compressed and digitized to 
12 bits. Data were further compressed to 8 bits for screen display. The ultrasound probe was positioned so 
that the central portion of the thyroid nodule was contained within the focal zone of the ultrasound 
transducer. The probe position, gain settings, and midfield focus were initially optimized and maintained 
throughout each experiment. The goal of the ultrasonographic image acquisition and analysis protocol 
(Figure 1) was to differentiate the backscattered acoustic signal due to MBs retained by the tumor from the 
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background signal of the tumor itself and MBs still freely circulating in the bloodstream. CEUS imaging was 
paused for 4 minutes after injection. This time allowed binding and retention of targeted MBs while awaiting 
wash-out of the unbound contrast agent.
After the 4-minute waiting period, approximately 300 ultrasonographic frames of the tumor were acquired at 
a temporal resolution of 10 seconds. A high-power ultrasound destruction sequence was then applied (20
cycles with a frequency of 10 MHz and a mechanical index of 0.59). After the destruction pulse, the system 
A)0"8&0&."A$./"$1&-.$%)6"$#)*$-*"7)8)#&.&80")0"?&('8&"./&"1&0.8B%.$'-"&5&-.C")-1")-'./&8"0&."'("$#)*&0"DE<=="
frames) was acquired. Image processing and quantification were performed with the software implemented 
in the ultrasound scanner. Image processing used in the Vevo770 system relies on 2 sets of images: a 
predestruction set and a postdestruction data set. The received log compressed signals were expressed in an 
arbitrary scale unit called Video Intensity (VI). The average VI of predestruction and postdestruction 
(background) sonograms was measured in a region of interest encompassing the centre of examined tumor. 
The difference in VI between predestruction and postdestruction ultrasonographic frames was calculated and 
expressed as VI difference (VID) that provided a relative measure of the amount of the UCA retained by the 
tumor and was considered to represent MBs adherent to molecular endothelial markers. 
Histology and Immunohistochemistry 
After CEUS imaging, mice were euthanized and thyroids were immediately fixed in buffered formalin for 4 
h. Tissues underwent automated processing and paraffin embedding; 5>m sections were cut and hematoxylin 
and eosin stained for microscopic analysis. Thyroid tissues were classified according to the World Health 
Organization criteria for the evaluation of mouse thyroid tumors (33). Briefly, thyroid was considered as 
normal when composed by variable-sized follicles covered by flattened monolayered epithelial cells. 
Hyperplastic thyroid was defined by the occurrence of small follicles with scant colloid and tall epithelial 
cells merging with normal areas. Follicular adenoma was defined as a well demarcated nodule with a distinct 
papillary and/or follicular architecture. Malignant lesions were defined based on the invasion of the 
surrounding glandular parenchyma and stroma. 
To confirm expression of VEGFR-2, immunohistochemistry analysis of tumor sections was performed. 
Formalin-fixed and paraffin-embedded 3–F">#"0&%.$'-0"A&8&"1&7)8)(($-$G&1C"76)%&1"$-")"0'6B.$'-"'(")?0'6B.&"
methanol and 0.3% hydrogen peroxide for 30 min, and treated with blocking serum for 20 min. After 
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blocking, slides were incubated with a mouse monoclonal anti-VEGFR-2 antibody (dilution 1:200) in a 
moist chamber at 4 C and processed according to standard procedures. Negative controls by omitting the 
primary antibody were included. Cases were scored as positive when unequivocal brown staining was 
observed. Immunoreactivity was expressed as the average percentage of positively stained target cells [(-): 
no stain$-*"DH"F3"7'0$.$5&"%&660IJ"DKIL"6'AMA&)N"DO"F3"- +"PF3"7'0$.$5&"%&660IJ"DKKIL"#&1$B#M#'1&8).&"D4"
25% - H"F=3"7'0$.$5&"%&660IJ"DKKKIL"/$*/M"0.8'-*"DO"F=3"7'0$.$5&"%&660IQR"S%'8&"5)6B&0"A&8&"$-1&7&-1&-.6@"
assigned by two blinded investigators (G. C. and R.P.) and a consensus was reached on all scores used for 
computation. All histological and immunohistochemistry studies were performed and interpreted by 
pathologists, who did not know the diagnosis determined by ultrasonography.
Statistical analysis
Data were reported as median and range. Paired non parametric Wilcoxon’s test was used to compare data 
from different VID (UCAIGg UCAVEGFR-2). ANOVA of Kruskal-Wallis was used to compare the contrast 
measurements of the three groups. Post hoc analysis was performed using the Dunn test. The correlation 
between the contrast signal and the VEGFR-2 expression was assessed by the Spearman coefficient.
A P < 0.05 was considered statistically significant. All statistical analysis were performed with MedCalc 
12.0 statistical software.
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RESULTS
Examination of the thyroid gland was performed by CEUS with UCAVEGFR-2 and UCAIgG. The UCA 
administration showed no notable toxicity, and all animals recovered after US imaging without any 
detectable signs of distress.
At the ultrasound evaluation in 16 mice examined: in 4 the thyroid showed normal size and homogeneous 
echotexture of parenchyma, without nodules, and therefore classified as normal, 2 mice showed features of 
benign diffuse hyperplasia and 10 mice had a nodular process.
At the histological examination 4 normal thyroids, 2 hyperplasias, 3 adenomas, 7 papillary thyroid carcinoma 
were found, confirming Ulttasound diagnosis. The benign thyroid nodules measured 0.11–0.27 mm (median 
0.17 mm) while the tumors measured 0.16–5.51 mm (median 0.54 mm).
For thyroid tumors the VID was significantly higher when using UCAVEGFR-2 compared with UCAIgG whereas 
for normal thyroids or in mice harboring benign thyroid nodules the VID for UCAVEGFR-2 was equal to the VID
for UCAIgG (Table 1 and Fig. 2). Median range VID UCAVEGFR2 thyroid tumors, 30.1 (range 25.1-35.6) versus 
VID UCAIgG 19.4 (range 11.4-22.6) (P< 0.01).
Benign nodules VID UCAVEGFR-2 13.3 (range 10.8-15.8) versus VIDUCAIgG 11.82 (range 8.5-19.6) (P= n.s).
Normal thyroids VID UCAVEGFR-2 10.9 (range 10.3-14.9) versus VID in UCAIgG 11.3 (9.4-14.7); (P= n.s)
(Table 1). These values were used as relative measures of the VEGFR-2 over-expression within tumor 
vasculature and the UCAIgG served as a control for demonstration of the specificity of UCAVEGFR-2 retention.
The median difference between VID UCAIGg and VID of UCAVEGFR-2 was considered as a measure of VEGFR-
2 specific binding, was 11.6 (range 9.6-19.2) VI units for thyroid carcinoma significantly higher (p=0.0037) 
than for normal thyroid (median 0.3, range -1.57-1.32) and hyperplasia/benign nodules (median 2.3 range -
3.8-3.0).
Figure 2 shows representative VI curves of a thyroid malignant nodule, normal thyroid and benign nodule 
imaged with the UCAVEGFR-2 and UCAIgG. There was a moderately intense signal from the UCAVEGFR-2
retained by the tumor (Fig.2F). The corresponding images for the UCAIgG showed no retention of MBs in the 
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tumor (Fig.2C). The UCAVEGFR-2 in the vascular bed of benign nodules and normal thyroids showed very low
retention in UCAVEGFR-2 (Fig 2 D-E). 
After CEUS imaging, mice were subjected to general anesthesia and than euthanized.
In the group of examined animals the greatest UCAVEGFR-2 Video Intensity for normal or benign thyroid 
nodules was 15.8 units while the lowest UCAVEGFR-2 Video Intensity  for carcinomas was 25.1 units. 
Therefore, we propose a cut-off value of 20 VI units to discriminate normal or benign nodules from 
malignant thyroid, that may be verified using a larger number of subjects.
To confirm expression of VEGFR-2, immunohistochemistry analysis of tumor sections was performed. The 
strength of the ultrasound signal from the UCAVEGFR-2 was significantly correlated with the level of actual 
VEGFR-2 expression (rho 0.793, P=0.0003).
DISCUSSION
In this study we have evaluated the expression levels of a well-described tumor angiogenic marker i.e. 
VEGFR-2 in a mouse model of thyroid tumor (Tg-TRK-T1) compared with normal or benign tumors and 
whether targeted CEUS allows assessment of this marker noninvasively. The in vivo binding of the VEGFR-
2 targeted UCA in thyroid tumors was substantially higher compared with control UCA. This difference in 
retention affirmed the specificity of a VEGFR-2- conjugated UCA for endothelial targeting. 
Vascular endothelial growth factor receptor 2 (VEGFR-2) is one of the best-characterized molecular marker 
of tumor angiogenesis (34-37). It is overexpressed on tumor vascular endothelial cells in several solid 
tumors, including breast (38,39), ovarian (40-41), pancreatic (42) and thyroid cancer (19) and it is considered 
an important factor in tumor angiogenesis. VEGFR-2 is an endothelium-specific receptor tyrosine kinase that 
is activated by VEGF A. Activation of the VEGF/VEGFR-2 pathway triggers multiple signaling networks 
that result in endothelial cell survival, mitogenesis, migration, differentiation, and vascular permeability (43). 
Insights into the expression levels of tumor angiogenic markers during the progression of cancer, could be of 
great importance in developing novel molecular imaging strategies aimed at visualization of tumor 
angiogenesis markers that are overexpressed in particular in early stage cancer for screening purposes. 
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The in vivo US imaging signals of the injected targeted UCA was correlated with results from 
immunochemistry analysis of VEGFR-2 expression and this positive correlation suggested that targeted 
contrast-enhanced US imaging could be used to monitor expression levels of angiogenic markers 
noninvasively. Thus retention of a VEGFR-2-targeted UCA is a more specific as in vivo marker for the level 
of VEGFR-2 expression than for the quantification of tumor vascularity.
The ability to visualize and quantify tumor angiogenesis may allow screening and detecting cancer at an 
early stage and antiangiogenic treatment monitoring in patients (34). 
Targeted-CEUS is a promising non invasive molecular imaging approach that allows in vivo assessment of 
molecular markers of tumor angiogenesis (44-46). The number of attached MBs depends on various factors, 
including the extent of tumor vascularization, physical forces that translate the freely circulating contrast 
MBs to the vessel wall, and the affinity of the binding ligand to the molecular targets, as well as the 
expression level of the molecular targets on tumor vessels (47-50). 
Our study has several limitations. Molecular imaging of VEGFR-2 expression was performed in developed 
tumors (0.16–5.51 mm in diameter) in which it is very likely that the receptor is expressed at more. Thus, the 
usefulness and accuracy of VEGFR-2-targeted UCA imaging at earlier stages of tumor development needs to 
be evaluated.
A 2-dimensional image acquisition method was used, and it is very difficult to know whether ultrasound 
scans perfectly correspond with the region subjected to histological examination. Studies carried out in 3D 
mode could ensure greater correspondence between quantitative ultrasonographic assessment of VEGFR-2
expression and results of immunochemical analysis. 
The small animal Vevo770 US system for dedicated small-animal imaging used in our study for MBs
detection operates on received signals that undergo log-compression prior to image display. Log-compressed 
gray scale image values referred as “Video Intensity” can produce inaccurate estimation of perfusion user
and instrument-dependent.
In conclusion the results of our study suggests that targeted CEUS imaging allows a non-invasive assessment 
of VEGFR-2 expression levels in thyroid in vivo. The results provide further insights into the biology of 
angiogenesis in thyroid tumors and may help in defining promising imaging targets for both early cancer 
detection and antitumor therapies.
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Table 1: Quantitative Video Intensity for Ultrasound Contrast agent targeted with isotype control 
antibody (UCAIGg) and anti-VEGFR2 monoclonal antibody (UCAVEGFR2)
Normal Thyroid 
(n.4)
Hyperplasia/Benign 
Nodules
(n.5)
Thyroid Carcinoma
(n.7)
Video Intensity UCAIGg
Video Intensity Difference 11.3 (9.4-14.7) 12.2 (8.5-19.6) 19.4 (11.4-22.6)
Video Intensity UCAVEGFR2
Video Intensity Difference 10.9 (10.3-14.9) 13.3 (10.8-15.8) 30.1 (25.1-35.6)* §
*Statistical significant difference between Thyroid carcinoma and  normal thyroid or Hyperplasia/benign 
nodules p<0.05
§  Statistical significant difference between UCA targeted with anti-VEGFR2 monoclonal antibody and 
isotype control antibody  p=0.0156
Figure captions
Fig 1 Targeted US of endothelial antigens in vessels of a tumor tissue.
Endothelial cells of vessels (red) of tumor tissues expresses specific antigens. After intravenous 
administration targeted microbubbles (blue) float in vessels and remaining exclusively in the vascular 
compartment. Many of them bind to antigens of endothelial cells, whereas others remains in the vessel lumen 
freely circulating. After high-power destructive pulse, all microbubbles are destroyed (bound + circulating), 
following circulating microbubbles, that arrives from outside of scan plane, remain freely circulating for 
several seconds. On the top of the figure time/video intensity curve analysis before and after high-power 
destructive pulse and bottom a diagram representation of destructive methodology. Contrast intensity is the 
sum of the intensity from tissue, intensity from microbubbles not bound to receptors (circulating 
microbubbles), and intensity from microbubbles bound to receptors on endothelial cells. After digital 
subtraction of 300 predestruction frames from 300 postdestruction frames, resulting video intensity is due 
only to bound microbubbles.
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Fig.2 video intensities curves 
Predestruction and postdestruction video intensities curves for the control UCA (A–C) and the VEGFR2-
targeted UCA (D–F). The average video intensity of predestruction and postdestruction sonograms was 
measured and the difference in video intensity between the predestruction and postdestruction 
ultrasonographic frames was calculated and expressed as video intensity difference (VID). This value 
provided a relative measure of the amount of targeted microbubbles retained by the tumor. Video Intensities 
curves of a normal thyroid parenchyma (A,D), adenoma (B,E) and a thyroid tumor (C,F). These images 
show a significant difference between retention of the control and VEGFR2-targeted UCAs in a thyroid 
tumor.
Figure 3: Representative microphotographs of immunohistochemistry analysis of murine thyroid stained 
with antibodies against VEGFR type 2 receptor. Brown color indicate presence of VEGFR2 
Low grade expression of VEGFR-2 in normal thyroid (A) and in thyroid adenoma (B) and high grade 
expression in thyroid carcinoma (C).
Fig. 4:
Correlation between Video Intensity Difference  of VEGFR-2 targeted microbubbles and expression of 
VEGFR-2 determined by Immunohistochemistry expressed as the average percentage of positively stained 
cells in normal thyroids, in hyperplasia/adenoma and in carcinomas [white dot: no staining (< 5% positive 
%&660IJ"'8)-*&"0^B)8&L"6'AMA&)N"DO"F3"- +"PF3"7'0$.$5&"%&660IJ"?6B&"1'.L"#&1$B#M#'1&8).&"D4"PF3"- < 50% 
7'0$.$5&"%&660IJ".8$)-*6&L"/$*/M"0.8'-*"DO"F=3"7'0$.$5&"%&660IQR
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